Chimeric Antigen Receptor T Cell Therapy For The Treatment Of Hiv by Maldini, Colby
University of Pennsylvania 
ScholarlyCommons 
Publicly Accessible Penn Dissertations 
2020 
Chimeric Antigen Receptor T Cell Therapy For The Treatment Of 
Hiv 
Colby Maldini 
University of Pennsylvania 
Follow this and additional works at: https://repository.upenn.edu/edissertations 
 Part of the Allergy and Immunology Commons, Immunology and Infectious Disease Commons, 
Medical Immunology Commons, and the Microbiology Commons 
Recommended Citation 
Maldini, Colby, "Chimeric Antigen Receptor T Cell Therapy For The Treatment Of Hiv" (2020). Publicly 
Accessible Penn Dissertations. 4201. 
https://repository.upenn.edu/edissertations/4201 
This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/4201 
For more information, please contact repository@pobox.upenn.edu. 
Chimeric Antigen Receptor T Cell Therapy For The Treatment Of Hiv 
Abstract 
Due to the success of antiretroviral therapy (ART), Human Immunodeficiency Virus (HIV) infection has 
transformed from a terminal disease into a manageable chronic illness. However, ART is not curative, and 
individuals must endure the side-effects of long-term treatment and the social stigma associated with 
HIV infection. As such, the development of therapeutic strategies capable of eradicating HIV would 
improve the lives of infected individuals. Herein, we investigated the in vivo therapeutic potential of HIV-
specific Chimeric Antigen Receptor (CAR) T cell therapy as a means to reconstitute and optimize the 
antiviral T cell response. Through iterative in vivo development, we generated a novel T cell product that 
expressed two independent CD4-based CARs containing distinct costimulatory domains (4-1BB and 
CD28) on the T cell surface. These Dual-CAR T cells accentuated in vivo antigen-driven proliferation 
mediated by 4-1BB costimulation and preserved ex vivo effector functions mediated by CD28 
costimulation. Notably, Dual-CAR T cells mitigated disease pathogenesis by reducing both plasma 
viremia and tissue viral burden, as well as preserving CD4+ T cells from virus-induced depletion. 
Moreover, through extensive in vitro and in vivo characterization, we uncovered the antiviral role of HIV-
specific CAR-modified CD4+ T cells including their ability to both directly suppress virus replication and 
confer T cell-help to other virus-specific lymphocytes. Lastly, we developed an image-based cytometry 
method used to measure several quality control metrics of the CAR T cell manufacturing process, 
including ex vivo expansion criteria and cytotoxic function. We demonstrated that image-based cytometry 
overcomes several limitations associated with industry-standard equipment and assays, which could 
serve to improve the efficiency for identifying high-quality CAR T cell products with therapeutic utility. 
Collectively, our work focused on cell-based immunotherapy for the treatment of HIV; however, both the 
development of a next-generation CAR T cell product and the in-depth characterization of CAR-modified 
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CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY FOR THE TREAMTNET OF HIV 
Colby R. Maldini 
James L. Riley 
 
 Due to the success of antiretroviral therapy (ART), Human Immunodeficiency 
Virus (HIV) infection has transformed from a terminal disease into a manageable chronic 
illness. However, ART is not curative, and individuals must endure the side-effects of 
long-term treatment and the social stigma associated with HIV infection. As such, the 
development of therapeutic strategies capable of eradicating HIV would improve the 
lives of infected individuals. Herein, we investigated the in vivo therapeutic potential of 
HIV-specific Chimeric Antigen Receptor (CAR) T cell therapy as a means to reconstitute 
and optimize the antiviral T cell response. Through iterative in vivo development, we 
generated a novel T cell product that expressed two independent CD4-based CARs 
containing distinct costimulatory domains (4-1BB and CD28) on the T cell surface. 
These Dual-CAR T cells accentuated in vivo antigen-driven proliferation mediated by 4-
1BB costimulation and preserved ex vivo effector functions mediated by CD28 
costimulation. Notably, Dual-CAR T cells mitigated disease pathogenesis by reducing 
both plasma viremia and tissue viral burden, as well as preserving CD4+ T cells from 
virus-induced depletion. Moreover, through extensive in vitro and in vivo 
characterization, we uncovered the antiviral role of HIV-specific CAR-modified CD4+ T 
cells including their ability to both directly suppress virus replication and confer T cell-
help to other virus-specific lymphocytes. Lastly, we developed an image-based 
cytometry method used to measure several quality control metrics of the CAR T cell 
manufacturing process, including ex vivo expansion criteria and cytotoxic function. We 
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demonstrated that image-based cytometry overcomes several limitations associated with 
industry-standard equipment and assays, which could serve to improve the efficiency for 
identifying high-quality CAR T cell products with therapeutic utility. Collectively, our work 
focused on cell-based immunotherapy for the treatment of HIV; however, both the 
development of a next-generation CAR T cell product and the in-depth characterization 
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Human Immunodeficiency Virus (HIV) induces profound loss of CD4+ T cells 
throughout all compartments of the body, increasing the susceptibility to AIDS-related 
opportunistic infections.1 However, in the era of antiretroviral therapy (ART), successfully 
treated individuals are expected to have a normal lifespan characterized by low levels of 
viremia, and restored CD4+ T cell counts. Despite effective treatment, ART is not 
curative as HIV largely persists within quiescent memory CD4+ T cells2 that can reignite 
a systemic infection within weeks after individuals stop therapy. Unfortunately, existing 
HIV-specific CD8+ T cells (CTLs) are generally compromised, even in the presence of 
ART, and are ill-prepared to eliminate latently infected cells upon virus reactivation.3 As 
such, the HIV cure field has placed increased emphasis on developing novel 
immunotherapeutic strategies aimed to both reduce the size of the latent reservoir and 
engender durable control over virus replication in the absence of ART. One attractive 
strategy employs the adoptive transfer of ex vivo expanded autologous HIV-specific T 
cells to bolster antiviral immunity. These T cell products mainly fall into three categories: 
i) the ex vivo expansion and re-infusion of natural HIV-specific CTLs, or infusion of ii) 
gene-engineered T cells expressing an HIV-specific T cell receptor (TCR) or iii) 
Chimeric Antigen Receptor (CAR) (Fig. 1-1). Currently, these approaches are at various 




HIV-specific CTL Response to HIV Infection 
 HIV infection induces a CTL response that fails to fully eradicate infection in most 
individuals, but numerous lines of evidence support that the de novo generation of CTLs 
directly impact disease progression. For instance, CTLs are readily identified during the 
acute phase of infection prior to the presence of detectable antibodies, and their 
emergence associates with the resolution of peak viremia.4,5 However, the HIV genome 
rapidly accumulates mutations leading to the outgrowth of virus escape variants that 
render infected cells insensitive to CTL-mediated recognition and killing.6,7 In addition, 
unless ART is initiated early, CTL escape mutations dominate the proviral DNA 
landscape,8 which can contribute to failed immune clearance of the latent reservoir. 
Moreover, unmitigated HIV replication and persistent exposure to viral antigen induces 
CTL exhaustion characterized by a progressive decline in effector functions, including 
proliferative capacity, cytokine secretion, and cell-mediated cytotoxicity.9 Exhausted 
CTLs preferentially express checkpoint inhibitors such as CTLA-4, 2B4, CD160 and PD-
1,9-11 which can attenuate immune activation and function. Indeed, there is considerable 
interest in evaluating the therapeutic effects of disrupting PD-1 signaling to reinvigorate 
exhausted CTLs in chronically infected individuals (clinical trial identifier, NCT03767465), 
given the positive clinical responses observed in patients with advanced melanoma 
undergoing checkpoint blockade therapy.12,13 
In rare instances, asymptomatic HIV-infected individuals known as elite 
controllers (ECs) spontaneously suppress virus replication (<50 RNA copies/mL of 
blood) and maintain CD4+ T cells (>350 cells/L blood) in the absence of ART.14,15 
Slower disease progression in ECs is predominately associated with the induction and 
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maintenance of polyfunctional CTLs restricted to particular HLA class I alleles, including 
HLA-B57 and HLA-B27.16-18 Evidence from rhesus macaques that similarly control 
pathogenic SIV infection demonstrate that in vivo depletion of CD8+ T cells results in 
virus re-emergence and systemic infection,19 indicating that CTLs from ECs actively 
patrol the body and control infection, but stop short of eradicating latent reservoirs. Thus, 
the protective role of CTLs in ECs provides immense promise that treatment 
interventions aiming to augment HIV-specific T cell immunity can improve disease 
outcomes for the broader population of infected individuals.  
 
Adoptive Transfer of Ex Vivo Expanded Natural HIV-specific CTLs 
 Several groups have explored the therapeutic efficacy of ex vivo expanded, 
naturally-derived antigen-specific T cells following adoptive transfer into humans 
diagnosed with chronic viral infections.20 In this process, autologous T cells are 
harvested from the donor and expanded by ex vivo stimulation in the presence of viral-
derived peptides and exogenous cytokines prior to infusion.21 Early on, this approach 
showed limited value in HIV-infected individuals as these CTLs showed poor in vivo 
persistence, primarily due to rapid virus escape from HIV-specific CTL clones with one 
epitope specificity,22 as well as intrinsic functional deficits associated with the ex vivo 
manufacturing process.23 Since these early attempts, the immunoncology field has 
significantly advanced this technology. For instance, the infusion of ex vivo expanded, 
polyclonal CTLs targeting multiple viral-derived epitopes have reduced the rates of 
morbidity and mortality caused by EBV, CMV and adenovirus reactivation in 
immunocompromised individuals following hematopoietic stem cell transfer.24 Indeed, 
researchers have leveraged these advances to overcome the hurdles that were 
identified in the first clinical assessment of adoptive T cell therapy for viral infection. 
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Recently, polyclonal HIV-specific CTLs have been generated from both HIV-infected and 
seronegative individuals after ex vivo stimulation with peptide mixes that comprise the 
most conserved and least mutable regions of the HIV genome.25 This approach complies 
with good manufacturing practice (GMP) standards and does not require genome 
engineering, which mitigates the risk of genotoxicity. Furthermore, since these mature T 
cells underwent normal development in the body, it is unlikely that there will be any off-
target reactivity by infusing more of these naturally-derived T cells. However, it remains 
unclear whether increasing the frequency of pre-existing HIV-specific CTLs alone, 
despite targeting conserved regions of the virus, will ultimately suppress HIV replication 
after ART cessation. Currently, a clinical trial (NCT03485963) is underway infusing multi-
HIV-specific CTLs into individuals to test the safety and feasibility of this approach. 
Notably, this study is designed to test whether these cells can reduce the size of the 
latent reservoir in the presence of ART, rather than the ability to delay or control viral 
rebound during an analytical treatment interruption.  
 
TCR Gene Therapy Confers HIV Specificity   
In addition to infusing ex vivo expanded, naturally-derived HIV-specific CTLs, 
researchers are actively exploring approaches to restore the HIV-specific response by 
introducing a virus-specific TCR into polyclonal T cells. In fact, several HIV-specific CTL 
responses associate with lower viremia during untreated infection, particularly T cell 
responses targeting the HIVGAG protein, whereas HIVENV and accessory/regulatory 
protein-specific responses correlate with higher viremia.26-28 In practice, TCRs that 
confer effective immunity can be sequenced and incorporated into a gene transfer vector 
(i.e. retroviral- or lentiviral-based) that confers expression of an HIV-specific TCR into a 
heterogeneous population of T cells. These re-directed TCR-transgenic T cells are then 
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expanded, typically though CD3/CD28 ligation, and infused into HIV-infected individuals 
thereby reconstituting antiviral immunity. However, this therapy is HLA-restricted, and in 
principle, participation is limited to individuals expressing specific HLA alleles, which has 
restricted widespread clinical evaluation. To further complicate this issue, a majority of 
the HIV-specific TCRs that exhibit enhanced control of infection are derived from ECs, 
and are restricted to relatively rare HLA alleles including HLA-B57 and HLA-B27, 
whereas more prevalent alleles, such as HLA-A2, are not associated with reduced 
viremia.26 Thus, emphasis has been placed on engineering affinity enhanced HIV-
specific TCRs restricted to common HLA alleles. In cancer, affinity-optimized tumor-
specific TCRs show improved efficacy compared to their natural counterpart,29 in part by 
conferring class I HLA/peptide specificity and reactivity to both CD8+ and CD4+ T cell 
subsets.30  
An affinity-enhanced HIV-specific TCR targeting the SL9 epitope in HIVGAG and 
restricted by HLA-A2 was reported by Varela-Rohena and colleagues.31 Unlike the wild-
type SL9-specific TCR, the affinity-enhance variant conferred T cells with superior in 
vitro effector functions and reactivity to common SL9 escape mutants. In 2009, a clinical 
trial was initiated (NCT00991224) to test the ability of both the wild-type and affinity-
enhanced SL9-specific TCRs to reconstitute HIV-specific immunity. However, 
recruitment into the trial was challenging as 4 out of 40 individuals screened positive for 
HLA-A2, and only 2 people consented to be part of the trial. However, this trial was 
suspended to due to the unfortunate death of two participants treated with an affinity-
enhanced HLA-A1-restricted MAGE-A3-specific TCR for myeloma and melanoma. 
Follow-up analysis of these two individuals revealed that affinity-enhancement of the 
MAGE-A3 TCR caused off-tissue recognition of an epitope within titan, an unrelated 
protein expressed in cardiac tissue that was not predicted by preclinical testing.32 The 
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findings from this trial underscored that extensive epitope screening is required to 
identify and characterize on-target, off-tissue reactivity brought about by TCR affinity-
enhancement. As a result, the adoptive transfer of T cells expressing a high-affinity HIV-
specific TCR offers some direct advantages to the infusion of ex vivo expanded HIV-
specific CTLs, but the therapeutic potential of this approach remains unknown. 
 
CAR T Cell Therapy for HIV Infection 
Chimeric antigen receptor (CAR) technology has emerged as a promising 
approach to reprogram T cells to overcome the barriers that confront naturally occurring 
T cells. Because CARs alter how T cells recognize antigen by directly binding to cell 
surface proteins without requiring peptide presentation by MHC molecules, there are 
fewer available targets for CARs to recognize relative to TCRs. However, in the setting 
of HIV, redirecting T cell specificity with a CAR may avoid many of the CTL escape 
mechanisms employed by HIV (Table 1-1). The concept of CAR T cells emerged in the 
1990s when investigators showed that T cell specificity could be redirected by fusing a 
targeting moiety that recognizes a cell surface protein with a T cell activation domain 
such as the CD3- cytoplasmic tail. The first example of this technology fused the CD4 
extracellular region to the CD3- chain. When expressed in T cells, this construct 
conferred T cell specificity to recognize HIV-infected cells by taking advantage of the 
interaction between the HIVENV protein and CD4.33 This concept was brought to the clinic 
in the late 1990s; although it was shown to be safe and feasible, durable control of virus 
infection was not observed.34-36 These findings raised concerns about the ability of first-
generation CAR T cells, which only contain the CD3- signaling domain, to function in 
vivo. Since then, the cancer immunotherapy field has advanced the design and 
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manufacturing of CAR T cells to generate optimal antitumor responses.37 A key 
improvement in the design from first- to second-generation CARs has been the inclusion 
of costimulatory domains, such as those derived from 4-1BB and CD28, which modulate 
T cell function, persistence and susceptibility to exhaustion.37-39 Costimulatory domains 
can also influence memory development and metabolism of CAR T cells. For example, 
signaling from a CAR containing a 4-1BB domain promotes a central-memory phenotype 
in T cells and reliance on oxidative phosphorylation for energy, whereas signaling from a 
CAR containing a CD28 domain promotes an effector-memory phenotype in T cells and 
an augmented rate of glycolysis.39 These findings help to reconcile the differential 
persistence of CAR T cells that has been observed in vivo, whereby different types of 
costimulation can reprogram T cell metabolism to generate long-lived memory cells or 
short-term effector cells. 
Recently, we applied the lessons learned from CAR design in the cancer field to 
re-engineer the CD4-based CAR described in the first in-human clinical trial. The original 
CAR underwent substantial modifications including alterations to the vector backbone, 
promoter, and the structural and signaling domains. Optimized CD4-based CAR T cells 
containing the 4-1BB-CD3 intracellular signaling domain were at least 50-fold more 
potent at suppressing HIV replication in vitro than were T cells expressing the original 
CAR. Moreover, when the optimized CAR T cells were evaluated in a humanized mouse 
model of HIV infection, they preserved the CD4+ T cell count, reduced the HIV burden, 
and expanded in response to HIV to a much greater extent than did their first-generation 
counterparts.40 Moreover, several groups have explored targeting HIV-infected cells 
using second-generation CARs with alternative antigen-binding moieties. CARs 
containing single-chain variable fragments (scFvs) derived from broadly neutralizing 
antibodies have been developed that target conserved sites within the HIVENV protein, 
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including the CD4-binding site, the gp41 membrane-proximal external region and 
variable region glycans.41-43  
Despite the in vitro antiviral capacity exhibited by both CD4- and scFv-based 
CAR T cells, several factors may limit their therapeutic potential in humans. For 
instance, the over-expression of the CD4-based CAR on the T cell surface renders 
transduced cells susceptible to HIV infection,40 which may ultimately mitigate the 
persistence CAR T cells and limit the overall efficacy of treatment. Moreover, to become 
a broadly applicable therapy, scFv-based CAR T cells must overcome HIV escape, be 
effective against the diversity of HIV strains, and be non-immunogenic so that they can 
persist for decades. Despite the advantages and potential drawbacks of each type of 
antigen-targeting moiety, it is clearly possible that highly potent HIV-specific T cells can 
be generated by improving CAR design. This will likely impact the durability and function 















Figure 1-1. Schematic of adoptive T cell-based strategies to treat HIV infection. 
Adoptive T cell-based strategies to treat HIV infection fall largely into 3 categories: i) ex 
vivo expansion and infusion of existing naturally-derived HIV-specific T cells, ii) infusion 
of polyclonal T cells engineered to express a single HIV-specific T cell receptor, and iii) 









CHAPTER 2 - Dual CD4-based CAR T cells with Distinct Costimulatory 
Domains Mitigate HIV Pathogenesis In Vivo  
Parts of this chapter were previously published in: 
 
Maldini C.R., Claiborne D.T., Okawa K., Chen T., Dopkin D.L., Shan X., Power K.A., 
Trifonova R.T., Krupp K., Phelps M., Vrbanac V.D., Tanno S., Bateson T., Leslie G.J., 
Hoxie J.A., Boutwell C.L., Riley J.L., Allen T.M. (2020) Dual-CD4-based CAR T cells with 
Distinct Costimulatory Domains Mitigate HIV Pathogenesis In Vivo. Nat Med (in press). 
 
Abstract 
An effective strategy to cure HIV will likely require a potent and sustained 
antiviral T cell response. Here, we explored the utility of Chimeric Antigen Receptor 
(CAR) T cells expressing the CD4 ectodomain to confer specificity for the HIV envelope 
to mitigate HIV-induced pathogenesis in bone marrow, liver, thymus (BLT) humanized 
mice. CAR T cells expressing the 4-1BB/CD3- endodomain were insufficient to prevent 
viral rebound and CD4+ T cell loss after the discontinuation of antiretroviral therapy 
(ART). Through iterative improvements to the CAR T cell product, we developed Dual-
CAR T cells that simultaneously expressed both 4-1BB/CD3- and CD28/CD3- 
endodomains. Dual-CAR T cells exhibited expansion kinetics that exceeded 4-1BB-, 
CD28- and 3rd-generation costimulated CAR T cells, elicited effector functions equivalent 
to CD28-costimulated CAR T cells, and prevented HIV-induced CD4+ T cell loss despite 
persistent viremia. Moreover, when Dual-CAR T cells were protected from HIV infection 
through expression of the C34-CXCR4 fusion inhibitor, these cells significantly reduced 
acute phase viremia, as well as accelerated HIV suppression in the presence of ART 
and reduced tissue viral burden. Collectively, these studies demonstrate the enhanced 
therapeutic potency of a novel Dual-CAR T cell product with the potential to effectively 





Chimeric Antigen Receptor (CAR) T cell immunotherapies, in which engineered T 
cells are infused into patients, have induced durable remissions for treatment-refractory 
malignancies.44 Although a potent and sustained T cell response of the kind that CAR T 
cells can afford is likely to be essential for the development of an effective HIV cure45, a 
successful CAR T cell therapy for HIV infection has remained elusive.  CARs redirect T 
cell specificity by expressing an extracellular antigen recognition domain linked to an 
intracellular T cell costimulatory domain and the CD3- chain.37,46 The costimulatory 
domains for second-generation CARs are derived from the intracellular signaling 
domains of either CD28 or 4-1BB, which is one of the key differences between the two 
FDA-approved CD19-targeting CAR T cell therapies.47,48 Preclinical cancer models 
demonstrate that CD28-costimulated CAR T cells exhibit profound effector function 
resulting in rapid tumor clearance, but have limited persistence in vivo.49,50 In contrast, 4-
1BB-costimulated CAR T cells have a slower antitumor response but sustained 
proliferation and survival.51-54 The distinct signaling pathways used by CD28 and 4-1BB 
cause distinct metabolic, phenotypic and functional T cell profiles that can elicit optimal 
CAR T cell activity for specific diseases,39,55-58 and there is great interest in tuning 
costimulatory signals to optimize CAR T cell function.59,60 
 The earliest clinical trials of CAR T cell therapy utilized first-generation, CD4-
based CARs targeting the HIV Envelope glycoprotein via surface expression of the CD4 
ectodomain and proved ineffective for treatment of either chronic or antiretroviral therapy 
(ART)-suppressed infection.36,61,62 However, subsequent significant improvements in 
CAR technology by the cancer immunotherapy field has renewed interest in applying 
these advances to HIV treatment.40-43,63-65 The continued investigation of the mechanistic 
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underpinnings of successful and failed CAR T cell therapy, particularly in a model 
system that recapitulates HIV pathogenesis, will be critical for the development of a CAR 
T therapy for HIV cure initiatives.  
Here, we utilized the bone marrow, liver, thymus (BLT) humanized mouse model 
of HIV infection to iteratively test CD28 and 4-1BB costimulation in the context of 
optimizing HIV-specific CAR T cell therapy. We leveraged the BLT mouse model’s ability 
to support HIV infection, including high viral loads, rapid human CD4+ T cell depletion, 
and ultimately T cell exhaustion,66-69 to make stepwise improvements to the CAR T cell 
product. This effort culminated in the development of HIV-resistant (C34-CXCR4+), Dual-
CAR T cells that express two CD4-based CARs independently encoding the CD28/CD3-
 and 4-1BB/CD3- endodomains. Collectively, these data provide important insight 
regarding the development of an engineered T cell-based therapy of HIV infection and 




BLT mouse-derived CAR T cells are multifunctional and suppress HIV replication 
in vitro 
To determine whether T cells isolated from BLT mice generate potent CAR T cell 
products, we manufactured HIV-specific (CD4-based) CAR T cells expressing the CD3- 
endodomain (CAR.) from BLT mouse tissues and adult human PBMCs (Fig. 2-1A). 
BLT mouse- and human-derived CAR. T cells exhibited comparable in vitro expansion 
kinetics and CAR surface expression levels (Fig. 2-1B and Fig. 2-2A). Antigen-specific 
stimulation with K562 cells expressing HIVYU2 Envelope (K.Env) induced similar cytokine 
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expression and polyfunctionality profiles between the CAR T cell sources (Fig. 2-2B,C 
and Fig. 2-1C-E). Furthermore, CAR. T cells from both donors suppressed viral 
outgrowth down to a 1:50 effector-to-target ratio in vitro (Fig. 2-2D,E), and induced 
similar levels of cleaved caspase-3 in HIV-infected CD4+ T cells (Fig. 2-1F and Fig. 2-
2F,G). The induction of caspase-3 combined with the co-upregulation of granzyme B 
and perforin by CAR. T cells (Fig. 2-1G,H) indicate that elimination of virus-infected 
cells likely occurred via granule-mediated cytolysis. In total, the in vitro functional profile 
of BLT mouse-derived CAR. T cells was indistinguishable from that of human-derived 
CAR. T cells, demonstrating that highly functional CAR T cells can be manufactured 
from BLT mice. 
 
Costimulation modulates CAR T cell persistence and function in vivo 
To identify a CAR T cell product capable of long-term persistence against HIV, 
we compared the contribution of costimulatory domains to in vivo engraftment of T cells 
by creating an infusion product comprising equal frequencies of HIV-specific CAR.CD3-
 (CAR.), 4-1BB/CD3- (CAR.BB), and  CD28/CD3- (CAR.28) T cells, each of which 
was linked to a distinct fluorescent protein (Fig. 2-3A). After infusion, CAR.BB T cells 
exhibited significantly greater survival in the absence of HIV antigen (Fig. 2-3B-D), and 
constituted approximately 80% of total CAR T cells in tissues (Fig. 2-3E). Consistent 
with reports from the cancer field,51-54 CAR.BB T cells also demonstrated superior in 
vivo antigen-driven proliferation upon infusion of K.Env cells (Fig. 2-3F). In contrast, 
CAR.28 T cells only exhibited a transient expansion followed by a progressive decline, 
and CAR. T cells steadily declined demonstrating no evidence of expansion. Notably, 
however, CAR.28 T cells exhibited greater effector functions when stimulated ex vivo 
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with K.Env cells, upregulating more MIP-1, TNF and IL-2, and co-expressing greater 
levels of granzyme B and perforin than CAR.BB T cells from the same mice (Fig. 2-
3G,H and Fig. 2-4). Finally, we confirmed the in vivo cytotoxic potential of BLT mouse-
derived CAR T cells by infusing CD19-specific CAR.BB T cells into recipient mice. We 
observed rapid and profound B cell aplasia in the blood (Fig. 2-3I), as well as in the 
spleen, lung, liver, and bone marrow, consistent with a sustained cytotoxic CAR T cell 
response (Fig. 2-3J,K). Together, these data demonstrate the suitability of BLT mice for 
studying in vivo CAR T cell function, and the degree to which costimulation can 
modulate CAR T cell activity. 
 
CAR.BB T cells fail to control HIV rebound upon ART discontinuation 
After determining that the 4-1BB/CD3- endodomain confers superior in vivo 
antigen-driven CAR T cell expansion and persistence, we sought to test the therapeutic 
potential of CAR.BB T cells in the context of ART-suppressed HIV infection. To do so, 
we infected BLT mice with CCR5-tropic HIVJRCSF and after 3 weeks initiated ART. Two 
weeks later ART-suppressed mice were allocated into groups that received an infusion 
of either CAR.BB T cells (G1 and G3), or inactive control CAR.BB T cells (G2 and 
G4), which express a truncated CD3- chain. In G1 and G2, ART was ceased 
immediately after infusion, whereas in G3 and G4 ART was continued for an additional 3 
weeks to test whether the timing of ART interruption impacted the efficacy of CAR T cell 
therapy. In all groups, HIV rebounded by 2 weeks after treatment interruption, regardless 
of timing, and there were no observable differences in the kinetics or magnitude of 
viremia in CAR.BB-treated mice compared to matched control mice (Fig. 2-5A). 
Moreover, CAR.BB T cell therapy did not prevent memory CD4+ T cell loss in peripheral 
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blood or tissues (Fig. 2-5B,C and Fig. 2-6), which in BLT mice represent the CD4+ T cell 
subset preferentially infected and depleted by HIV due to high levels of CCR5 
expression (Fig. 2-7). Together, these data indicate that CAR.BB T cell therapy did not 
impact HIV progression. 
 
CAR.BB T cells display features of T cell exhaustion during uncontrolled HIV 
replication 
Despite the lack of efficacy following ART discontinuation, we observed profound 
CAR.BB T cell expansion during viral recrudescence with a median 75-fold increase in 
the blood (Fig. 2-5D,E). As expected, the control T cells did not expand in response to 
viral rebound (Fig. 2-5D,E), and the CAR.BB T cells were substantially more abundant 
throughout the body 12 weeks after infusion (Fig. 2-5F). These findings suggested that 
the inability of CAR.BB T cells to control viremia and HIV pathogenesis was not the 
result of poor proliferation, persistence, or lack of migration to relevant anatomical 
compartments of virus replication.70-72 
 The proliferation of CAR.BB T cells was associated with upregulation of 
inhibitory receptors including PD-1, TIGIT, and 2B4, which increased over time (Fig. 2-
5G and Fig. 2-8A-D). Importantly, these inhibitory receptors were not expressed to the 
same extent on endogenous CAR- T cells within the same mice, suggesting a CAR T 
cell-specific effect rather than generalized activation from inflammation or viral load (Fig. 
2-8E,F). Notably, elevated inhibitory receptor expression on CAR.BB T cells from 
chronically infected mice was associated with the expression of TOX (Fig. 2-5H,I), a 
transcription factor that regulates the T cell exhaustion program.73-77 Further supporting 
the gradual emergence of a dysfunctional CAR T cell phenotype, T-bet expression in 
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CAR.BB T cells waned as HIV infection progressed culminating in a population of 
EomeshiT-betdim CAR T cells that were enriched in TOX expression and accumulated in 
tissues with higher viral burden (Fig. 2-5J,K and Fig. 2-9). In addition, expression of 
multiple inhibitory receptors on CAR.BB T cells from chronic infection was linked to a 
transitional memory state that also displayed an EomeshiT-betdim phenotype (Fig. 2-5L), 
all of which is congruent with prior studies identifying dysfunctional HIV-specific CD8+ T 
cells within this compartment in chronic human HIV infection.11,78  
 Finally, we compared the ex vivo functions of CAR.BB T cells isolated during 
chronic infection to the pre-infusion CAR T cell product (TCP). Although the CD8+ 
CAR.BB T cells from chronic infection retained the ability to upregulate MIP-1 and 
granzyme B, and degranulate based on CD107a expression, the degree of -chemokine 
production and cytotoxic potential was attenuated (Fig. 2-10). Taken together, these 
data indicate that CAR.BB T cells recognize HIV-infected cells, rapidly expand and 
upregulate markers of cellular activation, but that uncontrolled virus replication ultimately 
drives an exhaustion program that may diminish T cell function and subvert efficacy. 
 
Augmented HIV-specific CAR T cell product reduces CD4+ T cell loss during acute 
infection 
We hypothesized that combining the superior in vivo expansion and persistence 
of CAR.BB T cells with enhanced effector function could provide the necessary 
improvement to control HIV replication. To this end, we co-transduced CAR.BB T cells 
with the CD4-based, CD28-costimulated CAR that exhibited notable effector function 
(Fig. 2-4) to create a novel Dual-CAR T cell product (TCP). Due to co-transduction 
probabilities, the Dual-CAR TCP comprises three populations: CAR.BB, CAR.28 and 
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Dual-CAR T cells, the latter of which simultaneously expresses both CD4-based CARs 
(Fig. 2-11A). Inclusion of the CD28-costimulated CAR increased in vitro cytokine 
production of Dual-CAR T cells over CAR.BB T cells (Fig. 2-12). To evaluate the Dual-
CAR TCP in vivo, we used an acute infection model in which mice received CAR T cells 
48 hours after HIVJRCSF challenge to provide a more rapid model to test therapeutic 
efficacy. Although we observed no differences in acute viremia between the Dual-CAR 
TCP-treated and untreated groups (Fig. 2-11B), CAR T cell-treated mice exhibited a 
significant, albeit transient delay in the loss of peripheral memory CD4+ T cells (CAR-), 
which coincided with peak expansion of total CAR T cells in peripheral blood (Fig. 2-
11B,C and Fig. 2-13A), Notably, this delay in CD4+ T cell loss was observed in central, 
transitional, and effector memory subsets (Fig. 2-13B), an effect that was not observed 
after ART discontinuation in the CAR.BB-treated mice in the prior study (Fig. 2-11B,C).  
 We next assessed the efficacy of the Dual-CAR TCP in the context of a more 
physiologically relevant strain of HIV. To do so, we infected additional mice from the 
same cohort as above with HIVMJ4, which exhibits slower acute phase replication kinetics 
than HIVJRCSF, but ultimately achieves equivalent set-point viremia (Fig. 2-14). Although 
the infusion of CAR T cells 48 hours post-infection, again, did not alter viremia (Fig. 2-
11D), we now observed more profound CD4+ T cell preservation and maintenance of the 
Dual-CAR TCP in peripheral blood as compared to the CAR T cell-treated mice infected 
with HIVJRCSF (Fig. 2-11E,F and Fig. 2-15A). The preservation of CD4+ T cells was 
particularly accentuated in transitional and effector memory populations, which express 
greater levels of CCR5 (Fig. 2-15B). Similarly, the percentage of all memory CD4+ T cell 
subsets in the tissues at necropsy were substantially preserved in Dual-CAR TCP-
treated compared to untreated HIVMJ4-infected mice (Fig. 2-11F and Fig. 2-15C), 
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whereas there was no difference between CAR T cell-treated and control HIVJRCSF-
infected mice (Fig. 2-11F and Fig. 2-13C). Thus, treatment with the Dual-CAR TCP can 
effectively limit HIV-induced depletion of memory CD4+ T cells, an effect that is 
modulated by the pathogenicity of the infecting virus.   
 
Dual-CAR T cells exhibit vigorous in vivo proliferation in a competitive 
environment 
The linkage of each CAR to a unique fluorescent protein allowed for independent 
quantification of each CAR T cell type within the Dual-CAR TCP and revealed increased 
in vivo expansion of Dual-CAR T cells relative to either of the single costimulatory 
domain-expressing CAR T cells (Fig. 2-11G). Notably, significant differences were 
observed in the peak expansion and cumulative proliferation of Dual-CAR T cells (Fig. 2-
11H,I), which remained significant after correcting for the baseline absolute count of 
each population (Fig. 2-16A). In addition, we compared the proliferative capacity of 
Dual-CAR T cells to 3rd-generation (3G) CAR T cells, which express CD28 and 4-1BB 
linearly in the same construct (Fig. 2-16B). Here, we combined an equal amount of 
Dual-CAR and 3G-CAR T cells prior to adoptive transfer into recipient mice (Fig. 2-16C). 
After infusion, Dual-CAR T cells showed significantly greater antigen-independent 
engraftment (Fig. 2-16D), and also demonstrated superior antigen-driven proliferation 
after infusion of K.Env cells (Fig. 2-16E). In contrast, 3G-CAR T cells marginally 
expanded and then progressively declined. Notably, during HIVMJ4 infection, Dual-CAR T 
cells exhibited profound proliferation (Fig. 2-11J,K) and long-term survival (Fig. 2-
11L,M) relative to 3G-CAR T cells within the same mice. Together, these studies reveal 
the striking proliferative capacity exhibited by Dual-CAR T cells in a competitive setting 




Engineering HIV-resistance augments CAR T cell persistence and function 
Despite the CD4-based CAR’s ability to more efficiently suppress in vitro HIV 
replication versus several HIV-specific antibody-based CARs,40 and the reduced 
likelihood for viral escape due to the requirement for HIV to bind CD4 for infection, this 
CAR results in the over-expression of the CD4 extracellular domain on the T cell surface 
potentially increasing susceptibility to infection. Indeed, HIV-infected CAR T cells were 
detected in vivo, although the extent of total infection appeared to be indistinguishable 
from endogenous CAR- T cells (Fig. 2-17A,B). More importantly, ex vivo stimulation 
revealed functional deficits in the capacity of HIV-infected CAR T cells to co-upregulate 
granzyme B and perforin (Fig. 2-17C,D). To confer HIV resistance, we co-transduced 
the Dual-CAR TCP with the surface-expressed HIV fusion inhibitor C34-CXCR479 (Fig. 
2-18A and Fig. 2-19A). C34-CXCR4 was expressed on up to 50% of cells in the Dual-
CAR TCP and provided protective benefit as the C34-CXCR4+ CAR T cells harbored 
significantly less HIV DNA than their unprotected counterparts (Fig. 2-18B), and were 
selected for over time in chronically infected mice (Fig. 2-20A,B). Importantly, C34-
CXCR4+ CAR T cells from chronic infection had markedly improved cytotoxic potential 
and MIP-1 expression relative to unprotected CAR T cells within the same mice (Fig. 2-
20C,D). Somewhat paradoxically, however, infusion of a Dual-CAR TCP where 50% of 
all cells were HIV-resistant was still insufficient to reduce acute virus replication (Fig. 2-
19B). These results demonstrate that CD4-based CAR T cells can be protected from 
HIV infection by the C34-CXCR4 fusion inhibitor and that such protection can preserve 




HIV-resistant Dual-CAR T cells are responsible for mitigating HIV-induced CD4+ T 
cell loss 
To determine whether an infusion product of Dual-CAR T cells alone exhibits 
enhanced virus-specific responses during HIV infection, we infused a low dose of C34-
CXCR4+, purified Dual-CAR T cells, CAR.BB, or CAR.28 T cells into separate groups 
of HIVMJ4-infected mice. Dual-CAR T cells exhibited notable in vivo expansion kinetics 
that exceeded both single CAR-transduced T cell populations (Fig. 2-18C,D), and 
mitigated HIV-induced CCR5+ CD4+ T cell loss (Fig. 2-21). However, to more stringently 
control for CAR surface expression we performed an additional study in another cohort 
of mice where HIV-resistant, purified Dual-CAR T cells were compared to HIV-resistant, 
purified CAR T cells transduced with two independent CAR.BB or CAR.28 constructs 
(Fig. 2-22). Dual-CAR T cells again demonstrated remarkable sensitivity to acute virus 
replication expanding 300-fold to represent 30% of total human cells in blood 3 weeks 
post-infection, whereas CAR.BB.BB and CAR.28.28 T cells reached only 3% and 
1%, respectively (Fig. 2-18E and Fig. 2-23A). In addition, Dual-CAR T cells sustained 
greater long-term proliferation and maintenance in blood and tissues than CAR.28.28 
or CAR.BB.BB T cells (Fig. 2-18F,G and Fig. 2-23B). Importantly, the infusion of 
purified Dual-CAR T cells resulted in the greatest protection against CD4+ T cell loss 
during HIVMJ4 infection (Fig. 2-18H-J), reflected in the preservation of total memory and 
CCR5+ CD4+ T cells especially late in the infection (Fig. 2-23C,D). Furthermore, the 
magnitude of early CAR T cell expansion across all groups, but exemplified by Dual-
CAR T cells, was positively correlated with CD4+ T cell preservation (Fig. 2-23E). 
Together, these data indicate that after controlling for CAR surface expression, Dual-




Ex vivo effector function of Dual-CAR T cells exceeds 4-1BB-costimulated CAR T 
cells 
We next interrogated the ex vivo effector functions of CAR T cells from 
chronically infected mice. Dual-CAR T cells were superior to CAR.BB.BB T cells and 
equivalent to CAR.28.28 T cells in their ability to produce MIP-1 and degranulate 
based on CD107a expression (Fig. 2-18K,L). Notably, a majority of CD107a+ Dual-CAR 
T cells co-expressed granzyme B and perforin compared to CAR.BB.BB T cells, 
indicating these cells possess cytotoxic potential (Fig. 2-18M,N). In further support of 
cytolytic function, CAR T cells comprising the Dual-CAR TCP induced active caspase-3 
expression in K.Env cells after ex vivo stimulation (Fig. 2-24). Moreover, comparison of 
IL-2, TNF, MIP-1 and CD107a expression revealed distinct effector profiles between 
these CAR T cell populations (Fig. 2-25A,B). Dual-CAR and CD28-costimulated CAR T 
cells clustered in a similar fashion, with CD4+ CAR T cells expressing more TNF and IL-
2, and CD8+ CAR T cells upregulating more CD107a and MIP-1. In contrast, CD4+ and 
CD8+ 4-1BB-costimulated CAR T cells clustered together and exhibited attenuated 
levels of effector molecules (Fig. 2-25C). Together, these findings support our 
hypothesis that Dual-CAR T cells harness both the antigen-driven proliferation and 
effector functions mediated by 4-1BB- and CD28-costimulation, respectively, for 
improved potency.  
 
Protecting CAR T cells from HIV infection improves control over virus replication 
We hypothesized that the contribution of HIV-infected CAR T cells to viremia may 
be significant, in that virus secreted from infected CAR T cells could mask reductions in 
23 
 
viral load caused by clearing infected CD4+ T cells. Indeed, after aggregating the data 
from all infection studies, we observed that infusion of HIV susceptible CAR T cells 
significantly magnifies plasma viremia (Fig. 2-27A), as well as viral burden in tissues 
(Fig. 2-28A,B). Thus, to test whether HIV infection of CD4-based CAR T cells negates 
CAR T cell-mediated reductions in viremia, we compared the outcomes of infusing a 
fully-protected (>98% C34-CXCR4+) or a partially-protected (<20% C34-CXCR4+) Dual-
CAR TCP into HIVMJ4-infected, ART-suppressed mice followed by ART cessation. 
Strikingly, infusion of the partially-protected Dual-CAR TCP increased rebound viremia 
over untreated mice to an average peak rebound of 4.6 log HIV RNA copies/mL versus 
3.8 log copies/mL, whereas the fully-protected Dual-CAR TCP significantly reduced viral 
load to 3.0 log copies/mL (Fig. 2-28C). We confirmed this result by infusing the fully-
protected, Dual-CAR TCP into a larger cohort of BLT mice and observed significant 
reductions in acute viremia compared to untreated mice (Fig. 2-27B). Notably, treatment 
with the C34-CXCR4+ Dual-CAR TCP reduced the frequency of HIV-infected cells in 
tissues (Fig. 2-27C,D), contrasting the effect of unprotected CAR T cells on tissue viral 
burden in viremic mice (Figure 2-28A,B). Together, these data demonstrate the 
importance of safeguarding CAR T cells as HIV infection of unprotected CAR T cells can 
contribute to plasma viremia and potentially overwhelm CAR T cell-mediated control 
over virus replication. 
 Although C34-CXCR4 reduces HIV infection of CAR T cells, we have shown that 
the protection is not sterilizing in the presence of persistent viremia (Fig. 2-18B). To test 
whether providing ART to prevent new rounds of infection at the time of CAR T cell 
infusion could further reveal CAR T cell-mediated viral load reduction we challenged 
mice with HIVJRCSF and initiated combination therapy (ART and Dual-CAR TCP) at peak 
viremia. After one week of combination therapy, the Dual-CAR TCP-treated mice 
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achieved approximately a 1-log greater reduction in viral load relative to the ART only 
control group, which corresponded to a 50% reduction in viremia from pre-treatment 
levels (Fig 2-26E,F). We confirmed the suppressive effect of the Dual-CAR TCP in a 
separate cohort of mice infected with a different HIV strain (HIVBAL) (Fig. 2-28D,E). 
Aggregation of the data from the two studies showed that the magnitude of early viral 
load reduction was associated with the contemporaneous concentration of CAR T cells 
in peripheral blood (Fig. 2-26G), and that CAR T cell treatment significantly accelerated 
HIV suppression, with nearly all combination therapy-treated mice reaching full 
suppression by 2 weeks after treatment initiation versus 4 weeks for ART-treated control 
mice (Fig. 2-26H). Furthermore, the Dual-CAR TCP reduced tissue viral burden in mice 
with suppressed plasma viremia, evidenced by fewer HIV-infected CD8- T cells (CAR-) 
and CD14+ macrophages in the tissues (Fig. 2-26I,J). Notably, central memory CD4+ T 
cells (CAR-) sorted from mice treated with the Dual-CAR TCP exhibited a significant, 
albeit modest, reduction in cell-associated HIV DNA load compared to the control group 
(Fig. 2-26K), suggesting that CAR T cell therapy is capable of reducing the size of the 
virus reservoir that forms during ART. Together, these findings highlight the potential for 




Here, we use the BLT humanized mouse model to iteratively develop a novel 
CD4-based CAR T cell treatment of HIV infection. Although initially, 4-1BB-costimulated 
CAR T cells demonstrated marked in vivo antigen-driven proliferation and survival, they 
failed to control viremia after ART cessation. In order to increase effector function, we 
created a novel Dual-CAR T cell that simultaneously expresses two CD4-based CARs 
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independently encoding 4-1BB/CD3- and CD28/CD3- endodomains. These Dual-CAR 
T cells exhibited both the cytotoxic potential and cytokine expression of CD28-
costimulated CAR T cells and the proliferative capacity of 4-1BB-costimulated CAR T 
cells, suggesting concurrent contribution by both costimulatory signals. In contrast, 3rd-
generation (3G) CD4-based CAR T cells exhibited the more limited expansion of 
CAR.28 T cells despite containing a 4-1BB costimulatory domain within the same 
construct, likely the result of a dominant effect of the membrane proximal CD28 domain 
as described for 3G cancer-specific CAR T cells.80-83 This novel Dual-CAR approach 
introduces the potential to produce a CAR T cell with the benefits of both 4-1BB and 
CD28 costimulation. 
The immunodeficiency caused by HIV infection is characterized by infection of 
CD4 T cells and concomitant immune activation and dysfunction.84 Importantly, the rapid 
antigen-driven proliferation of CAR T cells makes them susceptible to these same 
pathogenic mechanisms. In particular, the CD4-based CAR’s extracellular domain 
renders both CD4+ and CD8+ CAR T cells infectable, resulting in a substantial 
contribution to plasma viremia, as well as functional deficits. To combat this, we co-
expressed a C34-CXCR479 fusion inhibitor, which significantly improved CAR T cell 
survival and effector function during early HIV infection. Notably, the HIV-resistant Dual-
CAR T cell treatment also resulted in a reduction in HIV burden in a variety of tissues 
and cell types, including long-lived memory CD4+ T cells, which suggests for the first 
time that a CAR T cell therapy targeted the HIV reservoir. However, the benefit of C34-
CXCR4 waned over time, which highlights the need to confer complete and permanent 
HIV resistance, perhaps through the deletion of CCR5.85-88     
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 The HIV-resistant Dual-CAR T cell treatment resulted in substantial protection of 
memory and CCR5+ CD4+ T cells from HIV-induced depletion despite failing to durably 
control viremia. Interestingly, the degree of protection was associated with the viral 
replication capacity (vRC) of the infecting strain. This is consistent with prior findings that 
vRC affects many aspects of HIV-associated pathogenesis, including the kinetics of 
CD4+ T cell loss in acute infection.89 Since the vRC of transmitted/founder viruses can 
vary by orders of magnitude across infected individuals,90-92 vRC may become an 
important clinical consideration for the efficacy of CAR T cell treatment of HIV. 
The HIV/BLT mouse model recapitulates key characteristics of HIV infection that 
are necessary to explore the efficacy of HIV-specific CAR T cell therapy. This small 
animal model may actually provide an overtly stringent test of CAR T cell efficacy given 
the general inability of BLT mice to develop affinity-matured antibodies,93-95 We have 
used this model to develop a Dual-CAR T cell that successfully exhibits the 
functionalities mediated by both CD28 and 4-1BB costimulation, and was capable of 
reducing viremia, limiting HIV-induced CD4+ T cell loss, and diminishing viral tissue 
burden in the context of a fully disseminated infection. Collectively, these findings 
provide critical insight into the iterative development of an engineered T cell-based 
therapy for HIV and describe a novel product that not only mitigates HIV pathogenesis 
but also has broad utility for viral infections and malignancies. 
 
Materials and Methods 
 
Ethics: 
Anonymized human fetal tissue (17-19 weeks of gestational age) was acquired 
with informed consent from healthy donors by Advanced Bioscience Resources (ABR, 
Alameda, CA), and used under Partners Healthcare Institutional Review Board-
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approved protocols. Humanized mouse experiments performed at the Ragon Institute 
and at UPenn were approved by the Massachusetts General Hospital and UPenn 
Institutional Animal Care and Use Committee under the approved protocol 
2016N000483 and 805606, respectively. Animal studies were performed following the 
instructions detailed in the Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health. Purified CD3+ and CD4+ T cells from anonymous healthy 
human donors were obtained by the UPenn Human Immunology Core/CFAR 
Immunology Core. 
 
Humanized mice:  
Male and female NOD/SCID/IL2R-/- (NSG) mice (Jackson Laboratory) were 
maintained in pathogen-free facilities at the Ragon Institute of MGH, MIT and Harvard or 
the University of Pennsylvania. Microisolator cages were used to house mice and were 
fed autoclaved food and water. Animal rooms were maintained at 72 ± 2 °F (22.2 ± 1.1 
°C) and 30% to 70% relative humidity and were on a 12:12-hour light:dark cycle. BLT 
humanized mice were generated at the Ragon Institute as previously described68,96,97. 
Briefly, 6-8-week-old NSG mice were anesthetized, whole-body irradiated (2 Gy), 
followed by implantation with 1 mm3 fragments of human fetal liver and thymus tissue 
under the murine kidney capsule. Following, 105 autologous fetal liver-derived CD34+ 
hematopoietic stem cells were injected intravenously (IV) within 6 hours of 
transplantation. BLT humanized mice were also generated at the UPenn as previously 
described98. Briefly, 1-1.5x105 human fetal liver-derived CD34+ HSCs were administered 
IV into 7 to 10-week old NSG mice 24 hours after busulfan (30 mg kg-1) conditioning. 3 to 
6 days following stem cell transplant, mice were surgically implanted with 3 to 5 
fragments of autologous human fetal thymus tissue measuring 3 to 5 mm3 under the 
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murine kidney capsule. For all BLT humanized mice, human immune reconstitution was 
assessed from 12 to 17 weeks after transplantation. Mice were included in experiments 
when over 50% of cells in the lymphocyte gate were positive for human CD45 and, of 
those human cells, greater than 40% were CD3+ T cells.  
 
Flow Cytometry and Cell Sorting:  
Washed cells were resuspended in 50 L PBS containing 2mM EDTA and 2% 
fetal calf serum, and then surface stained with anti-human antibodies from BioLegend: 
CD45 (HI30 and 2D1), CD19 (HIB19), CD3 (OKT3), , CD45RA (HI100), CD27 
(LG.3A10), CD8 (RPA-T8), CCR7 (G043H7), CCR5 (J418F1), CD4 (OKT4), CD271 
(ME20.4), PD-1 (EH12.2H7), TIGIT (VSTM3), 2B4 (C1.7), CD107a (H4A3); BD 
Biosciences: CD45 (HI30), CD3 (UCHT1), CD8 (SK1), CD45RA (HI100), CCR7 (3D12); 
and R&D: Human EGFR (Cetuximab Biosimilar, Hu1). Live cells were identified through 
staining negative for Fixable Viability Dye eFlour 780 (eBioscience) or LIVE/DEAD 
Fixable Blue (Invitrogen). For the detection of intracellular proteins, the cells were 
treated with Cell Fixation & Cell Permeabilization Kit (Invitrogen) or True-Nuclear 
Transcription Factor Buffer Set (BioLegend) in accordance with the manufacture’s 
protocol with antibodies from: BioLegend: IL-2 (MQH-17H12), Perforin (B-D48); BD 
Biosciences: TNF (Mab11), IFN- (4S.B3), Granzyme B (GB11), MIP-1 (D21-1351), 
GM-CSF (BVD2-21C11), Active Caspase-3 (C92605); Beckman Coulter: HIV-1 Core 
Antigen (KC57); eBioscience: T-bet (4B10), EOMES (WD1928), TOX (TXRX10). Flow 
cytometry data were acquired on a BD LSR II, BD LSRFortessa, and BD FACS 
Symphony instruments using BD FACSDiva Software version 8.0.1 (BD Biosciences). 
Data were analyzed using FlowJo software version 10 (TreeStar). Sorting of C34-
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CXCR+ and C34-CXCR4- CAR T cells for quantitation of viral burden by digital-droplet 
PCR was performed by sorting live C34-CXCR4+ and C34-CXCR4- CAR T cells from 
splenocytes after surface staining with the following Biolegend antibodies: CD45 (2D1), 
CD3 (OKT3), CD8 (RPA-T8), CD4 (OKT4). Living CAR T cells were identified by staining 
negative for Fixable Viability Dye eFlour 780 (Fig. 2-29A). Sorting  of endogenous 
central memory CD4+ T cell populations for quantitation of viral burden by droplet-digital 
PCR was performed by staining splenocytes with the following antibodies from 
BioLegend: anti-mouse CD45 (30-F11), anti-human CD45 (HI30), CD20 (2H7), CD14 
(HCD14), CD56 (HCD56), CD3 (OKT3), CD4 (RPA-T4), CD8 (SK1), CCR7 (G043H7), 
CD45RA (HI100). Live cells were discriminated using LIVE/DEAD Fixable Blue 
(Invitrogen). FACSAria II (BD Biosciences) was used for all cell sorting (Fig. 2-29B). A 
complete list of antibodies used including additional technical information for flow 
cytometry experiments can be found in the Life Sciences Reporting Summary. 
 
HIV inoculum preparation: 
Viral stocks of the molecular clones, HIVJRCSF and HIVMJ4, were generated 
through transfections of HEK293T cells (ATCC: CRL-3216) and tittered as previously 
described99. HIVBAL virus stocks were generated by passage in anti-CD3/CD28 
Dynabead stimulated human CD4+ T cells as previously described40.  
 
Viral (HIV) load quantification:  
Peripheral blood plasma-derived HIV RNA was isolated using the QiaAmp Viral 
RNA Mini Kit (Qiagen). Quantitative RT-PCR using the QuantiFast Syber Green RT-
PCR kit (Qiagen) was used as previously described to measure viral loads99. Data was 
collected on a LightCycler 480 Sysytem (Roche) or a ViiA 7 real-time PCR system 
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(Applied Biosystems) using Lightcycler 480 software release 1.5.1.62 SP3 or Viia 7 
QuantStudio Real-time PCR Software v1.3, respectively.  
 
Plasmid construction:  
Amino acid sequences specific to the CD4-based CAR constructs containing the 
intracellular signaling domains: CD3-, 4-1BB/CD3-  and CD28/CD3-  are described 
elsewhere40. Each CAR was amplified from their parent plasmid with 5’- 
CACGTCCTAGGATGGCCTTACCAGTG and 5’- 
GTGGTCGACTTATGCGCTCCTGCTGAAC and inserted into the AvrII and SalI 
restriction enzyme sites of the pTRPE transfer plasmid downstream of GFP, mCherry or 
iRFP670, and an intervening T2A linker permits expression of both proteins. To 
construct the plasmids for CAR T cell selection, double-stranded DNA fragments (IDT) 
encoding NGFR (CD271)100 and truncated EGFR101 were custom synthesized, flanked 
with suitable restriction enzyme sites and cloned into the second position of the pTRPE 
plasmid preceded by the CAR-BB and CAR-28 gene and T2A linker. The C34-CXCR4 
construct’s sequence is denoted elsewhere79. We A previously described102 Asp 
mutation (D97N) in CXCR4 was introduced to impair SDF-1 binding and limit receptor 
internalization.    
 
Lentivirus production and transfection: 
Lentiviral particles were generated using packaging expression vectors that 
encode VSV or Cocal glycoprotein, HIV Rev, and HIV Gag/Pol (pTRPE pVSV-g, pCocal-
g, pTRPE.Rev, and pTRPE g/p, respectively), and synthesized using DNA 2.0 or ATUM 
(Newark, CA). The packaging plasmids along with the appropriate pTRPE transfer 
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vector were transfected into HEK293T using Lipofectamine 2000 (Life 
Technologies)40,103. At 24 and 48 hours after transfection, the HEK293T cell supernatant 
was harvested, filtered through a 0.45 m syringe-driven filter, and then concentrated by 
ultracentrifugation for 2.5 hours at 25,000 rpm at 4°C. The supernatant was aspirated 
and the virus pellet was resuspend in 800 L of complete RPMI and stored at -80°C. 
 
Cell Culture:  
For preparation of CAR T cells: de-identified human donor T cells were isolated 
by negative selection with RosetteSep Human CD3+ Enrichment Cocktails (Stem-Cell 
Technologies) following manufacturer’s protocol. T cells from BLT humanized mice were 
purified by processing spleen, bone marrow, and liver tissues into a single-cell 
suspension. Density gradient centrifugation using Lymphoprep (Stem-Cell Technologies) 
was used to isolate Mononuclear cells. Human CD2+ cells were purified by CD2 
Microbeads (Miltenyi Biotec) per the manufacturer’s protocol. T cells were placed in 
culture at 106 cells mL-1 in either complete RPMI: RPMI 1640, 1% Penicillin-
Streptomycin, 2mM GlutaMax and 25mM HEPES buffer from Life Technologies, and 
10% fetal calf serum (Seradigm), or CTS OpTmizer T-Cell Expansion SFM (Gibco) with 
1% Penicillin-Streptomycin, 2mM GlutaMax and 25mM HEPES buffer. T cell expansion 
medium was complemented with human IL-15 (5 ng mL-1, Biolegend) and IL-7 (10 ng 
mL-1, R&D). T cells were stimulated at a 3:1 (bead to cell) ratio with anti-
CD3/CD28Dynabeads (Life Technologies), and incubated at 37°C, 5% CO2 and 95% 
humidity. 18 hours after stimulation the medium was reduced by and replaced with 300 
L of the appropriate lentivirus supernatant for CAR transduction. 5 days after T cell 
activation, magnetic separation was used to remove Dynabeads. Throughout CAR T cell 
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manufacturing medium was changed every second day, which spanned 8 to 10 days, or 
as needed to adjust cell counts to 0.5x106 cells mL-1. 
 Two-step immunomagnetic selection of CAR T cells during manufacturing: On 
day 4 after initial T cell activation, anti-CD3/CD28 Dynabeads were removed by 
magnetic bead separation. T cells were counted and then incubated at a 1:2 cell-to-bead 
ratio with CELLection Biotin Binder Dynabeads (Life Technologies) conjugated to anti-
EGFR (Cetuximab) antibody.  Truncated EGFR+ T cells were isolated according to the 
manufacturer’s protocol. The cell concentration was adjusted to 0.5x106 cells mL-1 with 
medium and expanded as described above. 7 days after initial activation, EGFRt+ T cells 
were counted and incubated with CD271 Microbeads (Miltenyi Biotec) to positively select 
for NGFR+ T cells according to the manufacturer’s instructions. The eluted fraction of T 
cells contained 85% to 95% EGFR+NGFR+ T cells. Prior to infusion into BLT mice the T 
cells were cultured for an additional day at the adjusted cell concentration. 
 
HIV treatment and ART discontinuation mouse model: 
BLT humanized mice were administered 2 mg of medroxyprogesterone 
(McKesson) subcutaneously 1 week prior to intravaginal challenge with 20,000 TCID50 
HIVJRCSF in 20 L total volume. 75 to 100 L of blood was obtained through puncture of 
the retro-orbital sinus weekly to quantify viral load and immunophenotype circulating 
blood cells. 3 weeks post-HIV challenge all infected mice were administered daily IP 
injections of antiretroviral therapy (ART) consisting of 10 mg kg-1 EFdA (4′-ethynyl-2-
fluoro-2′-deoxyadenosine, LeadGen Labs) and 50 mg kg-1 Dolutegravir (Sigma) for 1 
week and then every second day thereafter. Following 2 weeks of ART, four treatment 
groups were defined based on normalization of plasma viral load, body weight, and 
human reconstitution percentages. Group 1 (G1; n=6) and group 3 (G3; n=10) are 
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treatment groups that were infused with 107 CAR-BB T cells, while group 2 (G2; n=6) 
and group 4 (G4; n=9) are control groups that were infused with 107 CAR-BB T cells 
that express a defective CD3- endodomain. T cells were administered in a 300 L 
volume via tail vein injection. ART was interrupted immediately after adoptive T cell 
transfer for G1 and G2, while ART discontinuation was delayed for 3 weeks in G3 and 
G4. At necropsy, 17 weeks after HIV challenge, various tissues were collected to 
analyze the CAR T cells. 
BLT humanized mice were infected via the intraperitoneal (IP) route with 20,000 
TCID50 HIVMJ4. At 3 weeks post-infection, all mice received ART and either an HIV-
resistant (<20% C34-CXCR4+) Dual-CAR T cell product (n=7), an HIV-resistant Dual-
CAR T cell product with further magnetic bead selection to obtain a >98% C34-CXCR4+ 
transfer product (n=5), or no CAR T cells (n=9). After plasma viremia was fully 
suppressed in all 3 groups, ART was discontinued and virus rebound was monitored via 
weekly blood draws from the retro-orbital sinus. 
 
Acute HIV infection treatment model: 
BLT humanized mice were challenged with 20,000 TCID50 HIVJRCSF or HIVMJ4 via 
IP injection. For the study comparing the replication capacity of HIVJRCSF and HIVMJ4: 
HIVJRCSF-infected mice (n=6) and HIVMJ4-infected mice (n=6) were infused with the Dual-
CAR T cell product consisting of 2x107 total CAR T cells. T cells were administered via 
tail vein injection 48 hours after HIV challenge. Control mice that were infected with 
HIVJRCSF (n=5) or HIVMJ4 (n=6) received no T cells. For the study comparing Dual-CAR T 
cells and 3rd-generation (3G) CD4-based CAR T cells: Dual-CAR TCP was combined 
with 3G-CAR T cells, normalizing the frequency of Dual-CAR and 3G-CAR T cells prior 
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to infusion into mice. 9 HIV-uninfected mice were infused with this mixture, where each 
mouse received 2.5x106 Dual-CAR T cells and 2.5x106 3G-CAR T cells via tail vein 
injection. After 2 weeks, 6 mice were infused via IV injection with 107 irradiated K.Env 
cells and 3 mice received 107 irradiated K.WT cells. Additional mice (n=6) were 
challenged with 20,000 TCID50 HIVMJ4 and infused 48 hours later with same Dual-CAR 
TCP/3G-CAR T cell mixture described above.  
HIVMJ4-infected mice were allocated into 4 groups. The groups were infused with 
106 C34-CXCR4+, CAR.BB  (n=6), CAR.28  (n=5), or purified Dual-CAR (n=4) T cells, 
while the remaining mice were untreated (n=6). For the study comparing purified Dual-
CAR and double CAR-transduced BB.BB and 28.28 T cell populations: HIVMJ4-
infected mice were distributed into 4 groups and normalized based upon body weight 
and the absolute count of CD4+ T cells in blood. The groups were infused with 106 C34-
CXCR4+, purified CAR.BB.BB (n=5), CAR.28.28 (n=5) or Dual-CAR (n=5) T cells via 
tail vein injection 48 hours after HIV challenge. Control mice did not receive T cells 
(n=5). For the study evaluating efficacy of enriched C34-CXCR4+ (>98%) Dual-CAR T 
cells. HIVMJ4-infected mice were divided into two groups that received 107 C34-CXCR4-
enriched Dual-CAR T cell product (TCP) (n=12) or were untreated (n=12). In all studies 
mice were bled by retro-orbital puncture 1 day after adoptive T cell transfer, and then 
weekly thereafter until their respective endpoint and tissue collection. 
 
CAR T cell therapy and ART model: 
In the study described in, BLT humanized mice were challenged with 20,000 
TCID50 HIVJRCSF via IP injection. 3 weeks post-HIV challenge all infected mice were given 
low-dose ART consisting of 1 mg kg-1 EFdA and 25 mg kg-1 Dolutegravir every other day 
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by IP injection for 4 weeks. At the time of ART initiation, HIV-infected mice were 
allocated into 3 groups. Treated mice (n=11) were infused with an HIV-resistant (C34-
CXCR4+) Dual-CAR TCP consisting of 107 total CAR T cells. Control mice were infused 
with either 107 total CAR T cells from the HIV-resistant Dual-CAR T cell product which 
expresses defective CD3- signaling domains (n=5) or were untreated (n=7). The mice 
were euthanized and tissues were harvested for analysis 7 weeks post-infection. For the 
study described in, BLT humanized mice were challenged with 20,000 TCID50 HIVBAL via 
IP injection. 3 weeks post-HIV challenge all infected mice were administered ART 
consisting of 10 mg kg-1 EFdA and 25 mg kg-1 Dolutegravir every other day by IP 
injection for 2 weeks. At the time of ART initiation, HIV-infected mice were distributed 
into 2 groups. Treated mice (n=6) were infused with an HIV-resistant (C34-CXCR4+) 
Dual-CAR TCP comprising of 107 total CAR T cells, or untreated (n=6).  
 
C34-CXCR4 protection of CAR T cells in vivo: 
BLT humanized mice were challenged with 20,000 TCID50 HIVJRCSF via IP 
injection. 48 hours after challenge, mice received the HIV-resistant (C34-CXCR4+) Dual-
CAR TCP consisting of 2x107 total CAR T cells. In one-week intervals after challenge, 
mice were euthanized and tissues were collected at necropsy. Splenocytes were 
prepared and freshly sorted; isolated cells were used to quantify the amount of cell-
associated HIV DNA harbored within C34-CXCR4+ and C34-CXCR4- CAR T cells. 
 
HIV suppression assay:  
Seven days following initial activation with anti-CD3/CD28 Dynabeads, we 
infected primary CD4+ T cells with CCR5-tropic HIVJRCSF at an MOI of 1. After one day, 
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we washed HIV-challenged CD4+ T cells with complete RPMI supplemented with 100 U 
mL-1 IL-2 and mixed with CAR. or control untransduced (UTD) T cells at effector-to-
target (E:T) ratios of 1:12.5, 1:25, 1:50, 1:100 and 1:200. The E:T ratios reflect the 
number of CAR. T cells to HIV-challenged, CD4+ T cells. Mixtures of cells were plated 
in triplicate and HIV replication was measured by sampling 100 L per well for flow 
cytometric detection and intracellular cytokine staining for HIV-1 Core Antigen at 2, 4 
and 6 days post-coculture. We added fresh media to each well following staining. 
 
HIV-infected cell elimination assay:  
A similar target cell elimination assay was performed as described104. Here, we 
prepared HIV-infected CD4+ T cells as described above. Once 30% of total cells 
positively stained for HIV-1 Core Antigen, cells were membrane labeled using CellTrace 
Violet (CTV) (ThermoFisher) to identify HIV-infected cells from CAR or UTD T cells. For 
characterizing the cytotoxic function of the pre-infusion T cell product, CAR- and UTD T 
cells were cultured with CTV-labelled HIV-infected cells at 0.25:1, 1:1 and 4:1 E:T ratios. 
For ex vivo stimulation, single cell suspensions of bone marrow from HIV-infected mice 
treated with the Dual-CAR T cell product were cultured with CTV-labelled HIV-infected 
target cells at 1:1, 5:1 and 10:1 E:T ratios. HIV-infected cells were assessed for the 
induction of active caspase-3 24 hours later by flow cytometry. Active caspase-3 was 
identified in living CTV+ HIVGAG+ T cells. 
 
Cytotoxicity, CD107a degranulation, and cytokine assays:  
In vitro CAR T cell functionality was assessed following stimulation of 2x105 
CAR- or UTD T cells with 2x105 wild-type K562 cells (K.WT) or K562 cells engineered to 
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express the extracellular and transmembrane regions of HIVYU2 (K.Env). Anti-CD107a 
antibody was included at the beginning of the stimulation followed by 1X Brefeldin A and 
Monensin Solution (BioLegend) an hour later. In total, cells incubated for 6 hours at 
37°C. Cytokine production was measured by flow cytometry and intracellular staining 
with anti-human antibodies specific for IL-2, IFN-, MIP-1, TNF and GM-CSF, while 
cytotoxic potential was measured by staining with antibodies specific for granyzme B 
and perforin. Cytokine-positive CAR T cells were reported as the difference in the 
production of cytokines after stimulation with K.Env and K.WT cells. 
 
Measurement of CAR T cell responses ex vivo:  
Functionality of CAR T cells from HIV-infected BLT humanized mice was 
measured after ex vivo stimulation with K562 target cells. Density gradient centrifugation 
was used to isolate mononuclear cells after preparing a single-cell suspension from 
tissues. Between 0.5–1x106 mononuclear cells were cultured with 2x105 K562.WT or 
K562.Env cells. The assessment of cytotoxic potential, degranulation and cytokine 
production was performed using the same protocol described above. 
 
Cell-associated HIV DNA quantitation: 
Mononuclear cell suspensions obtained from spleens were stained and sorted as 
described above. After sorting, samples were frozen as cell pellets and stored at -80°C. 
To obtain genomic DNA, cell pellets were thawed and total DNA was extracted using the 
QIAamp DNA Mini Kit (QIAGEN) per the manufacturer’s protocol. Total HIV DNA was 
measured in each sample using a multiplexed droplet-digital PCR (ddPCR) assay 
specific for HIV gag and the human RPP30 gene. Gag forward and reverse amplification 
primer sequences were 5’- AGTGGGGGGACATCAAGCAGCCATGCAAAT and 5’-
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TGCTATGTCAGTTCCCCTTGGTTCT-CT, respectively. Gag sequence was detected 
using a 5’ HEX-labeled hydrolysis probe (HEX-
CCATCAATGAGGAAGCTGCAGAATGGGA). RPP30 forward and reverse amplification 
primer sequences were 5’- GATTTGGACCTGCGAGCG and 5’- 
GCGGCTGTCTCCACAAGT, respectively. Human RPP30 sequence was detected with 
a 5’ 6-FAM-labeled hydrolysis probe (6-FAM-CTGACCTGAAGGCTCT). The RPP30 
primer/probe set has been described previously105. ddPCR reactions were performed 
using the manufacturer recommended consumables and the ddPCR supermix for 
probes (No UTP) (Bio-Rad). Thermal cycling conditions are as follows: 1 cycle of 95°C 
for 10 minutes, 45 cycles of 94°C for 30 seconds followed by 60°C for 1 minute, 1 cycle 
of 98C for 10 minutes. Droplets were generated using a QX100 droplet generator and 
subsequently analyzed on a QX200 droplet reader (Bio-Rad) using the QuantaSoft 
version 1.7.4.0917 software (Bio-Rad). All samples were run in duplicate. 
 
Viral replication capacity assay: 
In vitro replication assays were performed essentially as previously described92. 
Human PBMCs were isolated from whole blood by density gradient centrifugation using 
Histopaque-1077 (Sigma). PBMCs were stimulated with 3 g mL-1 PHA in complete 
RPMI (1% Penicillin-Streptomycin, 2mM L-Glutamine, 25mM HEPES buffer, and 10% 
fetal calf serum) supplemented with 20 U mL-1 of recombinant human IL-2 at a 
concentration of 1x106 cells mL-1. After 72 hours of stimulation, PBMCs were washed 
twice with complete RPMI, and resuspended in complete RPMI supplemented with 50 U 
mL-1 IL-2 at a concentration of 5x106 cells mL-1. Cells were infected by combining 1000 
TCID50 HIVJRCSF or HIVMJ4 with 5x105 cells and a final concentration of 5 g mL-1 
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polybrene in 200 L total volume. Cells were infected by spinoculuation at 1200 rpm and 
25°C for 2 hours. Cells were then washed 5 times to remove excess virus, and plated in 
500 L of complete RPMI including 50 U mL-1 IL-2 in a 48-well plate. Infections were 
incubated at 37°C and 5% CO2, and 50 L of media was removed every 2 days and 
frozen. Supernatant Gag p24 levels were measured using the Alliance HIV-1 p24 
antigen ELISA kit per the manufacturer’s instructions (Perkin Elmer). Plates were read 
on a Tecan Infinite 200 Pro plate reader (Tecan Life Sciences) using the Magellan 
software version 7.2. All infections were carried out in triplicate. 
 
Statistical analysis: 
Statistical analyses were performed using JMP Pro, version 14.2.0 (SAS Institute 
Inc.) and Prism, version 7 for PC v7.05 and Prism, version 8 for macOS v8.2.1 
(GraphPad). Spearman’s rank correlation was used to test for all bivariate continuous 
correlations. Wilcoxon rank sum test was conducted to test for all one-way comparison 
of means from unpaired samples, and Wilcoxon matched pairs signed rank test used for 
comparing means of paired samples. Kaplan-Meier survival curves were performed 
using an endpoint defined as the limit of detection of the viral load quantification assay 
(1.81 log RNA copies mL-1), and statistics are generated from the log-rank test. K-means 
clustering was performed using the JMP Pro version 12 statistical package to generate 
principal component plots with circles denoting where 90% of the observations would 
fall. We performed area under the curve calculations in GraphPad Prism version 7 using 










Figure 2-1. BLT-mouse derived HIV-specific CAR T cells are multifunctional in 
vitro. (a) Schematic for the manufacturing of BLT mouse-derived CAR T cells. (b) 
Representative growth kinetics of BLT mouse-derived and adult human PBMC-derived 
CAR. T cells following activation with anti-CD3/CD28 Dynabeads. (c) FACS plots of 
CD4+ CAR. T cells expressing MIP-1, TNF, IL-2 and GM-CSF after in vitro stimulation 
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with HIVYU2 GP160+ K562 cells (K.Env). (d) Quantification of intracellular expression of 
the indicated effector molecules by CD8+ CAR. T cells and (e) CD4+ CAR. T cells. 
Data shows expression of each molecule from 3 distinct donors per source. (f) 
Schematic of gating strategy used to identify active caspase-3+ HIVGAG+ target cells for 
analysis of HIV elimination assay. (g) FACS plots and (h) cumulative data demonstrating 
the coordinated upregulation of granzyme B and perforin in BLT mouse-derived and 
human donor-derived CAR. T cells following in vitro stimulation with K.Env (stim) or 
K.WT (unstim) cells. Data shows expression from 3 distinct donors per source. For data 















Figure 2-2. BLT mouse-derived HIV-specific CAR T cells are functionally 
indistinguishable from human-derived CAR T cells in vitro. CD3/CD28 Dynabeads 
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were used to activate purified human T cells from a BLT mouse and healthy human 
donor, and then cells were transduced with the CD4-based CAR. construct co-
expressing GFP. (a) FACS plots identify CAR. T cells from each T cell source as GFP+ 
and CD4+. (b) Following 10 days of culture, CD8+ CAR. T cells were mixed with HIVYU2 
Envelope+ K562 cells (K.Env) and upregulation of human cytokines was measured. (c) 
Polyfunctionality profiles for combinatorial subsets of CD4+ and CD8+ CAR. T cells 
producing 0 to 5 of the human cytokines GM-CSF, IFN-, IL-2, MIP-1, and TNF. 
Average of 3 unique donors per T cell source. (d-e) HIV suppression assay as described 
in Materials and Methods. (d) FACS plots indicating the frequency of HIV-infected cells 6 
days after co-culturing with BLT mouse- or human-derived CAR. T cells at denoted 
effector-to-target (E:T) ratios. (e) Summary of frequency of HIV-infected cells (live CAR- 
CD8- cells) at 2, 4 and 6 days after co-culture with BLT mouse- or human-derived CAR. 
and untransduced (UTD) T cells at indicated E:T ratios. (f,g) HIV elimination assay as 
described in Materials and Methods. (f) FACS plots and (g) summarized data for 
frequency of active caspase-3 within HIV-infected cells (live CTV+ HIVGAG+ cells) 24-
hours after co-culture with BLT mouse- or human-derived CAR. and UTD T cells at 1:1 
E:T ratio. Each symbol represents the average of technical duplicates per donor (n=3 
biologically independent donors). (e,g) Symbols and lines reflect mean and error bars 











Figure 2-3. CAR T cells expressing the 4-1BB costimulatory domain exhibit a 
proliferative advantage and induce B cell aplasia in vivo. (a-e) BLT mouse-derived T 
cells were transduced with either mCherry.T2A.CAR., iRFP670.T2A.CAR.BB, or 
GFP.T2A.CAR.28. 5x106 CAR-transduced T cells of each type were mixed prior to 
infusion into syngeneic mice (n=8). (a) Frequency of each CAR T cell type within the pre-
infusion T cell product. (b) Frequency of peripheral CAR T cells within the same mouse 
5 weeks post-infusion. (c) Peripheral concentration and (d) cumulative persistence of 
each CAR T cell type over 5 weeks of engraftment. (e) Relative tissue frequency of each 
CAR T cell type 7 weeks post-infusion. (f) In a separate study, 2 weeks after infusion of 
the CAR T cell mixture described in (a), BLT mice received 107 irradiated wild-type K562 
(K.WT; n=8) or HIVYU2 Envelope+ K562 (K.Env; n=8) cells. Peripheral concentration of 
each CAR T cell type following K.WT or K.Env infusion. (g) FACS plots indicating 
frequency of MIP-1+ and TNF+ CAR.BB and CAR.28 T cells within the same mouse 
after ex vivo stimulation. CAR. T cells were too infrequent for analysis. (h) Frequency of 
granzyme B+ perforin+ CD8+ CAR T cells within the same mice ex vivo. (i-k) Mice were 
infused with 5x106 CD19-specific CAR.BB (n=4) or control CD4-based CAR.BB T cells 
(n=3). (i) Concentration of peripheral CD19+ cells following infusion. (j) FACS plots 
showing frequency of CD19+ cells, and (k) number of CD19+ cells in tissues 7 weeks 
post-infusion. For all data, symbols and bars reflect mean and error bars show ± SEM, 
except (d,k) where symbols represent individual mice. (d) Friedman’s test with Dunn’s 
multiple corrections test, and (f,h), two-sided Wilcoxon matched-pairs signed rank test 
was performed to calculate significance. Sample size for all mouse groups indicate 





Figure 2-4. CD28 costimulation enhances the ex vivo effector function of CAR T 
cells. HIV-uninfected mice were infused with an equal mixture of CD4-based CAR T 
cells expressing either CD3-, 4-1BB/CD3- and CD28/CD3- costimulatory domains 
linked to unique fluorescent proteins to facilitate identification in vivo as described in 
Figure 2-3. Cumulative data indicating the frequency of TNF+, IL-2+ and MIP-1+ 
CAR.BB and CAR.28 T cells within the same mice after ex vivo stimulation with K.Env 
(stim) or K.WT (unstim) cells. Data represents the aggregate of cytokine producing cells 
from liver and terminal blood (n=8). CAR. T cells were too infrequent for analysis. Data 
shows box and whisker plots and bars indicate min and max values. Significance was 












Figure 2-5. HIV-specific CAR.BB T cells display features of T cell exhaustion after 
failing to control viral rebound. (a) Mean log plasma viral RNA (copies mL-1) in 
HIVJRCSF-infected mice treated with ART from week 3 to 5 (G1 and G2 mice; gray box) or 
from week 3 to 8 (G3 and G4 mice; brown box). At 5 weeks post-infection, mice in G1 
(n=6) and G3 (n=10) received 107 CAR.BB T cells, and mice in G2 (n=6) and G4 (n=9) 
received 107 inactive control CAR.BB T cells. Thin dotted line denotes limit of 
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quantification. Sample sizes in these studies indicate biologically independent animals. 
(b) FACS plots and (c) summary data illustrate the frequency of total memory CD4+ T 
cells (CAR-) following ART cessation in CAR.BB and CAR.BB T cell-treated mice. (d) 
Concentration of peripheral CAR T cells for G1/G2 and (e) G3/G4. (f) Frequency of CAR 
T cells in tissues 12 weeks post-CAR T cell infusion for G1/G3 and G2/G4. (g) PD-1 and 
TIGIT expression on peripheral CAR.BB or CAR.BB T cells from G1/G2 after ART 
discontinuation. (h-l) FACS analysis of splenic tissue of BLT mice (G1 and G2) 12 
weeks after ART cessation. (h) Co-expression of TOX and 2B4, PD-1 or TIGIT on 
peripheral CAR.BB or CAR.BB T cells. (i) Frequency of TOX- and TOX+ CAR.BB T 
cells positive for indicated inhibitory receptors. (j) Frequency of T-bet and Eomes 
expressing CAR.BB and CAR.BB T cells. (k) Frequency of TOX expression within T-
bet+ and Eomes+ CAR.BB and CAR.BB T cells. (l) Memory distribution of 2B4+PD-
1+TIGIT+ and EomeshiT-betdim CAR.BB T cells. For all data, symbols and bars reflect 
mean and error bars indicate ± SEM, except (f,i-l) where symbols represent individual 











Figure 2-6. CAR.BB T cells fail to prevent CD4+ T cell loss after the 
discontinuation of ART. (a) Schematic of gating strategy used to identify total memory 
CD4+ T cells (CAR-). (b) Percentage of CD4+ T cells (CAR-) out of total CD3+ cells from 
the indicated tissues in BLT mice treated with CAR.BB T cells (G1) or control 
CAR.BB (G2) T cells, 12 weeks after the discontinuation of ART, and (c) 9 weeks 
after the discontinuation of ART for G3/4. Symbols represent individual mice. Bars 
indicate mean and error bars show ± SEM. N/A denotes tissue samples where viable 




Figure 2-7. HIV infection preferentially depletes memory CD4+ T cells in BLT mice. 
(a) Mean plasma viral RNA (copies mL-1) for mice in G1 (thick line; right axis) and 
frequency of post-challenge peripheral memory (CD45RA-) CD4+ T cells in HIV- mice 
(white circles) and HIV+ mice (G1; black circles) (left y-axis). Thin dotted line denotes 
limit of viral load quantification. Shaded box indicates window of ART. Symbols indicate 
mean and error bars show ± SEM. (b) Frequency of CCR5 expression on the indicated 














Figure 2-8. CAR.BB T cells accumulate multiple inhibitory receptors as disease 
progresses. (a) Frequency of CD4+ and (b) CD8+ CAR.BB T cells (G1) and control 
CAR.BB T cells (G2) co-expressing TIGIT and PD-1 after infusion. Shaded box 
indicates the window of ART. Symbols indicate mean and error bars show ± SEM. (c) 
Frequency of CD4+ and (d) CD8+ CAR.BB T cells (G1) and control CAR.BB T cells 
(G2) co-expressing TIGIT, PD-1 and 2B4 in tissues 12 weeks post-infusion. (e) 
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Cumulative data indicating the frequency of 2B4+, PD-1+ and TIGIT+ CD4+ CAR.BB T 
cells (G1) compared to CAR- CD4+ T cells (G1) within the spleens of the same mice, and 
(f) CD8+ CAR.BB T cells (G1) compared to CAR- CD8+ T cells (G1) within the spleens 
of the same mice. (c-f) Bars indicate mean, error bars show ± SEM and symbols 
represent individual mice. Significance was calculated using Wilcoxon rank sum test 











Figure 2-9. EomeshiT-betdim CAR.BB T cells accumulate from acute to chronic 
phases of infection. Mice were infected with HIVJRCSF and infused 48 hours later with 
either 2x107 CAR.BB T cells (n=5) or inactive control CAR.BB T cells (n=3). (a) 
FACS plots show the change in Eomes and T-bet expression within the different CAR T 
cell types over time. (b) Summary data indicating the longitudinal frequency of 
EomeshiT-betdim CD8+ (left panel) and CD4+ (right panel) CAR T cells (left y-axis), and 
mean log plasma viral RNA (copies mL-1) (right y-axis). Thin dotted line denotes limit of 
viral load quantification. Symbols indicate mean and error bars show ± SEM. (c) 
Spearman correlation analysis of frequency of EomeshiT-betdim CD8+ CAR.BB T cells 
compared with viral burden measured as the frequency of HIVGAG+ CD8- T cells in 




Figure 2-10. CAR.BB T cells from chronic infection exhibit attenuated ex vivo 
function compared to CAR T cell product. CAR.BB T cells (n=14) and inactive 
control CAR.BB T cells (n=10) were isolated from the livers of chronically infected 
mice 12 weeks post-infusion, and the pre-infusion CAR.BB T cell product (TCP) were 
ex vivo stimulated. (a) FACS plots and (b) cumulative data for the expression of MIP-1, 
CD107a and granzyme B in CD8+ CAR.BB or CAR.BB T cells. The dotted line 
indicates the frequency of CD8+ CAR.BB T cells from the pre-infusion TCP expressing 
the indicated protein. The bars indicate mean and the error bars show ± SEM. 












Figure 2-11. Dual-CAR T cell product mitigates CD4+ T cell loss and exhibits 
superior proliferative capacity. (a-j) Mice were challenged with HIVJRCSF (n=12) or 
HIVMJ4 (n=12) and 48 hours later 6 mice from each group were infused with Dual-CAR T 
cell product (TCP, green lines) or were untreated (Untx, black lines). (a) Dual-CAR TCP 
comprises CAR.BB, CAR.28 and Dual-CAR T cells. (b,d) Concentration of total 
peripheral CAR T cells in individual mice (green dotted lines; left y-axis) and mean log 
plasma viral RNA (copies mL-1) (solid lines; right y-axis) in HIVJRCSF- and HIVMJ4-infected 
mice, respectively. Thin black dotted line denotes limit of quantification. (c,e) Frequency 
of peripheral memory CD4+ T cells (CAR-). (f) Frequency of CD4+ T cell (CAR-) memory 
subsets in tissue from HIVMJ4- (left) HIVJRCSF-infected mice (right) 8 weeks post-CAR T 
cell infusion. Six distinct tissues were analyzed from 3 biologically independent animals 
per infection cohort. (g) Peripheral longitudinal frequency of each CAR T cell type 
present in the Dual-CAR TCP. (h) Peak peripheral frequency and (i) cumulative 
persistence of CAR T cells. Data is aggregated from both infection cohorts (n=12). (j-m) 
Equal frequencies of Dual-CAR TCP and 3rd-generation (3G) CD4-based CAR T cells 
were combined (Supplementary Fig. 12c) prior to infusion into HIVMJ4-infected mice 
(n=6). (j) Overlaid FACS plots showing frequency of peripheral Dual-CAR 
(iRFP670+NGFR+) and 3G-CAR (GFP+) T cells within the same mouse. (k) 
Concentration of peripheral CAR T cells. (l) Total number of splenic CAR T cells and (m) 
cumulative CAR T cell persistence 5 weeks post-infection. For all data, bars and error 
bars show mean ± SEM, and symbols represent individual mice, except (c,e) where 
symbols represent mean. Two-sided Wilcoxon rank-sum test was used to calculate 
significance, except (h,i) where Friedman’s test with Dunn’s multiple corrections test was 





Figure 2-12. Dual-CAR T cells exhibit similar in vitro effector functions as CAR.28 
T cells. The Dual-CAR T cell product comprises CAR.BB, CAR.28 and Dual-CAR T 
cells, where each population is identified by a unique fluorescent protein. Upregulation of 
cytokines was measured after in vitro stimulation with K.Env and K.WT cells. Each 

















Figure 2-13. Dual-CAR T cell product transiently delays CD4+ T cell loss despite 
persistent HIVJRCSF infection. Mice received Dual-CAR T cell product (TCP) (n=6) 48 
hours post-HIVJRCSF challenge, while control mice were untreated (Untx) (n=5). (a) 
Concentration of peripheral total memory CD4+ T cells (CAR-). (b) Concentration of 
peripheral central memory (CD45RA-CD27+CCR7+; left panel), transitional memory 
(CD45RA-CD27+CCR7; middle panel), and effector memory (CD45RA-CD27-CCR7-; 
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right panel) CD4+ T cells (CAR-). Significance was calculated using Wilcoxon rank sum 
test (*P<0.05, **P<0.01). (c) Frequency of memory CD4+ T cell (CAR-) subsets in tissues 















Figure 2-14. HIVJRCSF and HIVMJ4 exhibit different replication kinetics in vitro and in 
vivo. (a) In vitro replication assay comparing the replication kinetics of HIVJRCSF and 
HIVMJ4 in human PBMCs stimulated with PHA and infected at a matched multiplicity of 
infection of 0.002. Virus replication was assessed by measuring p24 antigen in culture 
supernatants. (b) Mean log plasma viral RNA (copies mL-1) in BLT mice challenged with 
HIVJRCSF (n=3) or HIVMJ4 (n=4). Thin dotted line denotes limit of quantification. Symbols 
indicate mean values and error bars show ± SEM. Significance was calculated using 












Figure 2-15. Dual-CAR T cell product prevents CD4+ T cell loss despite persistent 
HIVMJ4 infection. Mice were infused with Dual-CAR T cell product (TCP) (n=6) 48 hours 
post-HIVMJ4 challenge, while control mice were untreated (Untx) (n=6). (a) Concentration 
of peripheral total memory CD4+ T cells (CAR-). (b) Concentration of peripheral central 
memory (CD45RA-CD27+CCR7+; right panel), transitional memory (CD45RA-
CD27+CCR7-; middle panel), and effector memory (CD45RA-CD27-CCR7-; left panel) 
CD4+ T cells (CAR-). Significance was calculated using Wilcoxon rank sum test 
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(**P<0.01). (c) Frequency of memory CD4+ T cell (CAR-) subsets in tissues 8 weeks 














Figure 2-16. Dual-CAR T cells exhibit superior in vivo expansion compared to 4-
1BB, CD28, and 3rd-generation CAR T cells. (a) BLT mice were challenged with either 
HIVJRCSF (n=6) or HIVMJ4 (n=6) and infused with 2x107 Dual-CAR T cell product (TCP). 
Fold-change in CAR T cell concentration from baseline to peak levels in peripheral 
blood. Data is the aggregate of both infection cohorts. (b) Schematic shows the 
components of the 3rd-generation (3G) CD4-based CAR construct. (c-e) Dual-CAR T cell 
product and 3G-CAR T cells were combined, equalizing the frequency of Dual-CAR and 
3G-CAR T cells prior to infusion into uninfected mice (n=9). (c) FACS plots indicate the 
frequency of Dual-CAR and 3G-CAR T cells present within the pre-infusion T cell 
product. (d) Longitudinal concentration of peripheral CAR T cells following adoptive 
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transfer into HIV-negative mice. Symbols indicate mean and error bars show ± SEM. (e) 
At 2 weeks post-infusion, mice received either 107 irradiated K.Env cells (n=6) or 107 
irradiated K.WT cells (n=3). Fold change in the concentration of peripheral CAR T cells 
1-week post-K562 boost from baseline concentration prior to K562 infusion. Bar 
indicates mean, error bars show ± SEM and symbols represent individual mice. (a,d,e), 










Figure 2-17. CD4-based CAR T cells are susceptible to infection in vivo. (a) FACS 
plots and (b) cumulative data show the frequency of HIVGAG+ T cell populations sampled 
within the same mice (n=5) 10 weeks post-HIVJRCSF infection. Data in (b) is the 
aggregate of tissues: bone marrow, liver, lung, lymph node, terminal blood, and spleen 
from 5 mice. (c) FACS plots and (d) cumulative data showing the expression of 
granzyme B and perforin within HIVGAG+ and HIVGAG- CAR T cell populations from 
HIVJRCSF-infected mice after ex vivo stimulation with K.Env (stim) or K.WT (unstim) cells. 
For data in (d), the data is represented as the average of 3 distinct CAR T cell 
populations. Significance was calculated using paired t test (*P<0.05). Symbols and bars 




Figure 2-18. HIV-resistant Dual-CAR T cells mediate superior virus-specific 
immune responses. (a) Schematic of HIV-resistant (C34-CXCR4+) Dual-CAR T cells. 
(b) HIVJRCSF-infected BLT mice received 107 CAR T cells 48 hours post-challenge. HIV 
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DNA load in sorted CAR T cells from individual mouse splenic tissue (n=8). (c-d) HIVMJ4-
infected mice were infused 48 hours post-challenge with 106 C34-CXCR4+, CAR.BB 
(n=6), CAR.28 (n=5), or purified Dual-CAR (n=4) T cells. (c) Longitudinal peripheral 
concentration and (d) peak peripheral CAR T cell concentration. (e-n) HIVMJ4-infected 
mice were infused 48 hours post-challenge with 106 C34-CXCR4+, purified 
CAR.BB.BB (n=5), CAR.28.28 (n=5) or Dual-CAR (n=5) T cells, or were untreated 
(n=4). Purification strategy is described in Supplementary Figure 17. (e) Frequency of 
CAR T cell populations out of total human CD45+ cells 2 and 3 weeks post-infection. (f) 
Longitudinal concentration and (g) cumulative peripheral CAR T cell persistence. (h) 
FACS plots showing CCR5 expression within peripheral memory CD4+ T cells (CAR-). (i) 
Concentration of total memory and (j) CCR5+ CD4+ T cells (CAR-) at 6 weeks post-
infection. (k) FACS plots and (l) frequency of MIP-1+ and CD107a+ CD8+ CAR T cells 
from tissue at 8 weeks post-infection after ex vivo stimulation. (m) Distribution and (n) 
frequency of granzyme B+ perforin+ cells within CD107a+ CAR T cells from tissues after 
ex vivo stimulation. (b) Two-sided Wilcoxon matched pairs signed rank test was used to 
calculate significance. For remaining analyses, significance was calculated using a two-
sided Wilcoxon rank-sum test. Bars and error bars indicate mean ± SEM, and symbols 
represent individual mice, except for (c) where symbols indicate mean. Sample sizes in 









Figure 2-19. HIV-resistant Dual-CAR T cell product fails to inhibit acute HIV 
replication. (a) Dual-CAR T cell product (TCP) was co-transduced with C34-CXCR4 
linked to mCherry by an intervening T2A sequence. FACS plots indicate the frequency of 
C34-CXCR4+ cells within each cell population comprising the Dual-CAR TCP prior to 
infusion. (b) Log plasma viral RNA (copies mL-1) in individual BLT mice challenged with 
HIVJRCSF and 48 hours later mice were infused with HIV-resistant (C34-CXCR4+) Dual-






Figure 2-20. C34-CXCR4+ CAR T cells are selected for during chronic infection and 
exhibit superior ex vivo effector functions. (a) Mice were infected with HIVJRCSF and 
48 hours later infused with 107 C34-CXCR4+ Dual-CAR T cell product (TCP). FACS plots 
indicate the frequency of C34-CXCR4+ throughout infection. (b) Mice were infected with 
HIVMJ4 and 48 hours later were infused with 106 C34-CXCR4+ CAR.BB (n=5), CAR.28 
(n=5), or purified Dual-CAR (n=4) T cells. Frequency of C34-CXCR4+ CAR T cells in 
tissue 8 weeks post-infection. Thin dotted line indicates the frequency of C34-CXCR4+ 
CAR T cells in the pre-infusion TCP for the indicated CAR T cell type. (c-d) Mice were 
infected with HIVMJ4 and 48 hours later received 106 C34-CXCR4+, purified 
CAR.BB.BB (n=3), CAR.28.28 (n=4), or Dual-CAR (n=3) T cells. c) FACS plots and 
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(d) cumulative data show the frequency of each CD8+ CAR T cell population expressing 
MIP-1 and CD107a, and the frequency of CAR T cells with cytotoxic potential 
(granzyme B+ perforin+ CD107a+). CAR T cells were isolated from the spleen and bone 
marrow of mice 8 weeks post-infection and ex vivo stimulated. Significance was 
calculated using Wilcoxon matched-pairs signed rank test (**P<0.01). For all data, 
























Figure 2-21. Low dose Dual-CAR T cells mitigate CD4+ T cell loss during HIVMJ4 
infection. HIVMJ4-infected mice were infused 48 hours post-challenge with 106 C34-
CXCR4+, CAR.BB (n=6), CAR.28 (n=6), or purified Dual-CAR (n=4) T cells. For each 
group of mice, the change in peripheral cell concentration of CCR5+ CD4+ T cells (CAR-) 
was measured from the indicated time post-infection to pre-infection levels. Bars indicate 











Figure 2-22. Two-step immunomagnetic selection process yields purified T cells 
expressing two independent CARs. (a) Schematic of lentivirus constructs used to 
generate dual CD4-based CAR-transduced T cells. The CD4-based CARs with the 4-
1BB/CD3- or CD28/CD3- endodomains were linked with NGFR or truncated EGFR 
(EGFRt) to enable two-step positive magnetic selection during the T cell manufacturing 
process. (b) Time line for CAR T cell manufacturing. One day after T cell activation with 
CD3/CD28 Dynabeads, the cells were transduced with an equivalent MOI of lentivirus 
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depicted in (a). On days 4 and 7 after activation, the CAR T cells were positively 
selected using anti-EGFR and anti-NGFR coated magnetic beads, respectively, as 
described in Materials and Methods. (c) Representative FACS plots illustrating the purity 
of dual CAR-transduced T cells after EGFR and NGFR selection. (d) FACS plots 
indicate the frequency of CAR.BB.BB, CAR.28.28 and Dual-CAR T cells post-
selection in their respective pre-infusion T cell products, prior to adoptive transfer into 























Figure 2-23. Dual-CAR T cells mediate superior expansion and protection of CD4+ 
T cells during HIV infection in vivo. BLT mice were infected with HIVMJ4 and 48 hours 
later received 106 C34-CXCR4+, purified CAR.BB.BB (n=5), CAR.28.28 (n=5), Dual-
CAR (n =5) T cells, or were untreated (Untx; n=4). (a) Fold-change in the concentration 
of CAR T cells in peripheral blood between weeks 2 and 3 post-infection. The number 
above the bars indicate mean fold-change. Symbols represent individual mice. (b) 
Absolute count of each CAR T cell population in tissues 8 weeks post-infection. (c) 
Concentration of peripheral total memory (CD45RA-) and (d) CD45RA- CCR5+ CD4+ T 
cells (CAR-). Symbols represent mean. (e) Association between fold-change in the 
concentration of CAR T cells and change in total memory (CD45RA-) CD4+ T cells (CAR-
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) in peripheral blood between weeks 2 and 3 post-infection. Symbols represent individual 
mice. Spearman correlation test was used to calculate significance. (b-d) Error bars 





























Figure 2-24. CAR T cells from HIV-infected mice exhibit ex vivo cytotoxic function. 
HIVJRCSF-infected mice (n=3) treated with the Dual-CAR TCP were euthanized and the 
bone marrow cells were ex vivo stimulated with K.Env or K.WT cells for 24 hours at the 
indicated E:T ratios. (a) Representative FACS plots and (b) cumulative data shows the 
induction of active caspase-3 within target cells. Symbols indicate mean and error bars 







Figure 2-25. Dual-CAR and CAR.28 T cells exhibit similar ex vivo functional 
profiles. Mice were challenged with HIVJRCSF (n=5) and infused with 2x107 Dual-CAR T 
cell product (TCP) 48-hour post infection. (a) Frequency of CD8+ and (b) CD4+ CAR T 
cell populations from tissue at necropsy (8-weeks post-infection) within the same mice 
expressing CD107a, MIP-1, IL-2 and TNF after ex vivo stimulation. Bars indicate mean, 
error bars show ± SEM and symbols represent individual mice. Significance was 
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calculated using Wilcoxon rank sum test (**P<0.01). (c) Principle Components Analysis 
(PCA) of IL-2, TNF, MIP-1, and CD107a expression in ex vivo stimulated CD8+ and 






Figure 2-26. Mitigating CAR T cell infection improves control over HIV replication. 
(a) Mean log plasma viral RNA (copies mL-1) of active, unprotected CAR T cell-treated 
mice (n=38), and untreated/inactive CAR T cell-treated mice (n=36). Data are 
aggregated across 6 independent studies. Thin dotted line denotes limit of quantification. 
(b) Mean log plasma viral RNA (copies mL-1) in mice infused 48 hours post-HIVMJ4 
challenge with 107 protected (>98% C34-CXCR4+) Dual-CAR TCP (n=12) or untreated 
mice (n=12). (c) Frequency of splenic HIV-infectedCD8- T cells (CAR-) and (d) cell-
associated HIV DNA load in lymph nodes 6-8 weeks post-infection. (e-k) HIVJRCSF-
infected mice were ART-treated and simultaneously infused with 107 HIV-resistant Dual-
CAR TCP (n=12), inactive Dual-CAR TCP (n=5), or were untreated (n=7). (e) Mean log 
plasma HIV RNA (copies mL-1). Shaded box indicates ART and arrow indicates CAR 
TCP infusion. (f) Percent log reduction in plasma HIV RNA from pre-ART (week 3) to 1 
and 1.5 weeks post-ART. (g,h) Data are aggregated from HIVJRCSF- and HIVBAL-infected 
cohorts. (g) Correlation between percent viral load reduction at first post-ART time-point 
and contemporaneous peripheral CAR T cell concentration. (h) Kaplan-Meier curve of 
time to viral suppression after treatment initiation for Dual-CAR TCP versus control mice. 
(i) Frequency of HIV-infected CD8- T cells (CAR-) and (j) HIV-infected CD14+ 
macrophages aggregated from various tissues of plasma viremia suppressed mice. (k) 
Cell-associated HIV DNA load in sorted central memory (CAR-CD45RA-CCR7+) CD4+ T 
cells. Statistical significance calculated for (a,b) by one-sided unpaired Student’s t-test, 
(c-f,i-k) two-sided Wilcoxon rank-sum test, (g) Spearman correlation, and (h) Log-rank 
test. Bars and error bars indicate mean ± SEM. Symbols represent individual mice. 




Figure 2-27. HIV-resistant Dual-CAR TCP reduces virus replication in vivo. (a) 
Frequency of HIVGAG+ CD8- T cells (CAR-) within the bone marrow and spleen of 
HIVJRCSF-infected mice and (b) HIVMJ4-infected mice that were treated 48 hours post-
challenge with the Dual-CAR T cell product (TCP) or were untreated (Untx). (c) Mean 
log plasma HIVMJ4 RNA (copies mL-1) after ART discontinuation of mice infused at ART 
initiation with 107 fully-protected >98% C34-CXCR4+ (n=5) or partially-protected <20% 
C34-CXCR4+ (n=7) Dual-CAR TCP, or were untreated (n=9). (d,e) HIVBAL-infected mice 
were ART-treated and simultaneously infused with 107 HIV-resistant Dual-CAR TCP 
(n=6) or were untreated (n=6). (d) Mean log plasma HIV RNA (copies mL-1). Shaded box 
indicates ART and arrow indicates TCP infusion. (e) Percent log reduction in plasma 
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viral RNA from pre-ART (week 3) and 0.5 and 1 week post-ART. For all data, bars 
indicate mean, error bars show ± SEM and symbols represent individual mice. 










Figure 2-28. Gating strategy for FACS sorting of CAR T cells and endogenous 
central memory CD4+ T cells. (a) For the study described in Figure 5b, C34-CXCR4+ 
and C34-CXCR4- CAR T cells were bulk sorted by FACS following the depicted gating 
strategy. (b) For the study described in Figure 6e, endogenous central memory CD4+ T 
cells (CAR-) were sorted from splenocytes harvested at necropsy (7 weeks post 
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infection) following the depicted gating strategy. For all data, cell-associated HIV DNA 

















CHAPTER 3 - HIV-specific CAR-modified CD4+ T Cells Mitigate HIV Disease 
Progression and Confer CD4+ T Cell Help In Vivo  
Parts of this chapter were previously published in: 
 
Maldini C.R., Gayout K., Leibman R.S., Dopkin D.L., Mills J.P., Shan X., Glover J.A., 
Riley J.L. (2020) HIV-resistant and HIV-specific CAR-modified CD4+ T Cells Mitigate HIV 




HIV infection preferentially depletes HIV-specific CD4+ T cells thereby impairing 
antiviral immunity. Here, we explore the therapeutic utility of adoptively transferred CD4+ 
T cells expressing an HIV-specific Chimeric Antigen Receptor (CAR4) to restore CD4+ T 
cell function to the global HIV-specific immune response. We demonstrated that CAR4 T 
cells directly suppressed in vitro HIV replication and eliminated virus-infected cells. 
Notably, CAR4 T cells containing intracellular domains (ICDs) derived from the CD28 
receptor family (ICOS and CD28) exhibited superior effector functions compared to 
TNFR family ICDs (CD27, OX40 and 4-1BB). However, despite demonstrating limited in 
vitro efficacy, only HIV-resistant CAR4 T cells expressing the 4-1BB ICD exhibited 
profound expansion, concomitant with reduced rebound viremia after ART cessation and 
protection of CD4+ T cells (CAR-) from HIV-induced depletion in humanized mice. 
Moreover, CAR4 T cells enhanced the in vivo persistence and efficacy of HIV-specific 
CAR-modified CD8+ T cells expressing the CD28 ICD, which alone exhibited poor 
survival. Collectively, these studies demonstrate that HIV-resistant CAR4 T cells can 
directly control HIV replication and augment the virus-specific CD8+ T cell response, 
highlighting the therapeutic potential of engineered CD4+ T cells to engender a functional 






HIV infection induces profound CD4+ T cell loss resulting in impaired antiviral 
immunity, and the onset of overt immunodeficiency.106 In particular, HIV-specific CD4+ T 
cells are preferentially infected and exhibit defective immune responses characterized by 
poor proliferative capacity and IL-2 secretion.107-110 The collapse of CD4+ T cell-help 
during chronic infections compromises the generation of cytotoxic and memory CD8+ T 
cells,111-113 leads to pronounced CD8+ T cell exhaustion,111,114 and diminishes effective 
antibody production.115,116 Moreover, CD4+ T cells exhibit direct cell-to-cell mediated 
effector functions that contribute to disease resolution.117-120 Indeed, subjects that 
spontaneously control HIV replication demonstrate a significant expansion of cytolytic 
CD4+ T cells that associate with slower disease progression and improved clinical 
outcomes.120,121 Given the functional heterogeneity of HIV-specific CD4+ T cells and their 
ability to coordinate global antiviral immunity, therapeutic interventions that restore or 
augment CD4+ T cell function will likely be critical for the development of effective HIV 
cure strategies. 
Emerging data from cancer models demonstrate that CD4+ T cells redirected with 
a Chimeric Antigen Receptor (CAR4) can eradicate tumors in the absence of other 
immune cells, 122-124 indicating that CAR4 T cells can act as primary effectors in addition 
to providing help to other leukocytes. CARs confer novel T cell specificity through 
expression of an extracellular antigen-binding domain fused to the intracellular CD3 
chain and one or more costimulatory domains.37,46  The choice of costimulatory domain 
alters the metabolic, phenotypic, and functional CAR T cell profile.57,60 For instance, the 
CD28 costimulatory domain promotes glycolytic metabolism and the acquisition of an 
effector memory T cell phenotype capable of exhibiting rapid antitumor activity, whereas 
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the 4-1BB domain supports the long-term in vivo persistence and development of central 
memory T cells reliant on oxidative phosphorylation for energy.39,52,80 As such, the ability 
of CARs to engender unique T cell traits suggests that adoptively transferred HIV-
specific CAR4 T cells can restore many of the functions lost by HIV-induced destruction 
of CD4+ T cells. 
However, since CD4+ T cells are the primary targets of HIV, efforts to make CAR4 
T cells resistant to infection must be employed to ensure durable responses.125 Several 
approaches including HIV coreceptor disruption,85,126,127 restriction factor 
overexpression,103,128 and fusion inhibitors129,130 have been developed to confer HIV 
resistance. Of these, the fusion inhibitor C34 linked to CXCR4 is particularly potent and 
interferes with the entry of diverse HIV strains regardless of their tropism.79 Because of 
the need to protect and redirect CD4+ T cells, progress to engineer the best CD4+ T cells 
to control HIV replication has lagged behind studies examining CD8+ T cells. 
Nonetheless, HIV-specific CAR8 T cells have showed promise to inhibit virus replication, 
thereby providing the tools necessary to study CAR4 T cells. For instance, we recently 
reported on an HIV-specific CAR that expresses CD4 as the HIVENV binding motif and 
contains the 4-1BB costimulatory domain.40 This CAR was re-engineered from the 
original construct employed during the first in-human clinical trials,34-36 and was selected 
for its improved antiviral potency in CD8+ T cells,40 and potential to minimize virus 
escape.131 Other approaches have incorporated a similar CD4-based CAR into CD34+ 
hematopoietic stem cells to provide long-term in vivo production of HIV-specific immune 
cells,64,132 or have targeted infected cells using alterative antigen-binding 
moieties.42,43,65,133 Together, these strategies highlight the promise of CAR T cell-based 
therapies against HIV; however, critical knowledge gaps remain, especially in our 
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understanding of whether CAR4 T cells need to be engineered separately from CAR8 T 
cells to achieve the optimal HIV-specific response. 
 Here, we explored the therapeutic potential of CAR4 T cell therapy to mitigate 
HIV pathogenesis. Data from cancer studies indicate that CAR4 T cells require different 
costimulatory signals than CAR8 T cells to engender superior immune responses.81,134 
However, using a panel of HIV-specific (CD4-based) CARs expressing distinct 
intracellular domains (ICDs), we show that only HIV-resistant, 4-1BB-costimulated CAR4 
T cells limit in vivo HIV infection, congruent with our previous work identifying 4-1BB as 
the optimal ICD for HIV-specific CAR8 T cells.40 Notably, ICDs derived from the CD28 
receptor family (ICOS and CD28), which conferred the greatest CAR4 T cell effector 
function in vitro, did not induce protective responses in humanized mice, suggesting that 
favorable disease outcomes associate with factors beyond in vitro efficacy. These 
results, together with the observation that HIV-specific CAR4 T cells augment the CD8+ T 
cell response to infection, highlight the importance of exploiting engineered CD4+ T cells 




Costimulatory domains differentially modulate HIV-specific CAR4 T cell cytokine 
production. 
To engineer optimal HIV-specific CD4+ T cells for use in HIV cure strategies, we 
first generated an array of CAR4 T cells that expressed CD4, the natural ligand of 
HIVENV, as the extracellular antigen-binding moiety fused to an intracellular domain (ICD) 
comprising the TCR CD3 () chain and one costimulatory domain derived from CD27, 
OX40, 4-1BB, ICOS, or CD28. The CAR containing the CD28 ICD was linked to the 
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CD28 transmembrane (TM) domain, while the remaining CARs contained the CD8 TM 
domain. All of the HIV-specific CARs were efficiently expressed on the cell surface and 
could be identified by both the overexpression of CD4 relative to untransduced CD4+ T 
cells (UTD4) and co-expression of GFP, which was linked to each CAR by an intervening 
T2A sequence (Fig. 3-1A).   
 We then assessed the effects of individual ICDs on the in vitro effector function 
of CAR4 T cells after antigen-specific stimulation with target cells expressing HIVENV. All 
of the CAR4 T cell types upregulated TNF, MIP-1β, GM-CSF, IL-2 and IFN-γ  following 
antigen exposure; however, CAR4 T cells containing the CD28 receptor family ICDs 
exhibited the greatest production of these cytokines (Fig. 3-1B,C and Fig. 3-2). In 
particular, over 75% of CD28-costimulated CAR4 T cells elicited a cytokine response to 
stimulation, exemplified by IL-2 and TNF expression. Interestingly, we observed low 
expression levels of other cytokines associated with T-helper phenotypes including IL-
17A, IL-21, IL-22, IL-4 and IL-13 (Fig. 3-3). Moreover, combinatorial cytokine analysis 
indicated that ICDs from the CD28 receptor family increased the frequency of 
polyfunctional responses (Fig. 3-1D), where exhibiting ≥ 3 cytokine functions contributed 
over 20% of the total response, and was mainly driven by the GM-CSF+IL-2+TNF+ 
subset, compared to less than 10% by the TNFR family ICDs (CD27, OX40 and 4-1BB) 
(Fig. 3-1D,E). Somewhat paradoxically, in the absence of costimulation the CD3 ICD 
induced robust cytokine production (Fig. 3-1C-E), which may result from the high 
expression of this CAR on the CD4+ T cell surface (Fig. 3-4). Together, these data 
demonstrate that HIV-specific CARs redirect CD4+ T cell specificity, and distinct 
costimulatory signals within the CAR differentially modulate the magnitude and breadth 




HIV-specific CAR4 T cells durably suppress in vitro HIV replication  
 To determine whether HIV-specific CAR4 T cells could limit the spread of HIV 
infection, we performed an in vitro suppression assay comparing the ability CAR4 T cells 
containing different ICDs to inhibit virus outgrowth. Here, activated CD4+ T cells were 
infected with HIVBAL for 24 hours before co-culture with CAR4 or UTD4 T cells at different 
effector-to-target (E:T) ratios, and virus replication was measured over 8 days by 
determining the frequency of intracellular HIVGAG+ (CAR-) cells.  We observed 
widespread virus replication when infected cells were cultured with UTD4 T cells, 
whereas each CAR4 T cell population durably suppressed HIV at a 1:25 and 1:50 E:T 
ratio (Fig. 3-5A,B and Fig. 3-6A,B). However, further dilution of CAR4 T cells expressing 
the TNFR family ICDs resulted in rapid loss of virus control (Fig. 3-6A,C and Fig. 3-5C). 
In contrast, CAR4 T cells containing the CD28 receptor family and CD3 ICDs potently 
suppressed virus spread at lower E:T ratios (Fig. 3-5C,D and Fig. 3-5D).  
At the same time, we compared the protective role of CAR4 T cells to that of HIV-
specific CAR8 T cells expressing the 4-1BB ICD. We previously demonstrated that 4-
1BB costimulation conferred optimal CAR8 T cell antiviral activity in vivo,40 and now this 
construct is currently employed in a Phase I clinical trial (NCT03617198). CAR8 T cells 
exhibited potent HIV suppression below a 1:100 E:T ratio (Fig. 3-6E and Fig. 3-7A), and 
notably, CAR4 T cells expressing the CD28 and CD3 ICDs controlled virus spread to 
the same extent (Fig. 3-6F). For a direct comparison, we noted that CAR4 T cells 
expressing the 4-1BB ICD were approximately 3-fold less suppressive than CAR8 T 
cells harboring the same ICD (Fig. 3-7B). These results indicated that HIV-specific CAR4 
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T cells can solely control in vitro HIV replication, and that the ICD integrated into the 
CAR modulates the ability of CAR4 T cells to directly inhibit virus outgrowth.  
 
HIV-specific CAR4 T cells directly eliminate HIV-infected cells in vitro 
The effector mechanisms employed by CD4+ T cells largely fall into two 
categories: first, the production of broad-acting soluble factors, such as IFN- and TNF-
, that promote an antiviral state in surrounding tissue,135 and second, direct cytotoxic 
activity.136-138 In the context of CD19-targeted CAR T cell therapy, CAR4 T cells directly 
engage and kill tumor cells in vitro to the same extent as CAR8 T cells, but exhibit slower 
kinetics of cytotoxicity.139 Similarly, we examined whether HIV-specific CAR4 T cells elicit 
cytotoxic function by performing a short-term killing assay using primary HIV-infected 
cells as targets.104 CAR4 T cells expressing the CD3 ICD eliminated target cells in a 
dose-dependent manner, achieving an 80% reduction in the frequency of HIVGAG+ cells 
(30% to 6% HIVGAG+ cells) after 24 hours (4:1 E:T ratio) (Fig. 3-8A,B). The killing 
exhibited by CAR4 T cells was HIV-specific as indicated by the lack of infected cell lysis 
when cultured with UTD4 T cells (Fig. 3-8B). Furthermore, when we expanded the killing 
assay to include CAR4 T cells encoding distinct costimulatory domains, we observed 
marked reductions in the number of HIVGAG+ cells mediated by CAR4 T cells expressing 
the CD28 receptor family ICDs or CD3. Notably, the level of infected cell killing was 
equivalent between these CAR4 T cell types and CAR8 T cells (Fig. 3-8C and Fig. 3-9). 
In addition, inclusion of the TNFR family ICDs conferred cytolytic activity to CAR4 T cells, 
but not to the same magnitude (Fig. 3-8C and Fig. 3-9).  
We next examined whether CAR4 T cells could trigger activation of caspase-3 in 
HIV-infected cells, which acts as the primary executioner in the cell-death apoptosis 
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pathway140 and is a direct substrate of Granzyme B.141 Indeed, CAR4 T cells induced 
cleavage of caspase-3 in HIVGAG+ cells (Fig. 3-8D,E), suggesting that virus-infected cell 
death is mediated in part by caspase-dependent mechanisms. Furthermore, we 
assessed the expression of cytolytic effector molecules including Granzyme (Gzm) B, 
GzmA and GzmM in all CAR4 T cell populations. CAR4 T cells containing the CD28 
receptor family ICDs or CD3 harbored the greatest level of GzmB and GzmA (Fig. 3-8F 
and Fig. 3-10A), while GzmM expression was negligible (Fig. 3-10B), suggesting that 
signaling from ICDs influences the cytotoxic potential of CAR4 T cells independent of 
antigen exposure. However, these molecules were differentially regulated following in 
vitro antigen-specific stimulation, where after we observed a substantial increase in 
GzmB expression by all CAR4 T cell types, exemplified by the CD28 receptor family 
ICDs or CD3 (Fig. 3-8F and Fig. 3-10C), while GzmA expression waned (Fig. 3-
10A,D). Moreover, stimulation of CAR4 T cells resulted in the detection of CD107a, 
which occurs as cytotoxic granules mobilize from the cytosol to the cell surface (Fig. 3-
8G,H),142 and was coupled with the coordinated upregulation of perforin and GzmB (Fig. 
3-8I,J). Together, these data demonstrate that CAR4 T cells exhibit in vitro cytotoxic 
function that can at least be partially attributed to granule-mediated cytolysis. 
 
4-1BB-costimulated CAR4 T cells mitigate HIV pathogenesis in vivo 
We next sought to determine the in vivo therapeutic potential of distinct HIV-
specific CAR4 T cell populations using a humanized mouse model of HIV infection.40 To 
do so, we humanized NSG mice by adoptively transferring normal donor, CD8-depleted 
PBMCs. Two weeks later, the mice were infused with autologous, HIVBAL-infected CD4+ 
T cells that were treated with ART in vitro prior to infusion and the mice received daily 
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antiretroviral therapy (ART) (Fig. 3-11A). After 3 days, mice were allocated into groups 
based on the level of CD4+ T cells in peripheral blood (Fig. 3-11B), and infused with 
either one of the six CAR4 T cell types, or control CAR4 T cells expressing a truncated 
CD3 ICD (CD3) (Fig. 3-11A). We rendered each CAR4 T cell product HIV-resistant 
by co-transduction with the HIV fusion inhibitor C34-CXCR4,79 which was linked to 
NGFR by an intervening T2A sequence (Fig. 3-12A). Prior to CAR4 T cell infusion, the 
cells were positively selected for NGFR expression, achieving ≥ 90% NGFR+ (C34-
CXCR4+) T cell products (Fig. 3-12B). Of note, expression of C34-CXCR4 did not 
augment the functional potency of CAR T cells, as unprotected CAR T cells suppressed 
in vitro HIV replication to the same extent as CAR4 T cells expressing C34-CXCR4 (Fig. 
3-12C).  
We interrupted ART immediately after CAR4 T cell infusion and measured the 
kinetics of HIV rebound. In this model, the magnitude of virus replication directly 
correlates with the number of CD4+ T cells,143,144 thus to ensure fair comparison among 
treatment groups, we normalized plasma HIV RNA at each time point to the 
contemporaneous level of peripheral blood CD4+ T cells (CAR-). We observed that only 
CAR4 T cells expressing the 4-1BB ICD reduced the magnitude of rebound viremia for 
26 days after ART removal compared to control CAR4 T cell-treated mice (Fig. 3-11C-E 
and Table 3-1). This difference remained significant without normalizing viral load, 
particularly when assessing cumulative viral burden in plasma (Fig. 3-13). Furthermore, 
mice treated with 4-1BB-costimulated CAR4 T cells exhibited durable protection against 
HIV-induced CD4+ T cell (CAR-) depletion (Fig. 3-11F). These observations were striking 
given that the 4-1BB ICD underperformed in every in vitro measure of CAR4 T cell 




4-1BB-costimulated CAR4 T cells exhibit profound in vivo expansion post-ART 
removal 
Next, we characterized the immunologic response inherent of each CAR4 T cell 
type to viral recrudescence after ART cessation. CAR4 T cells were readily detected in 
peripheral blood by the co-expression of GFP and NGFR (Fig. 3-14A). 4-1BB-
costimulated CAR4 T cells exhibited rapid and profound expansion reaching a median 
peak concentration of 511 cells uL-1 blood (34 to 2732 cells uL-1) (Fig. 3-14B), and 
maintained greater long-term survival compared to the other CAR4 T cell populations 
(Fig. 3-14C). Surprisingly, CAR4 T cells expressing CD28 receptor family ICDs, which 
demonstrated superior in vitro potency, exhibited poor in vivo expansion kinetics and 
persistence (Fig. 3-14B,C). Moreover, CAR4 T cells containing the TNFR family ICDs 
expressed lower levels of inhibitory receptors including TIGIT and PD-1 early after ART 
cessation, which may have, in addition to the ICD, modulated early in vivo proliferation 
kinetics (Fig. 3-14D,E and Fig. 3-15). Notably, the magnitude of CAR4 T cell expansion 
across all types, but exemplified by the 4-1BB ICD, correlated with reductions in plasma 
viremia (Fig. 3-14F) and CD4+ T cell (CAR-) preservation (Fig. 3-14G). Together, these 
data demonstrate that CAR4 T cells expressing the 4-1BB costimulatory domain possess 
superior antiviral activity, and highlight that factors such as expansion potential are 
critical to mitigate HIV pathogenesis.  
 
HIV-specific CAR4 T cells improve the proliferation and survival of co-injected 
CAR8 T cells in vivo 
We hypothesized that HIV-specific CAR4 T cells will exhibit T cell-help to other 
lymphocytes in vivo. To test this, we examined whether CAR4 T cells expressing the 4-
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1BB ICD could augment the antiviral function of HIV-specific CAR8 T cells after ART 
removal in HIV-infected humanized mice. We recapitulated the study as described in 
Figure 3-11A, but here, mice were allocated into groups that received an HIV-resistant 
(C34-CXCR4+) CAR T cell product consisting of either CAR8 T cells alone (2.5x106 CAR+ 
cells), a 1:1 mixture of CAR4 and CAR8 T cells (1.25x106 CAR+/cell type), or a 1:1 
mixture of inactive control CAR4 and CAR8 T cells (1.25x106 CAR+/cell type) expressing 
the CD3 ICD. Of note, CAR8 T cells expressed the CD28 ICD, which previously 
demonstrated marginal in vivo expansion and protection against HIV infection.40 We 
observed that co-injection of CAR4 T cells enhanced the expansion (Fig. 3-16A,B) and 
persistence (Fig. 3-16C) of CD28-costimulated CAR8 T cells despite infusing half the 
dose, whereas alone these cells exhibited limited proliferation relative to control CAR8 T 
cells (Fig. 3-17). In a separate study CAR4 T cells also accelerated the early expansion 
kinetics of CAR8 T cells expressing the 4-1BB ICD (Fig. 3-18); this effect was surprising 
given the remarkable proliferation these cells exhibit on their own after ART cessation.40  
We next determined if the co-infusion of CAR4 T cells improved virologic 
outcomes following ART withdrawal. Notably, in this study we observed faster HIV 
rebound kinetics as viremia was detectable in mice 5 days after ART interruption (Fig. 3-
16D) compared to 12 days in our prior study (Fig. 3-11C). Nevertheless, combination 
therapy with CAR4 T cells and CD28-costimulated CAR8 T cells reduced rebound 
viremia (Fig. 3-16E) and effectively limited HIV-induced depletion of CD4+ T cells (CAR-) 
(Fig. 3-16F). In contrast, treatment with CAR8 T cells alone exhibited a transient 
reduction in viral load (Fig. 3-16E), but were unable to mitigate CD4+ T cell loss relative 
to control CAR T cell-treated mice (Fig. 3-16F). Together, these findings highlight that 
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CAR4 T cells provide T cell-help by improving the in vivo expansion and survival of CAR8 




HIV preferentially infects HIV-specific CD4+ T cells leading to the collapse of 
CD4+ T cell-help and impaired antiviral immunity.106,107 Thus, therapeutic approaches 
that restore CD4+ T cell function, such as adoptive T cell therapy, will likely be a critical 
component of any HIV functional cure or eradication strategy.145 Here, we interrogated 
the therapeutic potential of HIV-specific CAR4 T cells to limit HIV infection in vitro and 
after ART withdrawal in humanized mice. Given how costimulation tunes the functional 
heterogeneity of CD4+ T cells,146,147 we initially characterized how distinct ICDs modulate 
in vitro CAR4 T cell functions. We demonstrated that the CD28 receptor family ICDs 
(ICOS and CD28) induced potent functional profiles compared to the TNFR family ICDs 
(CD27, OX40 and 4-1BB), exemplified by polyfunctional cytokine responses and direct 
suppression of in vitro virus replication, which rivaled CAR8 T cell-mediated control of 
HIV. However, we did not observe an association between ICDs that conferred optimal 
in vitro function and the ability to mitigate HIV pathogenesis in humanized mice, 
suggesting that factors driving in vivo CAR4 T cell-mediated efficacy are not solely 
predicted in vitro.  
We identified CAR4 T cell expansion as a correlate of in vivo antiviral efficacy, 
supporting observations that CAR T cell persistence is necessary to engender long-term 
remission of certain B cell malignancies.47,148,149 Despite demonstrating limited in vitro 
efficacy, only HIV-resistant (C34-CXCR4+) CAR4 T cells expressing the 4-1BB ICD 
exhibited profound expansion and survival, and inhibited disease progression after ART 
removal. The remaining ICDs induced marginal proliferation notwithstanding abundant 
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HIV antigen, contrasting other studies that demonstrate ICOS81,122, CD27150 and 
CD28151,152 costimulatory signals mediate in vivo CAR4 T cell expansion and tumor 
eradication. Together, these data show that the 4-1BB ICD is necessary to potentiate 
rapid in vivo proliferation and long-term survival of CAR4 T cells during HIV infection. 
This finding is critical given that the stability of the latent reservoir in humans2,153 likely 
necessitates the persistence of CAR T cells for months, years or decades after infusion 
to respond to HIV reactivation.154  
Although the humanized mouse model described herein is well-suited to evaluate 
therapeutic interventions that mitigate active HIV replication and CD4+ T cell depletion, 
these animals eventually develop graft versus host disease (GVHD).155 This 
xenoreactivity induces substantial cellular activation and proliferation, resulting in the 
clinical manifestation of disease within 3-4 weeks after infusion,156 which diminishes the 
time to study the durability of CAR T cell therapy, and limits our ability to recapitulate all 
aspects of treatment performed in HIV-infected individuals. For instance, the constant 
immune activation drives supraphysiologic levels of virus replication and precludes the 
establishment of a latent HIV reservoir, which in humans, is comprised of a 
heterogeneous population of HIV-infected, transcriptionally quiescent memory CD4+ T 
cells.2,157 In contrast, treatments specifically targeting the latent reservoir may instead be 
accurately reflected in humanized BLT mice, a more complex small-animal model of HIV 
infection, which supports the generation of a latent reservoir under ART.158,159 
Nevertheless, our in vivo model enabled us to directly compare the ability of multiple 
CAR T cell products side-by-side to mitigate hallmarks of HIV disease progression 
following ART cessation, which is congruent with the study objectives being investigated 
by in-human clinical trials (NCT03617198).  
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Moreover, these findings along with our previous studies indicate that 4-1BB 
costimulation is essential for both CAR4 and CAR8 T cells to mitigate in vivo HIV 
pathogenesis after ART cessation,40 which contrasts recent data demonstrating that 
mesothelin-specific CAR4 and CAR8 T cells rely on distinct costimulatory signals for 
optimal function.81 However, within this study, we did observe the CD28 ICD 
differentially impact the efficacy of CAR4 and CAR8 T cell therapies in vivo. For instance, 
CD28-costimulated CAR4 T cells failed to proliferate and mount effective immunity 
against viral recrudescence compared to mice treated with 4-1BB-costimulated CAR4 T 
cells (Fig. 3-11D-F). In contrast, the data described herein supports our previous work,40 
showing that CAR8 T cells expressing the CD28 ICD were capable of reducing viremia 
and delaying CD4+ T cell (CAR-) depletion to the same extent as 4-1BB-costimulated 
CAR8 T cells early after ART cessation. These findings reinforce the notion that 
costimulatory signal(s) that engender favorable CAR T cell responses are likely both 
disease- and cell type-specific.60 
In addition to CAR4 T cells exhibiting direct control of in vitro HIV replication, we 
reasoned that they could also restore CD4+ T cell-help that is lost as a consequence of 
viral infection. To this end, we demonstrated that co-injection of CAR4 T cells enhanced 
the in vivo proliferation kinetics and survival of CD28-costimulated CAR8 T cells, 
concomitant with reduced HIV replication. Moreover, we have shown that in vitro 
activation of 4-1BB-costimulated CAR4 T cells upregulates IL-2 and IL-21, which are 
cytokines that augment the function of CD8+ T cells during viral infection,160-162 and thus, 
may have contributed to the sustained CAR8 T cell response that we observed in vivo. 
Furthermore, it is reasonable to believe that CAR4 T cell help will benefit endogenous, 
HIV-specific immunity. For example, previous studies have demonstrated that HIV-
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specific cytolytic CD4+ and CD8+ T cells exhibit strong cooperativity to suppress infection 
in vitro,163 and the addition of vaccine-primed HIV-specific CD4+ T cells reinvigorate the 
proliferative capacity of CD8+ T cells isolated from chronic infection.164 Finally, since our 
CAR4 T cells still express a functional TCR, it is likely that a portion of the infused CAR4 
T cells maintain specificity to other pathogens, and are able to confer help to immune 
responses towards other infections including EBV, flu, and CMV.  Interestingly, it was 
reported that repeated TCR stimulation of CAR T cells results in exhaustion of CAR8, but 
not CAR4 T cells,165 suggesting that CAR4 T cell-mediated help could be durable.  
The ability of HIV-specific CAR4 T cells to control HIV replication, as well as 
enable the function of other immune cells, highlights the therapeutic potential of this T 
cell population. However, we expect that next-generation CAR4 T cells will need to be 
infused into HIV-infected individuals as part of a defined formulation with CAR8 T cells to 
achieve a synergistic antiviral effect, similar to the cooperativity between these T cells 
during cancer treatment.149,166 Moreover, the potential of CAR T cell therapy alone to 
engender positive clinical outcomes may only occur after ART cessation when sufficient 
viral antigen is present to induce CAR T cell activation, as opposed to eliminating the 
latent reservoir during ART when antigen is restricted. In this way, CAR T cell therapy 
may resolve post-peak rebound viremia and contribute to an ART-free remission of HIV. 
Collectively, the findings described herein provide insight regarding the potential of 
engineered CD4+ T cells to both augment and restore the function of HIV-specific CD4+ 
T cells that is typically lost by virus-associated depletion, which could serve to 





Materials and Methods 
 
Ethics statement: 
Humanized mouse experiments performed at the University of Pennsylvania 
were approved by the University of Pennsylvania IACUC under the approval protocol 
805606. All animal studies were carried out in accordance with recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. 
Peripheral blood mononuclear cells and purified adult human CD8+ and CD4+ T cells 
were obtained by the University of Pennsylvania Human Immunology Core/CFAR 
Immunology Core from de-identified healthy donors.  
 
Flow cytometry: 
 Surface staining was performed in 1X PBS containing 2% fetal calf serum and 
2mM EDTA using anti-human antibodies from BioLegend: CD45 (2D1), CD3 (OKT3), 
CD4 (OKT4), CD8 (RPA-T8), TIGIT (VSTM3), PD-1 (EH12.2H7), CD107a (H4A3), and 
CD271/NGFR (ME20.4). Live cells were discriminated by staining with Fixable Viability 
Dye eFlour 780 (eBioscience). Intracellular proteins were stained for with Cell Fixation & 
Cell Permeabilization Kit (Invitrogen) according to the manufacturer’s instructions using 
antibodies from the following sources: BD Bioscience: TNF (Mab11), IFN- (4S.B3), GM-
CSF (BVD2-21C11), MIP-1 (D21-1351), IL-21 (3A3-N2.1), Granzyme B (GB11), and 
Active caspase-3 (C92605); BioLegend: IL-2 (MQH-17H12), IL-17A (BL168), IL-4 (8D4-
8), IL-13 (JES10), IL-22 (2412A41), Perforin (B-D48), and Granzyme A (CB9); 
eBioscience: Granzyme M (4B2G4); and Beckman Coulter: HIV-1 Core Antigen (KC57). 
Flow cytometry data were acquired on a BD LSRFortessa and analyzed using FlowJo 




HIV viral load quantitation: 
Viral RNA was isolated from plasma (40 L) using the QiaAmp Viral RNA Mini Kit 
(Qiagen). Viral loads were determined using quantitative RT-PCR using the QuantiFast 
Syber Green RT-PCR Kit (Qiagen) as previously described.99 The limit of quantification 
for this assay is 1.81 log RNA copies mL-1 plasma.  
 
Plasmid construction: 
The amino acid sequences for the HIV-specific CD4-based CAR constructs 
containing the following intracellular domains: CD3-, 4-1BB/CD3-, CD28/CD3-, 
CD27/CD3-, OX40/CD3- and ICOS/CD3- are described elsewhere.40 In this study, 
each CAR was amplified from their original plasmid with the following primer: 5’-
CACGTCCTAGGATGGCCTTACCAGTG and 5’- 
GTGGTCGACTTATGCGCTCCTGCTGAAC and cloned into pTRPE plasmid using the 
AvrII and SalI restriction enzyme sites. In this orientation, the CAR sequence is 
downstream of GFP and a T2A sequence intervenes to permit expression of both 
proteins. The amino acid sequence for the C34-CXCR4 construct is described 
elsewhere.79 We introduced a single Asp mutation (D97N), which has been shown to 
impair SDF-1 binding102 and limit CXCR4 internalization (Leslie et al. manuscript in 
preparation). C34-CXCR4 (D97N) was cloned upstream of T2A and NGFR167 sequences 
within the pTRPE backbone. 
 
Lentivirus production and transfection: 
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 Lentivirus particles were generated using expression vectors encoding VSV 
glycoprotein (pTRPE pVSVg-g), HIV Rev (pTRPE.Rev), and HIV Gag and Pol (pTRPE 
g/p). The plasmids were synthesized by DNA 2.0 or ATUM (Newark, CA) and 
transfected into HEK293T cells with pTRPE transfer vectors described above using 
Lipofectamine 2000 (Life Technologies) as previously described.103 Transfected 
HEK293T cell supernatant was collected 24 and 48 hours after transfection, filtered 
through a sterile 0.45 m nylon syringe driven filter and concentrated by 
ultracentrifugation at 25,000 rpm for 2.5 hours at 4°C. Supernatant was aspirated and 
the virus pellet was resuspended in 800 L total volume and stored at -80°C. 
 
Cell culture and selection: 
 To manufacture CAR T cells, CD4+ and CD8+ T cells from healthy adult human 
donors were purified by negative selection using RosetteSep Human CD4+ or CD8+ 
Enrichment Cocktails (StemCell Technologies) according to the manufacturer’s 
instructions. All cells were cultured at 106 cells mL-1 in complete RPMI (expansion 
medium): RPMI 1640, 2 mM GlutaMax, 25 mM HEPES and 1% Penicillin-Streptomycin 
from Life Technologies, and 10% fetal calf serum (Seradigm). T cell expansion medium 
was supplemented with 10 ng mL-1 human IL-7 (R&D) and 5 ng mL-1 human IL-15 
(BioLegend) or 100 U mL-1 human IL-2 (CLINIGEN). T cells were stimulated with 
CD3/CD28 Dynabeads (Life Technologies) at a 3:1 bead-to-cell ratio at 37°C, 5% CO2 
and 95% humidity incubation conditions. Roughly 18 hours after stimulation half of the 
medium was removed and replaced with 200 to 300 L of concentrated lentivirus 
supernatant for CAR transduction. On day 5, the Dynabeads were removed from cell 
culture by magnetic separation. Expansion medium was changed every other day 
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throughout cell culture spanning 8 to 10 days, or as necessary to adjust cell 
concentration to 0.5x106 cells mL-1. For in vivo studies, on day 7 after activation, C34-
CXCR4-transduced T cells were positively selected using CD271/NGFR Microbeads 
(Miltenyi Biotec) according the manufacturer’s protocol. Following selection, C34-
CXCR4+ T cells were placed in culture with expansion medium for one more day at the 
adjusted cell concentration prior to infusion into humanized mice. 
 
In vitro HIV suppression assay: 
 Two days after removing CD3/CD28 Dynabeads, activated CD4+ T cells were 
infected with CCR5-tropic HIVBAL at a multiplicity of infection (MOI) of 1. 24 hours later, 
HIV-challenged CD4+ T cells were washed with complete RPMI and mixed with the 
indicated type of HIV-specific CAR T cell, or untransduced (UTD) T cell at effector-to-
target ratios of 1:25, 1:50, 1:100 and 1:200. Cell mixtures were plated in duplicate and 
the spread of virus replication was assessed by flow cytometry by sampling 100 L per 
well for intracellular staining of HIV-1 Core Antigen (HIVGAG) at 2, 4, 6 and 8 days after 
co-culture. Fresh complete RPMI was added to all wells after staining. 
 
CD107a degranulation and intracellular staining assay: 
 The functionality of CAR T cells was measured in vitro after stimulating 2x105 
CAR T cells or UTD T cells with 2x105 wild-type K562s (K.WT) or K562 cells expressing 
HIVYU2 GP160 (K.Env). Anti-CD107a antibody was added at the start of stimulation 
followed by the addition of 1X Brefeldin A and Monensin Solution (BioLegend) 1 hour 
later. Cells were incubated for a total of 6 hours under incubation conditions. Detection 
of cytokines and cytolytic proteins were assessed by intracellular staining with antibodies 
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specific for human TNF, MIP-1, IFN-, IL-2, GM-CSF, Perforin, Granzyme B, Granzyme 
A, Granzyme M, IL-17A, IL-4, IL-13, IL-21 and IL-22. The percentage of cytokine-positive 
CAR T cells was calculated by subtracting background production after stimulation with 
K.WT cells. 
 
HIV-infected cell elimination assay: 
 This HIV-infected cell elimination assay is based on a previously described 
protocol.104 Briefly, HIV-infected CD4+ T cells were prepared as detailed above. When 
roughly 30% of total cells stained positive for intracellular HIVGAG, the cells were labeled 
with CellTrace Violet (CTV; ThermoFisher) to distinguish target cells from effector cells. 
CAR or UTD T cells were cultured with CTV+ target cells at various E:T ratios. After 24 
hours, target cells were analyzed for the reduction of HIVGAG+ cells and the induction of 
active caspase-3 by intracellular staining and flow cytometry. Elimination of HIV-infected 
cells was calculated by quantitation of live (Fixable Viability Dye eFlour780 negative) 
CTV+ CAR- HIVGAG+ cells. The percentage of residual HIV-infected target cells were 
calculated by dividing the percentage of live CTV+ CAR- HIVGAG+ target cells at the 
indicated E:T ratio by the percentage of CTV+ CAR- HIVGAG+ target cells at an E:T ratio of 
0. 
 
Humanized mice experiments: 
NOD/SCID/IL2R-/- (NSG) mice (The Jackson Laboratory) were housed in a 
pathogen-free facility at the University of Pennsylvania. Mice were maintained in 
microisolator cages and fed autoclaved food and water. Humanized mice were 
generated essentially as previously described.40 NSG mice were infused with 5x106 
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healthy donor PBMCs depleted of CD8+ T cells using CD8 Microbeads (Miltenyi Biotec) 
following the manufacturer’s protocol. Two weeks later mice initiated daily antiretroviral 
therapy (ART) consisting of 1 mg kg-1 EFdA (4′-ethynyl-2-fluoro-2′-557 deoxyadenosine, 
LeadGen Labs). After 1 day, mice were infused with 106 autologous HIVGAG+ CD4+ T 
cells and mixed with 9x106 uninfected CD4+ T cells. Prior to infusion CD4+ T cells were 
in vitro infected with HIVBAL (MOI 1) as described above and expanded in culture for 4 
more days, where during the last 2 days 1 M EFdA supplemented the expansion 
medium. Mice were bled 1 or 2 days after the infusion of HIV-infected cells, and then 
allocated into groups (n=6-8) based on the concentration of peripheral blood CD4+ T 
cells. Three days after the infusion of HIV-infected cells, mice were infused with HIV-
resistant (>90% C34-CXCR4+) CAR T cells as described above and ART was 
interrupted. For the study described in Figure 3-11, each group of humanized mice 
received an infusion of 2.5x106 CAR4 T cells expressing one of the six ICDs, or inactive 
control CAR4 T cells expressing a truncated CD3 ICD. For the study described in 
Figure 3-16, mouse groups received an infusion product consisting of either (CD28) 
CAR8 T cells (2.5x106 CAR+ cells), 1:1 ratio of CAR4 (4-1BB) and CAR8 (CD28) T cells 
(1.25x106 CAR+/cell type), or 1:1 ratio of inactive control CAR4 and CAR8 T cells 
(1.25x106 CAR+/cell type) expressing the CD3 ICD. In another study shown in Figure 
3-18, we recapitulated this experimental design, but the CAR8 T cells expressed the 4-
1BB ICD instead of the CD28 ICD. For all studies the mice were bled weekly via retro-





 All statistical analysis was performed using GraphPad Prism, version 7 (San 
Diego, CA). Comparison of means from unmatched samples were performed using the 
non-parametric Wilcoxon rank sum test or Kruskal-Wallis test followed by Dunn’s test for 
multiple comparisons. Comparison of means from matched samples was performed 
using paired student’s t test or Wilcoxon matched pairs signed rank test. Bivariate 
correlations were performed using Spearman’s rank correlation. Area under the curve 
calculations were performed using either cell concentration normalized to one microliter 











Figure 3-1. Intracellular costimulatory domains differentially modulate HIV-specific 
CAR4 T cell cytokine expression. (A) Schematic representation of each CAR construct 
and FACS plots identifying HIV-specific CAR-modified CD4+ T cells (CAR4) as GFP+ and 
CD4+ relative to untransduced CD4+ T cells (UTD4). Purified human CD4+ T cells from a 
healthy human donor were activated with CD3/CD28 Dynabeads and transduced with 
a lentiviral vector encoding one of six HIV-specific (CD4-based) CARs that express 
unique intracellular domains (ICD) either CD3 (), 4-1BB, CD28, CD27, OX40 or 
ICOS. Each CAR was linked to GFP by an intervening T2A sequence to facilitate in 
vitro detection.  (B) After 10 days of expansion, CAR4 T cells were in vitro stimulated 
with HIVYU2 GFP160+ K562 cells (K.Env) and intracellular cytokine analysis was 
108 
 
performed. Data are representative of 3 donors. (C) Heatmap showing the percentage of 
responding CAR4 T cells for each of the indicated cytokines. (D) Polyfunctionality profiles 
of combinatorial subsets for CAR4 T cells producing 0 to 5 human cytokines: TNF, IL-2, 
IFN-, GM-CSF and MIP-1. (C-D) Data are average of 3 donors. (E) Summary data of 3 
donors per CAR4 T cell population producing ≥ 2 cytokine functions after antigen 























Figure 3-2. Distinct HIV-specific CAR4 T cell types differentially express cytokines 
after in vitro antigen-specific stimulation.  (A) FACS plots indicating the frequency of 
cytokine expressing HIV-specific CAR4 T cells after in vitro stimulation with K.Env cells 
10 days after activation with CD3/CD28 Dynabeads. Data are representative of 3 
donors. (B) Summary data indicating the frequency of cytokine expressing CAR4 T cells. 
Each symbol represents a distinct donor. The percentage of cytokine expressing CAR4 T 
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cells was calculated by subtracting background production after stimulation with wild-


















Figure 3-3. Distinct HIV-specific CAR4 T cell types express low levels of Th17- and 
Th2-associated cytokines. Summary data indicating the frequency of cytokine 
expressing CAR4 T cells after in vitro stimulation with K.Env 10 days after activation with 
CD3/CD28 Dynabeads. Each symbol represents a distinct donor. The percentage of 
cytokine expressing CAR4 T cells was calculated by subtracting background production 











Figure 3-4. CD4-based CAR containing the CD3z intracellular domain exhibits the 
greatest surface expression on CD4+ T cells. Summary data indicates the geometric 
mean fluorescence intensity (MFI) determined by flow cytometry of CD4 on GFP+ CAR4 


















Figure 3-5. Intracellular domains modulate CAR4 T cell-mediated control of in vitro 
HIV replication. Each HIV-specific CAR4 T cell type and UTD4 T cells were mixed 
separately with HIVBAL-challenged CD4+ T cells at the indicated effector-to-target (E:T) 
ratios, and the level of virus spread was monitored by intracellular staining and flow 
cytometry for HIVGAG antigen on 2, 4, 6 and 8 days after co-culture. (A) FACS plots 
indicating the frequency of HIVGAG+ cells (CAR-) 8 days after co-culture with CAR4 or 
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UTD4 T cells at the 1:25 E:T ratio. (B) Summary of the frequency of HIVGAG+ cells at 2, 4, 
6 and 8 days after co-culture at 1:25 E:T ratio. Symbols represents the average of 3 
distinct donors in duplicate and error bars show ± SEM. (C) Cumulative infection 
calculated by area under the curve from the frequency of HIVGAG+ cells at 2, 4, 6 and 8 
days after co-culture at 1:100 and (D) 1:200 E:T ratios. Data are represented as box and 
whisker plots and bars show min and max values. Symbols indicate unique donors 
performed in duplicate. Kruskal-Wallis test and Dunn’s multiple comparison test was 


















Figure 3-6. HIV-specific CAR4 T cells durably suppress in vitro HIV replication. 
HIV-specific CAR T cells and UTD T cells were mixed separately with HIVBAL-challenged 
CD4+ T cells at the indicated effector-to-target (E:T) ratios, and the level of virus spread 
was monitored by intracellular staining and flow cytometry for HIVGAG antigen on 2, 4, 6 
and 8 days after co-culture. (A) FACS plots indicate the frequency of HIVGAG+ cells (CAR-
) 8 days after co-culture with each CAR4 T cell type or UTD4 T cells. (B) Summary of the 
frequency of HIVGAG+ cells at 2, 4, 6 and 8 days after co-culture at 1:50, (C) 1:100, and 
(D) 1:200 E:T ratio. For (B-D), symbols represent the average of 3 distinct donors in 
duplicate and error bars show ± SEM. (E) FACS plots show the frequency of HIVGAG+ 
cells (CAR- CD8-) 8 days after co-culture with UTD8 or HIV-specific CAR8 T cells 
expressing the 4-1BB intracellular domain. (F) Cumulative infection calculated by area 
under the curve from the frequency of HIVGAG+ cells at 2, 4, 6 and 8 days after co-culture. 
Data are represented as box and whisker plots and bars show min and max values. 
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Symbols indicate unique donors performed in duplicate. Kruskal-Wallis test and Dunn’s 













Figure 3-7. HIV-specific CAR8 T cells expressing the 4-1BBz ICD durably suppress 
in vitro virus replication. UTD and HIV-specific CAR4 and CAR8 T cells expressing the 
4-1BB intracellular domain were mixed separately with HIVBAL-challenged CD4+ T cells 
at the indicated effector-to-target (E:T) ratios, and the level of virus spread was 
monitored by intracellular staining and flow cytometry for HIVGAG antigen on 2, 4, 6 and 8 
days after co-culture. (A) Summary of the frequency of HIVGAG+ (CAR-) cells at 2, 4, 6 
and 8 days after co-culture. Symbols represents the average of 3 donors in duplicate 
and error bars show ± SEM. (B) Cumulative infection calculated by area under the curve 
from the frequency of HIVGAG+ cells at 2, 4, 6 and 8 days after co-culture. Data are 
represented as box and whisker plots and bars show min and max values. Symbols 




Figure 3-8. HIV-specific CAR4 T cells exhibit cytolytic function against virus-
infected CD4+ T cells. (A-E) CellTrace Violet labelled, HIVBAL-infected CD4+ T cells 
(30% HIVGAG+) were cultured with HIV-specific CAR or UTD T cells at the indicated E:T 
ratios. 24 hours later the frequency of HIVGAG+ cells (live CTV+ CAR-) was assessed by 
intracellular staining and flow cytometry for HIVGAG antigen. (A) FACS plots show the 
frequency of HIVGAG+ cells, and (B) summary data indicates the frequency of residual 
HIVGAG+ cells after co-culture with UTD4 or CAR4 T cells expressing the CD3 ICD. (C) 
Summary data of elimination assay at the 0.125:1 E:T ratio. (D) FACS plots and (E) 
summary data show frequency of active caspase-3 within HIVGAG+ cells after co-culture 
with UTD4 or CAR4 T cells expressing the CD3 ICD. (F) After 10 days of expansion, 
CAR4 T cells were stimulated with K.Env or wild-type K562 cells (K.WT) and FACS plots 
show upregulation of Granzyme B and TNF. Data are representative of 3 donors. (G) 
Histogram and (H) mean fluorescence intensity (MFI) indicate CD107a mobilization in 
CAR4 T cells after in vitro stimulation. (I) FACS plots and (J) summary data show the 
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coordinated upregulation of perforin and Granzyme B in CAR4 T cells expressing the 
CD3 ICD after in vitro stimulation. (B,E) Symbols indicate average of 3 donors 
performed in triplicate. Error bars show ± SEM. (C) Data are represented as box and 
whisker plots and bars show min and max values. Symbols indicate 3 donors performed 
in duplicate. Kruskal-Wallis test and Dunn’s multiple comparison test were used to 
determine significance. (H,J) Data shows 3 donors and significance was calculated 






















Figure S6. HIV-specific CAR4 T cells exhibit in vitro cytotoxic activity. CellTrace 
Violet labelled, HIVBAL-infected CD4+ T cells (30% HIVGAG+) were cultured with UTD or 
HIV-specific CAR T cells at the indicated E:T ratios. Frequency of HIVGAG+ cells (live 
CAR- CD8- T cells) was assessed by intracellular staining and flow cytometry for HIVGAG 
antigen 24 hours later. (A) Summary data indicates the frequency of residual HIVGAG+ 
cells that exist after co-culture with CAR T cells at the 0.25:1 and (B) 0.5:1 E:T ratio. 
Data are represented as box and whisker plots and bars show min and max values. 
Symbols indicate 3 donors performed in duplicate. Kruskal-Wallis test and Dunn’s 









Figure 3-10. HIV-specific CAR4 T cells differentially express Granzymes after in 
vitro stimulation. After 10 days of culture, each CAR4 T cell type was in vitro stimulated 
with K.Env or wild-type K562 cells (K.WT) and the intracellular expression levels of 
Granzyme B, A and M were assessed. (A) FACS plots show the frequency of Granzyme 
A and (B) Granzyme M expression in CAR4 T cells. Data are representative of 3 distinct 
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donors. (C) Summary data showing the change in Granzyme B and (D) Granzyme A 














Figure 3-11. HIV-specific 4-1BB-costimulated CAR4 T cells mitigate HIV disease 
progression post-ART. (A) Experimental design. NSG mice were infused with CD8-
depleted PBMCs from a healthy human donor. Two weeks later, mice initiated daily ART 
for one week and were infused with autologous, in vitro HIVBAL-infected CD4+ T cells. 
Mice were allocated into 7 groups (n=6-7) based on CD4+ T cell engraftment, and then 
each mouse received 2.5x106 HIV-resistant (C34-CXCR4+) CAR4 T cells expressing one 
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of the six intracellular domains (ICDs), or inactive control CAR4 T cells expressing a 
truncated CD3 ICD followed by ART cessation. (B) Concentration of peripheral blood 
CD4+ T cells prior to CAR T cell infusion. Data are represented as box and whisker plots 
and bars show min and max values. (C) HIV RNA copies mL-1 plasma normalized to 
contemporaneous peripheral blood CD4+ T cell concentration (CAR-) 12 days, (D) 19 
days, and (E) 26 days post-ART removal. (F) Longitudinal concentration of CD4+ T cells 
(CAR-) in peripheral blood. (C-F) Bars and symbols indicate mean and error bars show ± 




















Figure 3-12. Manufacturing and in vitro functional evaluation of HIV-resistant CAR 
T cells. HIV-specific CAR4 T cells were co-transduced with lentivirus encoding the HIV 
fusion inhibitor C34-CXCR4 linked to NGFR by an intervening T2A sequence. Seven 
days after activation with CD3/CD28 Dynabeads, T cells were positively selected for 
NGFR expression using NGFR antibody coated magnetic beads as described in 
Materials and Methods. (A) Schematic of the C34-CXCR4 construct used to confer HIV-
resistance to CAR4 T cells. (B) FACS plots indicate the purity of NGFR+ CAR4 T cells 
following magnetic bead selection prior to infusion into HIV-infected humanized mice. (C) 
HIV suppression assay as described in Materials and Methods. Viral outgrowth kinetics 
when HIV-infected CD4+ T cells are co-cultured with either C34-CXCR4+ or C34-CXCR4- 
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CAR T cells expressing the 4-1BBz intracellular domain or UTD. Symbols indicate mean 

















Figure 3-13. Plasma viral load comparison of normalized and non-normalized 
values. (A) Viral loads of 4-1BB CAR4 T cell-treated mice compared to control 
CD3 CAR4 T cell-treated mice (see also Figure 4). HIV RNA copies mL-1 plasma are 
either normalized to contemporaneous peripheral CD4+ T cell (CAR-) concentration or 
non-normalized (i.e raw concentration). (B) Cumulative viral load calculated by area 
under the curve from 5, 12, 19 and 26 days post-ART removal. For all data, bars indicate 









Figure 3-14. 4-1BB costimulation potentiates in vivo HIV-specific CAR4 T cell 
expansion and persistence. (A) FACS plots show the detection of each CAR4 T cell 
type in peripheral blood 26 days post-ART removal in HIV-infected humanized mice. 
CAR4 T cells are identified by the co-expression of GFP and NGFR, which are linked by 
intervening T2A sequences to the indicated CD4-based CAR and C34-CXCR4, 
respectively. (B) Peripheral blood concentration of each CAR4 T cell type at 12, 19 and 
26 days post-ART removal. (C) Cumulative peripheral CAR4 T cell persistence 
measured by area under the curve from 5, 12, 19 and 26 days post-ART removal. (D) 
FACS plots and (E) summary data show the frequency of TIGIT and PD-1 expression on 
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each CAR4 T cell type 5 days post-ART removal. (F) Correlation between CAR4 T cell 
concentration 19 days post-ART removal and contemporaneous viral load, and (G) CD4+ 
T cell (CAR-) concentration. Red symbols indicate 4-1BB-costimulated CAR4 T cells and 
white symbols indicate the remaining CAR4 T cell types. (B,C) Data are represented as 
box and whisker plots and bars show min and max values. Each symbol denotes one 
mouse. Wilcoxon rank sum test and (F,G) Spearman correlation were used to test for 


















Figure 3-15. HIV-specific CAR4 T cells expressing TNFR family intracellular 
domains exhibit lower inhibitory receptor expression post-ART. (A) Longitudinal 
expression of TIGIT and (B) PD-1 on peripheral blood HIV-specific CAR4 T cells post-
ART removal in HIV-infected humanized mice. Symbols indicate mean and error bars 





Figure 3-16. Co-injection of HIV-specific CAR4 T cells improves CAR8 T cell 
expansion and post-ART control of HIV infection. NSG mice were infused with CD8-
depleted PBMCs from a healthy human donor. Two weeks later, mice initiated daily ART 
for one week and were infused with autologous, in vitro HIVBAL-infected CD4+ T cells. 
Mice were allocated into 3 groups (n=7-8) based on CD4+ T cell engraftment, and then 
each group received either HIV-resistant (C34-CXCR4+) CAR8 (CD28) T cells (2.5x106 
CAR+ cells/mouse), 1:1 ratio of CAR4 (4-1BB) and CAR8 (CD28) T cells (1.25x106 
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CAR+/cell type/mouse), or 1:1 ratio of inactive control CAR4 and CAR8 T cells (1.25x106 
CAR+/cell type/mouse) expressing the CD3 ICD followed by ART interruption. (A) 
FACS plots show the frequency of peripheral CAR8 T cells identified by the 
overexpression of CD4 on the CD8+ T cell surface. (B) Longitudinal concentration of 
peripheral CAR8 T cells after ART interruption. (C) Cumulative peripheral CAR8 T cells 
persistence measured by area under the curve from 5, 12, 19 and 26 days post-ART 
removal. (D) HIV RNA copies mL-1 plasma normalized to contemporaneous peripheral 
CD4+ T cell (CAR-) concentration 5 days, and (E) 12, 19 and 26 days post-ART removal. 
(F) Longitudinal concentration of CD4+ T cells (CAR-) in peripheral blood. (B,C,F) Data 
are represented as box and whisker plots and bars show min and max values. (D,E) 
Bars indicate mean and errors show ± SEM.  For all data, each symbol denotes one 

















Figure 3-17. HIV-specific CD28-costimulated CAR8 T cells fail to expand post-ART 
removal in vivo. Longitudinal concentration of HIV-specific CAR8 T cells expressing 
either the CD28 or CD3 ICD in peripheral blood following ART withdrawal in HIV-
infected humanized mice. Data are represented as box and whisker plots and bars show 










Figure 3-18. Co-injection of HIV-specific CAR4 T cells improve early expansion 
kinetics of 4-1BB-costimulated CAR8 T cells post-ART removal. NSG mice were 
infused with CD8-depleted PBMCs from a healthy human donor. Two weeks later, mice 
initiated daily ART for one week and were infused with autologous, in vitro HIVBAL-
infected CD4+ T cells. Mice were allocated into 3 groups (n=4-6) based on CD4+ T cell 
engraftment, and then each mouse received either HIV-resistant (C34-CXCR4+) CAR8 
(4-1BB) T cells (2.5x106 CAR+ cells), 1:1 ratio of CAR4 (4-1BB) and CAR8 (4-1BB) T 
cells (1.25x106 CAR+/cell type), or 1:1 ratio of inactive control CAR4 and CAR8 T cells 
(1.25x106 CAR+/cell type) expressing the CD3 ICD followed by ART interruption. 
Longitudinal concentration of peripheral CAR8 T cells after ART interruption. Data are 
represented as box and whisker plots and bars show min and max values. Each symbol 

























CHAPTER 4 - High-throughput characterization of CAR T cell manufacturing 
criteria and cytotoxic potential using image-based cytometry 
Parts of this chapter are previously published: 
 
Maldini C.R., Love A.C., Tosh K.W., Chan L., Gayout K., Smith T., Riley J.L. (2020) 
Characterization of CAR T Cell Expansion and Cytotoxic Potential During Ex Vivo 




Since the FDA approval of two Chimeric Antigen Receptor (CAR) T cell therapies 
against CD19+ malignancies, there has been significant interest in adapting CAR 
technology to other diseases. As such, the ability to simultaneously monitor 
manufacturing criteria and functional characteristics of multiple CAR T cell products by a 
single instrument would likely accelerate the development of candidate therapies. Here, 
we demonstrate that image-based cytometry yields high-throughput measurements of 
CAR T cell proliferation and size, and captures the kinetics of in vitro antigen-specific 
CAR T cell-mediated killing. The data acquired and analyzed by the image cytometer are 
congruent with results derived from conventional technologies when tested 
contemporaneously. Moreover, the use of bright-field and fluorescence microscopy by 
the image cytometer provides kinetic measurements and rapid data acquisition, which 
are direct advantages over industry standard instruments. Together, image cytometry 
enables fast, reproducible measurements of CAR T cell manufacturing criteria and 






Adoptive immunotherapy involves the transfer of immunocompetent cells for the 
treatment of pathologies with the goal to replace, restore or augment the biological 
function of the native immune response.154 To date, the adoptive transfer of genetically-
modified, autologous Chimeric Antigen Receptor (CAR) T cells have significantly 
improved the clinical outcome of patients with treatment refractory B cell 
malignancies,47,48 culminating in two FDA-licensed CAR T cell therapies. CARs redirect 
T cell responses through surface expression of an extracellular antigen-binding domain, 
typically an antibody-derived single-chain variable fragment, fused to an intracellular 
domain comprising the TCR signal transduction domain (CD3-) and one or more 
costimulatory domains.37,46 Given the modular nature of CARs, each domain can be 
switched permitting the generation of engineered T cells with new specificities and 
functions. Due to recent success of CD19-targeted CAR T cell therapies many 
researchers are investigating novel CARs for other disease indications; however, 
preclinical evaluation including the simultaneous manufacturing and functional testing of 
multiple CAR T cell products can be time-consuming and labor-intensive168 As such, the 
ability to measure these criteria with a single instrument will likely accelerate the 
development and evaluation of novel immunotherapies. 
The adoptive transfer of CAR T cells relies on the large scale ex vivo activation 
and expansion of genetically-engineered T cells, generating >1 x 109 CAR T cells for re-
infusion into patients.169 This process involves activating purified, patient blood-derived T 
cells by ligating CD3 and CD28 surface receptors through monoclonal antibodies 
conjugated to beads170, or by co-culture with artificial antigen-presenting cells171,172. 
Activated T cells can be transduced with a viral vector containing the CAR, and then 
grow logarithmically in culture for 1 to 2 weeks prior to adoptive transfer into patients. 
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Throughout the expansion phase, CAR T cells are routinely counted using automated 
cell counters, which have largely replaced manual hemocytometers, given their ability to 
accurately quantify cell number and size173. During this time, the culture volume is 
continuously adjusted to lower the cell density and remove the buildup of waste products 
such as lactate and ammonia174, which improves cell growth and viability. In addition to 
measuring the growth rate, CAR T cells are screened for phenotypic characteristics such 
as memory distribution and functionality, including antigen-specific cytokine release and 
target cell killing. Collectively, these readouts represent critical measures of quality 
control that need to be defined in order to ensure consistent manufacturing of a uniform 
CAR T cell product.168 
Here, we have developed an efficient image-based cytometry method using the 
Celigo Image Cytometer (Nexcelom Bioscience LLC.) to overcome limitations of 
conventional instruments used to measure CAR T cell expansion criteria and effector 
function during the manufacturing process.175,176 We validated this novel technique 
against industry-standard equipment and assays by generating a panel of distinct HIV-
specific CAR T cell populations from multiple donors, and assessed the in vitro growth 
kinetics and cytotoxic potential of these CAR T lymphocytes against antigen-presenting 
target cells. Notably, image cytometry permitted the simultaneous evaluation of distinct 
CAR T cell populations, which enabled us to directly compare the growth rate and 
functionality of these cells. Image cytometry provided a sensitive, kinetic and high-
throughput method to assess the physiological functions of CAR T cells, which could 






Image-based cytometry measures CAR T cell expansion criteria during 
manufacturing 
Image cytometry uses the bright-field channel and auto-focus feature to identify 
individual cells that are seeded in a microwell plate (Fig. 4-1A), after which the well can 
be imaged and analyzed using the Celigo software to calculate cell density. We 
validated this cell counting method by comparing the image cytometer to the Multisizer 3 
(Beckman Coulter), an automated cell counter and particle sizing instrument frequently 
used in the hematology field that employs the coulter principle 177,178. To do so, we 
prepared a triplicate series of two-fold T cell dilutions from which cell counting 
measurements were made by each instrument. The cell concentrations measured by the 
image cytometer and Multisizer 3 maintained a high degree of linearity over the indicated 
range of dilutions compared to the theoretical values (Fig. 4-1B), and were strongly 
correlated with each other (r = 0.9996; Fig. 4-1C).  
The image cytometer was then used to monitor the cell density of multiple CAR T 
cell products, using a manufacturing process similar to one being employed in clinical 
trials 179,180. We generated seven distinct CAR T cell products per donor by transducing 
CD3/CD28 bead-activated CD4+ T cells with single lentiviruses containing an HIV-
specific CAR derived from the full-length CD4 extracellular region fused to an 
intracellular domain (ICD) comprising the TCR CD3- () chain and one or more 
costimulatory domains, including 4-1BB, CD28, CD28/4-1BB, CD27, OX40 or ICOS 
(Fig. 4-2). Beginning 5 days after the initial stimulation, we calculated the number of 
population doublings from baseline (day 0) using the cell density values measured by 
the image cytometer and Multisizer 3. The expansion curves of each CAR T cell type 
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generated by the image cytometer were nearly identical to the Multisizer 3 (Fig. 4-1D), 
and no statistical differences were observed between the two methods comparing total 
population doublings after 10 days of culture (Fig. 4-1E). Notably, we did not observe 
any substantial differences in proliferation among the CAR T cell populations with the 
exception of CAR T cells expressing the CD27/ ICD, which consistently exhibited fewer 
population doublings (Fig. 4-1D,E). 
Following cognate antigen stimulation, T cell size increases due to the 
accumulation of biomass prior to cellular division 181. As such, we simultaneously 
quantified the size of expanding CAR T cells throughout manufacturing as a surrogate 
readout of their activation state. However, to first validate the image cytometry-based 
object sizing protocol, we measured the diameter of CD3/CD28 Dynabeads. The image 
cytometer detected the beads using bright-field microscopy (Fig. 4-3A), and calculated 
an average bead diameter of 5.2 µm (Fig. 4-3B), which approximates the manufacturer 
(Gibco) listed width of 4.5 µm. This method was then applied to CAR T cells during the 
manufacturing process, and we observed that CAR T cell size (area, μm2) peaked 6 
days after the initial stimulation before gradually contracting to a smaller, ‘rested’ size on 
day 10 (Fig. 4-3C-E). The cell areas of each CAR T cell population were roughly similar 
during the expansion phase (Fig. 4-3F,G and Fig. 4-4), which was expected given their 
comparable proliferation kinetics (Fig. 4-1E). Moreover, the cell areas calculated by 
each method strongly correlated with one another (Fig. 4-3H). Together, the data 
acquired by image cytometry were directly comparable to conventional technologies and 





Image fluorescence microscopy captures the kinetics of in vitro CAR T cell-
mediated killing 
To align with traditional assays used to quantify the in vitro functional potency of 
CAR T cells, we determined if the image cytometer could detect antigen-specific effector 
function. To do so, we set up a cytotoxicity assay using untransduced (UTD) and HIV-
specific CD8+ CAR T cells expressing the CD3- ICD cultured at different effector-to-
target (E:T) ratios with on-target K562 cells expressing the HIVYU2 GP160 protein 
(K.Env) or off-target, wild-type K562 cells (K.WT). For this assay, we stably transduced 
these target cell lines with a lentiviral vector containing GFP linked to click beetle green 
luciferase by an intervening T2A sequence. The inclusion of GFP enabled the 
enumeration of GFP+ target cells by using the image cytometer, followed by the 
sequential detection of bioluminescence (BLI) from luciferase activity using the same set 
of effector CAR T cells and K562 target cells. As such, we were able to directly compare 
the extent of target cell killing measured by image cytometry to a standard BLI-based 
assay routinely used to characterize cytotoxic potential 182,183. 
The image cytometer accurately detected GFP+ target cells utilizing the bright-
field and green fluorescent channels, and we observed substantial CAR T cell-mediated 
reductions of on-target GFP+ K.Env cells (Fig. 4-5A), but not off-target GFP+ K.WT cells 
(Fig. 4-6). We then calculated specific lysis values using the image cytometer and BLI-
based assay at all E:T ratios 72-hours after co-culture. Both methods showed that CAR 
T cells exhibited dose-dependent cytotoxicity at E:T ratios <1; this effect was HIV-
specific as only limited off-target cytolysis occurred (Fig. 4-5B,C and Fig. 4-7A). In 
contrast, UTD T cells induced minimal killing as we observed less than 20% target cell 
lysis across all E:T ratios (Fig. 4-5D,E and Fig. 4-7B). Although the same cultures were 
analyzed by both methods, the specific lysis values obtained by the BLI-based assay 
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were marginally greater than the image cytometer (Fig. 4-7C), suggesting there may be 
slight differences in sensitivity. However, the BLI-based assay also measured greater 
off-target CAR T cell-mediated killing, likely resulting from background luciferase signals 
(Fig. 4-5C and Fig. 4-7A). It is important to note that both methods measured negative 
specific lysis, which indicated target cell growth in the control conditions, evidenced by 
the accumulation of target cells in the absence of CAR T cells (Fig. 4-5A and Fig. 4-6). 
Notably, image cytometry captured the kinetics of CAR T cell-mediated killing by 
enumerating GFP+ target cells without further manipulation unlike end-point BLI-based 
assays or the Chromium-51 release assay 182. We imaged the cells at 0, 24, 48 and 72-
hours after co-culture and observed marked CAR T cell-mediated reductions of on-target 
GFP+ K.Env cells beginning at 48-hours (Fig. 4-8A), and cell lysis increased through 72-
hours after co-culture indicating that CAR T cells were capable of sustained cytotoxic 
function (Fig. 4-8B and Fig. 4-9A). Importantly, we observed limited off-target toxicity as 
GFP+ K.WT cells continued to grow unabated when cultured with CAR T cells at the 
indicated E:T ratios (Fig. 4-8B, and Fig. 4-9A,B). Taken together, these data 
demonstrate that image cytometry is capable of quantifying in vitro antigen-specific CAR 
T cell-induced cytotoxicity, and that the sensitivity of this method is comparable to 
conventional assays that assess effector CAR T cell function. 
 
Discussion 
The ability to functionally characterize multiple CAR T cell products in a high-
throughput and comparative manner can expedite the discovery of novel CARs with 
therapeutic potential. Current methods to measure CAR T cell proliferation as well as 
cytotoxic potential during the manufacturing process can be time-consuming and 
requires the use of multiple equipment. The image-based cytometry method described 
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herein was designed to eliminate these issues. In our study, we noted several 
advantages of using image cytometry compared to conventional instruments. For 
instance, the average time to scan, image and count T cells seeded in a 96-well 
microplate by the image cytometer was 5 seconds per well compared to >30 seconds by 
the Multisizer 3 from Beckman Coulter. Moreover, the bright-field and fluorescent images 
acquired by the Celigo Image Cytometer led to the direct enumeration of multiple cell 
types without manipulating the culture system, which can serve to bolster readouts from 
assays that employ indirect, end-point assays to measure T cell proliferation (i.e. CFSE 
dilution)184 or cytotoxicity.185 
We first validated the image cytometer to measure the cell density of multiple 
CAR T cell products during the manufacturing process compared to the Multisizer 3. The 
cell concentration values from both instruments were nearly identical over the course of 
expansion (10 days), validating that image-based cytometry identified and accurately 
counted CAR T cells. Importantly, these data enabled us to expand CAR T cells at an 
optimal density by adding new expansion medium to the culture, which also serves to 
dilute the waste products that accumulate from cellular metabolism 186. Interestingly, 
despite each CAR T cell type expressing a unique intracellular costimulatory domain, 
which are known to impart distinct functional properties,60 the CAR T cells exhibited 
similar expansion kinetics over 10 days in culture. This contrasts data from the cancer 
field demonstrating that some scFv-based CARs expressing distinct costimulatory 
signals exhibit differential expansion kinetics during ex vivo manufacturing,39,81 
suggesting that the HIV-specific CAR mediates limited ligand-independent signaling, a 
property that may improve resistance to exhaustion.38  
Furthermore, we measured the area of expanding CAR T cells as a surrogate 
readout of cellular activation.181 Both instruments detected peak CAR T cell size 6 days 
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post-activation (>350 m2) before contracting to a rested size on day 10 (<250 m2). 
However, it is important to note that each instrument uses a unique method to calculate 
cell size. For instance, the Multisizer 3 determines cell area by detecting the impedance 
of an electrical current measured as a voltage or current pulse. This transient change in 
impedance results as cells pass through the aperture a volume of electrolyte solution is 
displaced from the sensing zone equivalent to the volume of the cell.187 In contrast, the 
image cytometer calculates cell size by measuring the finite pixels of a cell imaged in 2-
dimensional space contained within the segmentation boundary, and then factors in the 
resolution of the acquired image. This method produces a cross-sectional area, but for 
CAR T cells and other spherical objects this measurement can be easily adjusted to 
account for 3-dimensional area. Nevertheless, the cell sizes from both instruments 
strongly correlated with one another, indicating that image cytometry captured the 
pattern of cell size dynamics during CAR T cell manufacturing.  
Effector cell-mediated cytotoxicity assays are commonly used to detect the in 
vitro function of CAR-modified and other pathogen-specific T cells 185. These assays 
generally measure target cell death by 3 mechanisms: 1) the release of Chromium-51 
(radioactivity),188 lactate dehydrogenase (enzymatic reaction),189 or calcein 
(fluorescence)190 from dead cells into the culture supernatant; 2) the loss of viable target 
cells by flow cytometry;191,192 and 3) cell-associated luciferase activity.182 All three 
categories of assays typically provide a fixed end-point measurement of cytotoxicity and 
consumption of samples. End-point assays necessitate that replicate experiments need 
to be performed to capture the kinetics of T cell killing, which may require a large input of 
both effector and target cells. However, we demonstrated that an image cytometry-
based approach led to the reliable assessment of cytotoxic CAR T cell function over 
time. Notably, we measured the kinetics of target cell lysis by directly enumerating GFP+ 
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target cells without disturbing or sacrificing cell samples, whereas the BLI-based assay 
provided an indirect measurement of antigen-specific killing at a single time point (72-
hours after co-culture). Moreover, the image cytometry-based method utilizes cell counts 
within the same well at 0-hours to normalize the specific lysis values at 24, 48 and 72-
hours after co-culture. In this way, the reduction of GFP+ target cells reference their 
respective wells instead of separate control wells, thereby negating the potential 
variability inherent to pipetting or differences in target cell input between treatment and 
control wells. As such, the ability to assess and quantify cytotoxicity in a stringent, kinetic 
manner is a distinct advantage of image cytometry. 
In summary, with the advancements in camera, optics, and image analysis 
technologies, image cytometry has taken root in providing quantitative results to various 
aspects of biological assays.175,176,193,194 For CAR T cell therapy, conventional methods 
evaluating manufacturing criteria and effector function have resulted in the development 
of potent cellular products capable of inducing durable remissions for certain 
malignancies,47,48 but newer technologies are perhaps needed to advance the rapid 
development and evaluation of preclinical candidate therapies.  Here, image cytometry 
provided a novel, efficient, and high-throughput characterization of CAR T cells during 
the manufacturing process, and offered several direct advantages over industry-
standard equipment and routine assays. The findings described herein highlight the 
utility of image-based cytometry to assess multiple attributes of CAR T cells, and show 
the potential of this method to expedite the discovery and validation of novel CAR T cell 
products. 
 




De-identified, purified CD3+, CD8+ and CD4+ T cells from human donors were 
obtained by the University of Pennsylvania Human Immunology Core/CFAR Immunology 
Core under an institutional review board (IRB)-approved protocol. 
 
Plasmid construction 
The amino acid sequences for the HIV-specific CD4-based CAR constructs 
containing the following intracellular domains: CD3-, 4-1BB/CD3-, CD28/CD3-, 
CD28/4-1BB/CD3-, CD27/CD3-, OX40/CD3- and ICOS/CD3- have previously been 
described.40 In this study, each CAR was amplified from their original plasmid with the 
following primer: 5’-CACGTCCTAGGATGGCCTTACCAGTG and 5’- 
GTGGTCGACTTATGCGCTCCTGCTGAAC and cloned into pTRPE plasmid using the 
AvrII and SalI restriction enzyme sites. In this orientation, the CAR sequence is 
downstream of GFP or iRFP670 and a T2A sequence intervenes to permit expression of 
both proteins. 
 
Lentivirus production and transfection 
To generate the lentiviral particles, expression vectors encoding VSV 
glycoprotein, HIV Rev, HIV Gag and Pol (pTRPE pVSV-g, pTRPE.Rev, and pTRPE g/p, 
respectively) were synthesized by DNA 2.0 or ATUM (Newark, CA) and transfected into 
HEK293T cells with pTRPE transfer vectors encoding the CAR using Lipofectamine 
2000 (Life Technologies, Carlsbad, CA) as previously described.103 Transfected 
HEK293T cell supernatant was collected at 24 and 48 hours, filtered through a 0.45 m 
nylon syringe filter and concentrated by ultracentrifugation for 2.5 hours at 25,000 RPM 
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and 4°C. The supernatant was aspirated and the virus pellet was resuspended in 800 L 
total volume of RPMI 1640, and subsequently stored at -80°C. 
 
Preparation of CAR T cells 
Purified CD8+ and CD4+ T cells (RosetteSep, StemCell Technologies, 
Vancouver, Canada) were obtained by the University of Pennsylvania Human 
Immunology Core/CFAR Immunology Core from apheresis products of three de-
identified healthy human donors (Donor 1, 2, 3). T cells were cultured at 1x106 cells mL-1 
in complete RPMI 1640 with 10% FCS (Seradigm), 1% Penicillin-Streptomycin, 2 mM 
GlutaMax and 25 mM HEPES buffer (Life Technologies). T cell expansion medium was 
supplemented with 100 U mL-1 recombinant human IL-2 (Clinigen). T cells were 
stimulated with CD3/CD28 Dynabeads (Life Technologies) at a 3:1 bead-to-cell ratio at 
37°C, 5% CO2 and 95% humidity incubation conditions. Approximately 18 hours after 
stimulation, half of the medium was removed and replaced with 200 L of lentiviral 
supernatant encoding the appropriate HIV-specific CAR. 5 days post-stimulation, the 
Dynabeads were removed from cell culture by magnetic separation. T cells counts (cells 
mL-1) and size measurements (cell area, μm2) were measured daily using both the 
Celigo Image Cytometer (Nexcelom Bioscience LLC, Lawrence, MA) and Multisizer 3 
Coulter Counter (Beckman Coulter, Brea, CA) as described below. The cells were 
adjusted to 0.5x106 cells mL-1 with complete RPMI every second day.  
 
Preparation of K562 target cells 
The K562 cell line stably transduced to express the HIVYU2 GP160 Envelope 
protein (K562.Env) was a kind gift from Aimee Payne (University of Pennsylvania, 
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Philadelphia, PA) and wild-type K562 cell line (K562.WT) (ATCC CCL-243) were 
maintained in complete RPMI 1640 at a density of 0.1x106 cells mL-1. Both K562 cell 
lines were transduced with a lentiviral vector encoding GFP coupled to Click Beetle 
Green (CBG) luciferase by an intervening T2A sequence. The K562 cell lines were 
single-cell sorted on the Aria II (BD Bioscience) based on GFP expression. For each cell 
line, an individual single-cell clone was selected based on uniform GFP expression and 
subsequently propagated for use in the cytotoxicity experiments. 
 
T cell dilution series  
Approximately, 4x106 total T cells were transferred into a 96-well flat bottom plate 
(Corning #3596) in 200 L of 1X PBS (Corning). Subsequently, 7 two-fold serial dilutions 
were made by carrying over 100 L of liquid containing cells. After the dilution series, 
100 L of 1X PBS was added to all wells for a final volume of 200 L per well. The 
dilution series was performed in triplicate, where the cell concentration and average cell 
size were determined by the image cytometer and Multisizer 3. 
 
T cell proliferation and size measurement using image cytometry 
The Celigo Image Cytometer (Nexcelom Bioscience) utilizes one bright-field (BF) 
and four fluorescent (FL) imaging channels, blue (EX377/50 nm, EM470/22 nm), green 
(EX 483/32 nm, EM 536/40 nm), red (EX 531/40 nm, EM 629/53 nm), and far red (EX 
628/40 nm, EM 688/31 nm) for high-throughput cell-based assays 195-199. The target and 
effector cells seeded in standard multi-well microplates are auto-focused, imaged, and 
analyzed using the Celigo software (version 5.1). The software consists of five major 
steps START, SCAN, ANALYZE, GATE, and RESULTS, where the users can enter 
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general information, setup imaging/analysis parameters, perform imaging/analysis of 
cells, and view/export images and results.  
The Celigo Application “Target 1” was used to measure beads with specific 
diameter in the bright-field channel at an exposure time of ~2,800 s. The Celigo 
Application “Target 1 + Mask” was employed for measuring proliferation by directly 
counting total T cells in the bright-field channel in each well over time. Both Target 1 and 
Mask channels were set to bright-field illumination with exposure times 1 and ~3,250 s, 
respectively. The Mask channel allowed the dilation of the outline diameter to improve 
size measurement of T cells. In addition, a specific image analysis template was used 
from FCS Express 6 (De Novo Software, Pasadena, CA). The counted T cell data (.ice 
files) were exported from the image cytometer software and imported into the FCS 
Express (De Novo Software) template that automatically generated size histograms, cell 
count, cell concentration, diameter (m), minimum and maximum cell size (m2), and 
average cell size (m2). The average cell size values were multiplied by a factor of 4 to 
account for the surface area of spherical objects. It is important to note that software 
version 5.2 can directly export cell concentration and size data, as well as dilate the cell 
outline diameter without a Mask channel. 
 
T cell proliferation and size measurement using the Multisizer 3 
40 L of cell culture was transferred into individual Accuvette ST vials (Beckman 
Coulter) containing 20 mL of ISOTON II Diluent (Beckman Coulter). Vials were loaded 
onto the Multisizer 3 one at a time and cell concentration (cells mL-1) was based on 
volumetric sampling (500 L) under the following conditions: 70 m aperture, 1600 A 
current, and a gain setting of 2. Cell size was determined by applying a manual gate to 
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all samples (range 150 m2 to 1500 m2). The cell concentration and average cell size 
was determined by the Beckman Coulter Particle Characterization software (v3.51) 
using the ‘Statistics’ function. Similarly, CD3/CD28 Dynabeads beads at 4.5 m 
diameter (Gibco) were counted and analyzed following the procedure described above.  
 
CAR T cell-mediated cytotoxicity assay 
Untransduced (UTD) and CAR CD8+ T cells that expressed the CD3-  
endodomain coupled with iRFP670 were manufactured as described above. Prior to 
setting up the assay, CAR transduction efficiency was normalized across all donors 
based on positivity for iRFP670 expression. For each donor, 2x104 CAR T cells were 
seeded in complete RPMI, and then five 2-fold serial dilutions were performed in a 96-
well black polystyrene microplate (Corning #3603). 1x104 K562.Env.CBG.GFP or 
K562.WT.CBG.GFP cells were added to each well with final E:T ratios of 0.500, 0.250, 
0.125, 0.061, and 0.031:1. Target cells were also cultured in the absence of CAR T cells 
to account for spontaneous death, while wells containing complete RPMI only were 
included as a measure for maximal killing (used for BLI-based assay). Three technical 
replicates were performed for each donor. Plates were cultured at 37°C, 5% CO2, and 
95% humidity incubation conditions. The cytotoxicity measurements were analyzed at 0, 
24, 48 and 72 h using the image cytometer and the Synergy H4 Hybrid Microplate 
Reader (BioTek). 
 
Cytotoxicity measurement using image cytometry 
The Celigo application “Target 1” was used for CAR T cell-mediated cytotoxicity 
assay, which utilized only the green fluorescence channel. Green fluorescent images 
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were acquired with exposure times ranging from ~15,000 to 30,000 s. The image 
cytometer was used to directly count the number of GFP+ target cells in the wells with 
different donors and E:T ratios over time in triplicate for each condition. Since GFP 
fluorescence is significantly reduced as the target cells are killed during co-culture due to 
leakage, direct counting of the bright GFP+ cells represented viable cells in the well. 
Specific lysis was calculated by the following: % Specific Lysis = 100 x (# cells in no 
effector wells - # cells in treatment well) / (# cells in no Effectors – 0 (max killing). This 
calculation was performed to align with the normalized RLU data from BLI-based assay. 
 
Cytotoxicity measurement using BLI microplate reader 
Immediately after imaging the plate with the image cytometer at the 72 hour time 
point, D-Luciferin potassium salt was added to each well producing a final concentration 
of 15 µg mL-1 (GoldBio) and incubated at 37°C for 10 min. Luminescence was measured 
for 1 second with a luminometer (Synergy H4 Hybrid Microplate Reader) as relative light 
units (RLU). Triplicate wells were averaged and the percent specific lysis was calculated 
with the following equation 182 specific lysis (%) = 100 x [(spontaneous death RLU - 
treatment RLU)/(spontaneous death RLU - maximal killing RLU)]. 
 
Statistical analysis 
All statistical analysis was performed using GraphPad Prism, version 7 (San 
Diego, CA). Comparison of means from matched samples was performed using 
Wilcoxon matched pairs signed rank test. Bivariate correlations were performed using 







Figure 4-1. Image-based cytometry reliably measures the kinetics and magnitude 
of in vitro CAR T cell expansion. A) Bright-field image and segmentation of individual 
T cells (blue) seeded in a 96-well microwell plate using the Celigo Image Cytometer. B) 
Triplicate serial dilutions of CD3+ T cells were counted by the image cytometer and 
Multisizer 3 and mean cell densities were plotted against theoretical values. Slope of 
each line is denoted as “m”. C) Cell density values measured by the image cytometer 
and Multisizer 3 from (B) were plotted against each other. Spearman correlation test was 
used to calculate significance. D) CD4+ T cells were activated with CD3/CD28 
Dynabeads and 24-hours later were transduced with a lentivirus encoding an HIV-
specific CAR containing the indicated intracellular domain (ICD). Population doublings 
were calculated by measuring the total cell number in culture at the indicated time-points 
using the image cytometer (square) and Multisizer 3 (circle). E) Comparison of paired 
CAR T cell population doublings on day 10 post-activation measured by the image 
cytometer and Multisizer 3. Wilcoxon matched pairs sign rank test was used to calculate 




Figure 4-2. Schematic representation of HIV-specific CAR constructs. Activated 
CD4+ T cells were transduced with lentiviral vectors encoding the HIV-specific CAR 
expressing the CD4 extracellular domain fused to intracellular domains comprising CD3-
 (), 4-1BB/, CD28/, CD28/4-1BB/, CD27, OX40 and ICOS CD28 containing 
CARs used the CD28 transmembrane domain, whereas the remaining CARs used the 
















Figure 4-3. Image-based cytometry quantifies changes in CAR T cell size post-
activation. A) Bright-field image of CD3/CD28 Dynabeads seeded in 96-well microwell 
plate. B) Histogram of CD3/CD28 Dynabeads imaged in (A) shows average bead area 
and diameter within min (10 m2) and max (40 m2) limits. C) Bright-field image of CAR 
T cells on days 0, 6 and 10 post-activation. D) Histogram of CAR T cell area at days 0 
(red), 6 (black), 8 (blue) and 10 (green) post-activation by image cytometry and E) 
Multisizer 3. Data are representative of 2 donors. F) Longitudinal cell area of the 
indicated CAR T cell types measured by image cytometry and G) Multisizer 3. Data are 
representative of 2 donors. H) Correlation of cell size values from the image cytometer 
plotted against Multisizer 3. Each symbol represents a unique CAR T cell type 7 days 







Figure 4-4. Longitudinal changes in CAR T cell size post-activation. CD4+ T cells 
from a second donor were activated with CD3/CD28 Dynabeads and transduced with a 
lentiviral vector encoding the indicated HIV-specific CAR. A) Longitudinal cell area of the 
expanding CAR T cells measured by image cytometry and B) Multisizer 3 at the 














Figure 4-5. In vitro HIV-specific CAR T cell-mediated killing assessed by image-
based cytometry. HIV-specific CD8+ CAR T cells expressing the CD3- intracellular 
domain were mixed in triplicate with on-target K562 HIVYU2 GFP160+ cells (K.Env) or off-
target K562 wild-type cells (K.WT) at 0.5, 0.25, 0.125, 0.061 and 0.0306:1 effector-to-
target (E:T) ratios. Target cells stably expressed GFP linked to Click Beetle Green 
luciferase by an intervening T2A sequence. Cell lysis was determined by successive 
imaging of target cells using image cytometry and bioluminescence (BLI). A) Bright-field 
and fluorescence microscopy images of GFP+ K.Env cells and K.WT cells 72-hours after 
co-culture acquired by the image cytometer. B) Specific lysis of on-target and off-target 
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cells cultured with CAR T cells and measured by image cytometry and C) BLI. D) 
Specific lysis of on-target and off-target cells cultured with UTD T cells and measured 
with image cytometry and E) BLI. Specific lysis values were calculated as described for 
each method in Materials and Methods. Symbols represent mean and error bars show ± 























Figure 4-6. HIV-specific CAR T cells exhibit limited in vitro off-target cytotoxicity. 
HIV-specific CD8+ CAR T cells expressing the CD3- intracellular domain were mixed 
with off-target GFP+ K.WT cells at the indicated E:T ratios. Bright-field and fluorescence 
microscopy images are of off-target cells 72-hours post co-culture acquired by the image 












Figure 4-7. Comparison of CAR T cell-mediated killing using image cytometry and 
Bioluminescence-based cytotoxicity assays. HIV-specific CD8+ CAR T cells 
expressing the CD3- intracellular domain were mixed in triplicate with on-target K562 
HIVYU2 GFP160+ cells (K.Env) or off-target wild-type K562 cells (K.WT) at 0.5, 0.25, 
0.125, 0.061 and 0.0306:1 effector-to-target (E:T) ratios. Target cells stably express 
GFP linked to Click Beetle Green luciferase by an intervening T2A sequence. Cell lysis 
was determined by successive imaging of target cells using image cytometry and 
bioluminescence (BLI). A) Specific lysis of on-target cells and off-target cells when 
cultured with CAR T cells and B) UTD T cells at different E:T ratios. Specific lysis values 
were calculated as described for each method in Materials and Methods. Symbols 
represent mean and error bars show ± SD. C) Paired specific lysis values from image 
cytometry and BLI-based assay at the indicated E:T ratios. Each symbol represents a 




Figure 4-8. Image-based cytometry captures the kinetics of in vitro CAR T cell-
mediated cytolysis. A) Fluorescence microscopy images of on-target GFP+ K.Env cells 
alone, or mixed with HIV-specific CD8+ CAR or UTD T cells at 0.5:1 E:T ratio at the 
indicated time points after co-culture acquired by the image cytometer. B) Enumeration 
of on-target cells and off-target GFP+ K.WT cells mixed with CD8+ CAR or UTD T cells at 
different E:T ratios at the indicated time points after co-culture. Symbols represent 






Figure 4-9. Kinetics of in vitro HIV-specific CAR T cell-mediated killing. A) 
Enumeration of on-target GFP+ K.Env and off-target GFP+ K.WT cells mixed with CD8+ 
CAR or UTD T cells at different E:T ratios at the indicated time points post co-culture. 
Symbols represent average of triplicate values and error bars show ± SD. B) 
Fluorescence microscopy images of off-target K.WT cells alone, or mixed with HIV-
specific CD8+ CAR or UTD T cells at 0.5:1 E:T ratio at the indicated time points after co-




CHAPTER 5 - Conclusion 
 
Research Summary 
 The CTL response to HIV infection can shape the trajectory of disease 
pathogenesis. However, for most individuals HIV employs a variety of escape 
mechanisms that renders CTLs, as well as other arms of antiviral immunity ineffective. 
As such, HIV persists indefinitely by establishing latent reservoirs that necessitates 
lifelong treatment to subdue virus replication and prevent disease progression. The HIV 
cure field generally considers that reconstituting the HIV-specific CTL response will be a 
critical component of an HIV cure strategy. Of late, adoptive T cell-based therapies, 
specifically CAR T cells, have garnered significant attention for their ability to overcome 
the limitations that prevent naturally-derived CTLs from controlling infection (summarized 
in Table 1-1). This body of work represents an in-depth examination of CAR T cell 
therapy for the treatment of HIV using small animal models of HIV infection that 
recapitulates viral pathogenesis in humans. We leveraged in vivo models to describe the 
underpinnings of both successful and failed CAR T cell interventions. The major findings 
are addressed below: 
 BLT humanized mice are a viable approach to evaluate adoptive T cell-
based therapies for HIV. BLT mice are generated by implanting human fetal thymus 
and liver tissue into NSG mice, followed by the infusion of fetal liver-derived CD34+ 
hematopoietic stem cells, and over time, human immune cells of various lineages 
repopulate the mouse. These mice have been extensively used to study various aspects 
of HIV infection including the determinants of virus transmission,200 efficacy of new ART 
regimens,67 and to a lesser extent the generation of HIV-specific immunity.96 
Undoubtedly, the paucity of reports describing the development of antigen-specific CTL 
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responses induced either through natural infection or immunization initially tempered our 
expectations that these animals could support CAR T cell therapy. Nevertheless, we 
focused our efforts on BLT mice because these animals offer substantial advantages 
over less complex humanized mouse models, including the ability to recapitulate the 
study design of autologous CAR T cell therapy that would be performed in HIV-infected 
individuals (see in NCT03485963). We demonstrated that CAR T cells manufactured ex 
vivo from BLT mice are functionally indistinguishable from their healthy adult human 
donor-derived counterparts. After infusion into HIV-infected mice, these cells mount a 
vigorous response, evidenced by profound antigen-specific proliferation and activation 
during acute infection. Notably, CAR T cells expressing the 4-1BB/CD3- endodomain 
did not resolve infection, and as a result, these cells sustained expression of multiple 
inhibitory receptors (PD-1, TIGIT, 2B4) and transcription factors (Eomeshi, TOX, T-betlow) 
associated with an exhausted T cell phenotype.201 Together, these data support that BLT 
mouse-derived T cells are not functionally compromised, rather the immune response 
mounted by CAR T cells mimics the response pattern of other virus-specific CTLs, 
particularly in the setting of uncontrolled infection. Moreover, these data demonstrate 
that ex vivo manufacturing and infusion of autologous antigen-specific T cells overcomes 
the presumed defect in BLT mice that restricts the priming of de novo CTL responses to 
combat virus infection. 
 The inclusion of multiple costimulatory signals into CAR T cells are 
necessary to induce optimal antiviral activity. In addition to CD3-, costimulatory 
signals are required to potentiate the in vivo activity of CAR T cells, including 
proliferation, persistence and effector functions.37 The most common intracellular 
costimulatory domains under investigation are derived from the CD28 receptor family 
164 
 
(ICOS and CD28), and the tumor necrosis factor (TNF) receptor family (CD27, OX40 
and 4-1BB), but alternative mechanisms to provide costimulation have been explored, 
such as the co-expression of full-length costimulatory ligands (4-1BBL and CD40L).80,202 
However, CD28 and 4-1BB remain the archetypal costimulatory signals used by second-
generation CAR T cells, and each are incorporated into licensed CD19-targeted CAR T 
cell therapies. In the context of aggressive B cell non-Hodgkin’s lymphoma (B-NHL), 
CAR T cells with CD28 costimulation mediate higher response rates than 4-1BB-
costimulated CAR T cells, despite limited in vivo survival, whereas in B-cell acute 
lymphoblastic leukemia (B-ALL), 4-1BB costimulation induces longer progression free 
survival rates, which correlates with the persistence of CAR T cells.55,58 These findings 
suggest that favorable CAR T cell responses to B-NHL require rapid, cytolytic activity 
mediated by CD28 costimulation, while B-ALL likely requires a durable, prolonged CAR 
T cell-mediated response provided by 4-1BB costimulation. Together, this suggests that 
the costimulatory domain that engenders optimal CAR T cell activity is disease-specific. 
 Here, we reconciled the differential functional attributes that CD28 and 4-1BB 
costimulation impart on CAR T cells in the setting of HIV infection, by creating a novel 
dual CD4-based CAR-transduced T cell population that independently expresses 
CD28/CD3- and 4-1BB/CD3- endodomains on the same cell. In this way, we 
hypothesized that the CD28 and 4-1BB domains have the opportunity to signal 
autonomously in their native orientation when triggered. Indeed, Dual-CAR T cells 
exhibited profound in vivo expansion that exceeded 4-1BB-costimulated CAR T cells, 
and elicited effector functions, including ex vivo cytotoxicity and cytokine secretion, to 
the same extent as CD28-costimulated CAR T cells. Moreover, only Dual-CAR T cells 
were capable of mitigating HIV disease progression by preventing CD4+ T cell loss. 
Notably, the in vivo activity of Dual-CAR T cells contrasts that of 3rd-generation (3G) 
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CD4-based CAR T cells, which combine CD28 and 4-1BB costimulatory signals in a 
linear manner on the same molecule. In fact, the in vivo proliferation and survival 
exhibited by 3G-CAR T cells are similar to CD28-costimulated CAR T cells, suggesting 
that the costimulatory domain proximal to the cell membrane (i.e. CD28 in the 3G-CAR 
construct) exerts a dominant effect on T cell function, which has been demonstrated in 
the context of several cancer-specific 3G-CARs.82,83 Collectively, these data highlight the 
development of a new CAR T cell population with unique functional properties that can 
be applied to treat a variety of different disease indications beyond HIV. 
 The susceptibility of CD4-based CAR T cells to HIV infection accelerates 
disease progression. There exists several distinct antigen recognition moieties that 
engage the HIVENV glycoprotein on virally-infected cells, including scFvs derived from 
broadly neutralizing antibodies,42 carbohydrate recognition domains,133 and the CD4 
extracellular domain.40 We initially chose the CD4-based CAR for several reasons: i) 
demonstrated safety profile in humans;35 ii) greater in vitro antiviral potency than scFv-
based CARs;40 and iii) minimized likelihood of HIV to escape from binding to CD4.131 
Despite these advantages, the overexpression of a CD4-based CAR on CD8+ and CD4+ 
T cells renders these cells susceptible to HIV infection, but prior to this work the 
consequences of infection were unknown. We hypothesized that the rate of CAR T cell 
infection, and subsequent propagation of virions within expanding CAR T cells, negated 
CAR T cell-mediated reductions in the frequency of virus-infected cells that contribute to 
plasma viremia. To this end, we found that the infusion of CAR T cells into HIV-infected 
mice both accelerated the replication kinetics and increased the magnitude of plasma 
viremia compared to untreated mice. In addition, HIV-infected CAR T cells exhibited 
weaker functional responses after ex vivo stimulation than their uninfected counterparts. 
In contrast, only the infusion of CAR T cells expressing the HIV fusion inhibitor, C34-
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CXCR4, delayed the onset and reduced the magnitude of acute virus replication, but this 
effect was transient given that C34-CXCR4 does not confer sterilizing protection.79 As 
such, we have concluded that stringent mechanisms of HIV resistance need to be 
engineered into CAR T cells to prevent this treatment from worsening disease 
progression. 
 HIV-resistant and HIV-specific CD4+ CAR T cells exert direct antiviral 
activity and confer T cell-help to other lymphocytes. Given that HIV infection 
depletes CD4+ T cells, which compromises global antiviral immunity, we reasoned that 
reconstituting HIV-specific CD4+ T cells will be an essential component to an HIV cure 
strategy. We know from the initial in-human clinical trials that the co-infusion of HIV-
specific CD4+ CAR T cells were essential for the engraftment and survival of CD8+ CAR 
T cells,34 but due to the study design and the lack of therapeutic efficacy, the individual 
contribution of CD4+ T cells to treat HIV remains unknown. Herein, we explored the utility 
of CD4+ CAR T cells with regard to their ability to directly control infection and aid in the 
function other immune cells. In doing so, we identified an inverse relationship between 
costimulatory domains that confer the greatest in vitro and in vivo antiviral CD4+ CAR T 
cell function. Notably, only the 4-1BB costimulatory signal augmented CD4+ CAR T cell 
expansion and persistence in vivo, and importantly, enabled CD4+ T cells to suppress 
rebound viremia after ART cessation in humanized mice. These results were striking in 
that CD4+ CAR T cells expressing costimulatory domains from the TNF receptor family 
demonstrated inferior in vitro effector responses compared to CD4+ CAR T cells 
expressing CD28 receptor family costimulatory domains. In addition, CD4+ CAR T cells 
conferred T cell-help to co-infused CD8+ CAR T cells expressing the CD28 costimulatory 
domain. Here, we observed significantly improved CD8+ CAR T cell expansion and 
persistence in vivo relative to CD8+ CAR T cells that were infused alone. Given these 
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promising results, we believe that CD4+ CAR T cell-help can be extended to reinvigorate 
endogenous HIV-specific CTLs. 
 Furthermore, we investigated alternative applications of HIV-specific CAR T cells 
through external collaborations. For instance, Christopher Peterson’s group at the 
University of Washington and Fred Hutchinson Cancer Research Center previously 
observed limited persistence of adoptively transferred CAR T cells into SHIV-infected 
nonhuman primates (NHPs). Thus, as a means to boost the frequency of CAR T cells 
prior to ART interruption, we successfully infused HIVENV expressing artificial antigen 
presenting cells that induced marked in vivo antigen-specific expansion of NHP-derived 
CAR T cells,203 which we previously observed in BLT mice. In addition, we applied 
Therapeutic Interfering Particles (TIPs) developed in Leor Weinberger’s laboratory at the 
University of California, San Francisco in HIV-infected BLT mice to determine whether 
TIPs can reduce viremia by out-competing HIV for host machinery that is vital for virus 
replication [Tanner, EJ., et al. under review]. We then combined the TIPs with HIV-
specific CAR T cell therapy to determine if the addition of an antiviral immune response 
can synergize with these particles to further suppress viremia. Overall, the lessons 
learned from this body of work have demonstrated practical utility outside of our 
immediate scope, as we have showed that our findings have the potential to bolster the 




 The results described in this work highlight the promise of CAR T cell therapy as 
part of an effective HIV cure strategy. However, it is clear that additional studies are 
necessary to advance the efficacy of HIV-specific CAR T cells, as currently, they only 
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exert a modest impact on disease progression. As such, to achieve an ART-free HIV 
remission we believe future efforts should aim to further optimize the CAR T cell product, 
as well as investigate treatment protocols that combine CAR T cells with other 
therapeutic agents. These future directions are discussed in detail below. 
 Initially, we engineered a more potent HIV-specific CAR T cell product by co-
transducing T cells with independent lentiviruses encoding CD4-based CARs with 4-
1BB/CD3- and CD28/CD3- endodomains. Despite expressing distinct intracellular 
signaling domains, Dual-CAR T cells express two copies of the CD4-based targeting 
moiety. Thus, it is possible that competition exists between the two CARs for binding to 
the CD4-binding site of HIVENV, especially when antigen is limited, which may restrict full-
activation of 4-1BB and CD28 costimulatory signals. As such, the generation of multi-
specific Dual-CAR T cells should be employed to mitigate this concern. In this 
scenario, we envision that the ideal Dual-CAR T cell expresses two distinct targeting 
moieties in addition to the 4-1BB and CD28 endodomains. We believe it will be critical to 
keep the CD4-based CAR constant, while the second CAR needs to target a separate 
epitope on HIVENV. The second CAR will likely be derived from a broadly-reactive 
antibody, as opposed to a broadly-neutralizing antibody (bNab), which is capable of 
binding to diverse HIV strains. This scFv can be developed from any number of 
monoclonal antibodies with known specificities; however, one attractive choice may be 
an scFv that recognizes CD4-induced (CD4i) HIVENV epitopes. CD4i binding sites within 
the inner domain of gp120 are normally occluded by gp41 and are only exposed after 
gp120 engages CD4.204 In doing so, CD4i-targeted antibodies are known to inhibit the 
binding of gp120 to CCR5 chemokine receptor after undergoing conformational changes 
upon ligating CD4.205 Thus, the sequential binding of the CD4-based CAR followed by 
the CD4i-targeted CAR may induce full CAR T cell activation in the absence of 
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competition for the same epitope, and as an ancillary benefit the CD4i-targeted CAR 
may prevent infection of CAR T cells by blocking access to the HIV coreceptors. 
 Moreover, we have shown substantial evidence that HIV infection of CAR T cells 
compromises their ability to effectively control disease pathogenesis. For instance, we 
demonstrated that infusion of HIV susceptible CAR T cells both accelerates the kinetics 
and increases the magnitude of viremia. However, we observed the opposite trend when 
infection of CAR T cells was mitigated by 1) administering CAR T cells into HIV-infected 
mice concurrently with ART to prevent new rounds of virus replication, and 2) infusing 
HIV-resistant CAR T cells that express the C34-CXCR4 fusion inhibitor. In the latter 
case, expression of C34-CXCR4 clearly reduced the level of CAR T cell infection, but 
this protection rapidly waned upon exposure to persistent viremia. Thus, HIV-specific 
CAR T cells must be engineered with more stringent mechanisms of resistance to 
improve control over virus replication. To do so, preventing viral entry by targeted 
genetic disruption of the HIV coreceptors is likely the most effective strategy for 
engineering HIV-resistant CAR T cells. 
 The finding that individuals who lack functional CCR5 expression are both 
healthy and resistant to CCR5-tropic strains of HIV has prompted extensive investigation 
to recreate this phenomenon in the majority of people who are susceptible to infection. 
These HIV resistant individuals contain a naturally occurring 32 base pair deletion in 
CCR5 leading to the production of a truncated, non-functional chemokine receptor that 
does not permit HIV fusion.206,207 To date, several ex vivo gene-editing approaches have 
been clinically evaluated to protect CD4+ T cells from infection,85,208,209 including using 
zinc finger nucleases to genetically disrupt CCR5.87 More recently, gene-editing 
strategies have used homology-directed repair (HDR) to introduce new gene cassettes 
into specific genomic loci.210,211 One study, simultaneously disrupted CCR5 using site-
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directed megaTAL nuclease and drove HDR using an adeno-associated virus donor 
template encoding an HIV-specific scFv-based CAR.43 This method produced functional 
HIV-specific CAR T cells lacking CCR5 expression, and these cells suppressed virus 
replication in vitro  to a greater extent than unprotected CAR T cells. Despite the ability 
of various gene-editing approaches to attenuate CCR5 expression, the efficiency of 
gene-modification are modest.212 As such, manufacturing CCR5-edited CAR T cells may 
be the most significant challenge to successfully deploy this approach at a clinical scale, 
as an overwhelming majority of the T cell infusion product must be HIV-resistant. 
 HIV-specific CAR T cells may also benefit from new advances made in the 
cancer immunotherapy field to subvert T cell exhaustion. We thoroughly demonstrated 
that CAR T cells progressively accumulated an exhausted phenotype in the presence of 
persistent viremia in vivo. This phenotype was characterized by sustained co-expression 
of PD-1, TIGT and 2B4 and transcription factor usage that was dominated by Eomes 
and TOX expression, as well as attenuated effector functions. As a result, engineering 
HIV-specific CAR T cells to overcome exhaustion will likely promote durable 
immune responses that are necessary to control infection. Recently, emphasis has 
been paced on CRISPR/Cas9 gene-editing, as this approach is a powerful tool for 
multiplex genome editing.213 For instance, several groups have disrupted the expression 
of PD-1 in cancer-specific TCR- and CAR-modified T cells to promote antitumor 
immunity,214,215 and this technology has just been employed in a phase one clinical 
trial.216 Moreover, another group has engineered exhaustion-resistant CAR T cells by 
overexpressing the AP-1 family transcription factor, c-Jun.217 In doing so, these CAR T 
cells maintained their functional capacity, diminished terminal differentiation, and 
exhibited improved antitumor potency. These approaches can be adapted to HIV-
specific CAR T cells, and when tested in BLT humanized mice we will be able to 
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determine the extent to which anti-exhaustion mechanisms augment the durability of the 
CAR T cell response. 
 In addition to engineering an HIV-specific T cell product that can induce potent 
responses, CAR T cells have the potential to synergize with other treatment modalities 
to cure infection. One approach is to combine CAR T cell therapy with broadly 
neutralizing antibodies, where these bNabs have the ability to prevent new rounds of 
infection by neutralizing virions, as well as Fc-mediated effector functions to eliminate 
HIV-infected cells.218 To this end, we performed a proof of concept study where Dual-
CAR T cells were combined with a bNab cocktail (10-1074 and 3BNC117) to accelerate 
virus suppression under ART. 10-1074 and 3BNC117 engage HIVENV at distinct sites, 
the V3 loop and CD4 binding site, respectively,219,220 and were included in this study for 
their ability to delay virus rebound after ART interruption in humanized mice and 
humans.221,222 However, when tested in combination with CAR T cells we observed no 
synergistic effect on the kinetics of viral suppression relative to mice treated with only 
CAR T cells or bNabs in the presence of ART [unpublished]. One possible explanation 
for the lack of synergy may be that the 3BNC117 antibody and the CD4-based CAR T 
cell were competing for the same binding site on the gp120 subunit of HIVENV. As such, 
future studies should evaluate antibody cocktails that do not simultaneously target the 
CD4 binding site, which could potentially interfere with the CAR T cell recognition of 
infected cells. 
Furthermore, one of the largest hurdles for a successful HIV cure is the presence 
of a latent HIV reservoir. In this state, the virus genome stably integrates into the 
chromatin of resting memory CD4+ T cells and avoids immunosurveillance by persisting 
indefinitely in a transcriptionally quiescent state. Current eradication efforts, such as the 
“shock and kill” paradigm, aim to reactive HIV production from latent reservoirs using 
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latency reversing agents (LRAs).223 It is hoped that reactivated cells will die by virus-
induced cytopathic effects and/or be lysed by stimulating pre-existing or generating de 
novo immune responses.224 However, LRA treatment alone has failed to measurably 
reduce the size of the latent reservoir in HIV-infected individuals.225-227 These findings 
imply that additional immune mechanisms may be required to destroy infected cells 
upon latency reversal. Thus, there is an opportunity for HIV-specific CAR T cells to act in 
concert with LRAs. Of particular interest, are treatment regimens that use an IL-15 
superagonist,228 or stimulate toll-like receptors,229 or non-canonical NF-κB signaling.230 
Given the critical role each of these pathways have in developing cell-mediated 
immunity, it is likely that these approaches could synergize with CAR T cells by having 
an ancillary, beneficial effect on cellular function in addition to inducing viral gene 
expression.  
In summary, this work culminated in major improvements to the HIV-specific 
CAR T cell product that is currently under clinical investigation at the University of 
Pennsylvania, ultimately leading to the generation of HIV-specific Dual-CAR T cells. 
Notably, these findings may not have occurred if not for the rigorous in vivo testing using 
BLT humanized mice, which provided a stringent environment necessary to study the 
functional behavior of CAR T cells in the setting of virologic failure. We made step-wise 
improvements to the HIV-specific CAR T cell product, where during this process the 
susceptibility of CAR T cells to both exhaustion and HIV infection are critical hurdles that 
must be addressed in future studies. However, this body of work demonstrates a clear 
promise that CAR T cells can promote immune-mediated clearance of virus-infected 
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